# background genes,# genes,category,chart color,description,FDR value,genes,network.SUID,nodes.SUID,p-value,PMID,term name,transferred FDR value,year,FDR (-log10)
44,10,WikiPathways,,Integrated cancer pathway,9.64E-17,SMAD2|CDK2|TP53|PLK1|CASP3|SMAD3|E2F1|CDK1|AKT1|MYC,10163,10267|10303|10291|10297|10333|10252|10264|10327|10330|10318,1.23E-19,,WP1971,1.601592297,0,16.01592297
1146,20,COMPARTMENTS,,Nucleoplasm,1.05E-15,CSNK2A1|STUB1|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|PRKACA|CASP3|SMAD3|MYB|E2F1|SKI|E2F4|CDK1|SUMO2|AKT1|MYC|CTNNB1,10163,10306|10315|10267|10324|10303|10291|10297|10312|10261|10333|10252|10288|10264|10270|10321|10327|10273|10330|10318|10285,4.57E-19,,GOCC:0005654,1.49788107,0,14.9788107
517,16,GO Cellular Component,,Transcription regulator complex,2.98E-15,CSNK2A1|RBL2|SMAD2|RCOR1|CDK2|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F1|SKI|E2F4|SMAD5|MYC|CTNNB1,10163,10306|10276|10267|10324|10303|10291|10312|10282|10252|10288|10264|10270|10321|10258|10318|10285,1.46E-18,,GO:0005667,1.452578374,0,14.52578374
1850,22,COMPARTMENTS,,Nuclear lumen,6.96E-15,CSNK2A1|STUB1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|PRKACA|CASP3|SMAD3|MYB|E2F1|SKI|E2F4|CDK1|SUMO2|AKT1|MYC|CTNNB1,10163,10306|10315|10276|10267|10324|10309|10303|10291|10297|10312|10261|10333|10252|10288|10264|10270|10321|10327|10273|10330|10318|10285,6.05E-18,,GOCC:0031981,1.415739076,0,14.15739076
322,14,TISSUES,,Cervical carcinoma cell,1.04E-14,STUB1|SMAD2|RCOR1|CDK2|PLK1|PRKACA|CASP3|SMAD3|E2F1|E2F4|CDK1|AKT1|MYC|CTNNB1,10163,10315|10267|10324|10303|10297|10261|10333|10252|10264|10321|10327|10330|10318|10285,4.27E-18,,BTO:0000180,1.398296666,0,13.98296666
1215,19,Reactome Pathways,,Generic Transcription Pathway,1.08E-13,CSNK2A1|STUB1|RBL2|SMAD2|CASP6|CDK2|TP53|CEBPB|SMAD1|PRKACA|SMAD3|MYB|E2F1|SKI|E2F4|CDK1|AKT1|MYC|CTNNB1,10163,10306|10315|10276|10267|10309|10303|10291|10312|10282|10261|10252|10288|10264|10270|10321|10327|10330|10318|10285,4.74E-17,,HSA-212436,1.296657624,0,12.96657624
78,10,GO Molecular Function,,SMAD binding,1.12E-13,STUB1|SMAD2|SMAD1|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|SMAD5|CTNNB1,10163,10315|10267|10282|10252|10300|10270|10294|10279|10258|10285,2.26E-17,,GO:0046332,1.295078198,0,12.95078198
109,10,WikiPathways,,Androgen receptor network in prostate cancer,2.03E-13,SMAD2|CDK2|TP53|PLK1|CASP3|SMAD3|E2F1|CDK1|AKT1|MYC,10163,10267|10303|10291|10297|10333|10252|10264|10327|10330|10318,5.20E-16,,WP2263,1.269250396,0,12.69250396
120,10,WikiPathways,,Cell cycle,3.36E-13,RBL2|SMAD2|CDK2|TP53|PLK1|SMAD3|E2F1|E2F4|CDK1|MYC,10163,10276|10267|10303|10291|10297|10252|10264|10321|10327|10318,1.29E-15,,WP179,1.247366072,0,12.47366072
120,10,KEGG Pathways,,Cell cycle,4.33E-13,RBL2|SMAD2|CDK2|TP53|PLK1|SMAD3|E2F1|E2F4|CDK1|MYC,10163,10276|10267|10303|10291|10297|10252|10264|10321|10327|10318,1.29E-15,,hsa04110,1.23635121,0,12.3635121
141,10,KEGG Pathways,,Signaling pathways regulating pluripotency of stem cells,1.00E-12,SMAD2|SMAD1|SMAD3|BMPR1A|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10267|10282|10252|10300|10294|10279|10258|10330|10318|10285,5.96E-15,,hsa04550,1.2,0,12
121,10,Reactome Pathways,,Signaling by TGFB family members,1.06E-12,STUB1|SMAD2|SMAD1|SMAD3|BMPR1A|SKI|E2F4|BMPR1B|SMAD5|MYC,10163,10315|10267|10282|10252|10300|10270|10321|10294|10258|10318,1.39E-15,,HSA-9006936,1.197469413,0,11.97469413
150,10,KEGG Pathways,,Cellular senescence,1.09E-12,RBL2|SMAD2|CDK2|TP53|SMAD3|E2F1|E2F4|CDK1|AKT1|MYC,10163,10276|10267|10303|10291|10252|10264|10321|10327|10330|10318,1.07E-14,,hsa04218,1.19625735,0,11.9625735
91,9,KEGG Pathways,,TGF-beta signaling pathway,1.09E-12,SMAD2|SMAD1|SMAD3|BMPR1A|E2F4|BMPR1B|ACVR1|SMAD5|MYC,10163,10267|10282|10252|10300|10321|10294|10279|10258|10318,9.75E-15,,hsa04350,1.19625735,0,11.9625735
2540,22,Reactome Pathways,,Signal Transduction,2.27E-12,CSNK2A1|STUB1|SMAD2|RCOR1|CDK2|TP53|PLK1|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10267|10324|10303|10291|10297|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10258|10330|10318|10285,4.97E-15,,HSA-162582,1.164397414,0,11.64397414
1067,17,TISSUES,,Leukemia cell,4.93E-12,STUB1|RBL2|SMAD2|RCOR1|CDK2|TP53|PLK1|PRKACA|CASP3|SMAD3|MYB|E2F1|E2F4|CDK1|AKT1|MYC|CTNNB1,10163,10315|10276|10267|10324|10303|10291|10297|10261|10333|10252|10288|10264|10321|10327|10330|10318|10285,4.06E-15,,BTO:0001271,1.130715308,0,11.30715308
42,8,STRING Clusters,,"Signaling by BMP, and TGF-beta propeptide",1.29E-11,SMAD2|SMAD1|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|SMAD5,10163,10267|10282|10252|10300|10270|10294|10279|10258,2.83E-15,,CL:21275,1.088941029,0,10.88941029
1582,19,GO Biological Process,,Regulation of cell differentiation,1.56E-11,CYP27B1|SMAD2|RCOR1|TP53|CEBPB|SMAD1|PRKACA|SMAD3|MYB|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10255|10267|10324|10291|10312|10282|10261|10252|10288|10264|10300|10270|10327|10294|10279|10258|10330|10318|10285,5.81E-15,,GO:0045595,1.08068754,0,10.8068754
125,10,GO Biological Process,,Regulation of osteoblast differentiation,1.56E-11,CEBPB|SMAD1|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|SMAD5|CTNNB1,10163,10312|10282|10261|10252|10300|10270|10294|10279|10258|10285,1.90E-15,,GO:0045667,1.08068754,0,10.8068754
3166,24,GO Biological Process,,Positive regulation of nitrogen compound metabolic process,1.56E-11,CSNK2A1|STUB1|SMAD2|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10267|10309|10303|10291|10297|10312|10282|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,9.96E-16,,GO:0051173,1.08068754,0,10.8068754
1069,17,GO Biological Process,,Epithelium development,1.56E-11,SMAD2|CASP6|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|BMPR1A|SKI|E2F4|CDK1|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10267|10309|10291|10312|10282|10261|10333|10252|10300|10270|10321|10327|10279|10258|10330|10318|10285,4.19E-15,,GO:0060429,1.08068754,0,10.8068754
503,14,GO Biological Process,,Response to growth factor,1.56E-11,SMAD2|TP53|SMAD1|CASP3|SMAD3|E2F1|BMPR1A|SKI|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10267|10291|10282|10333|10252|10264|10300|10270|10294|10279|10258|10330|10318|10285,1.74E-15,,GO:0070848,1.08068754,0,10.8068754
5899,28,GO Biological Process,,Regulation of primary metabolic process,1.56E-11,CSNK2A1|STUB1|CYP27B1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,2.28E-15,,GO:0080090,1.08068754,0,10.8068754
3533,24,GO Biological Process,,Positive regulation of macromolecule metabolic process,2.82E-11,CSNK2A1|STUB1|SMAD2|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10267|10309|10303|10291|10297|10312|10282|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,1.26E-14,,GO:0010604,1.054975089,0,10.54975089
132,9,WikiPathways,,TGF-beta signaling pathway,4.52E-11,RBL2|SMAD2|TP53|SMAD3|SKI|E2F4|CDK1|AKT1|MYC,10163,10276|10267|10291|10252|10270|10321|10327|10330|10318,2.31E-13,,WP366,1.034486157,0,10.34486157
1723,19,GO Biological Process,,Tissue development,5.34E-11,CYP27B1|SMAD2|CASP6|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10255|10267|10309|10291|10312|10282|10261|10333|10252|10300|10270|10321|10327|10294|10279|10258|10330|10318|10285,2.73E-14,,GO:0009888,1.027245874,0,10.27245874
473,13,GO Biological Process,,Cellular response to growth factor stimulus,5.34E-11,SMAD2|TP53|SMAD1|CASP3|SMAD3|E2F1|BMPR1A|SKI|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10267|10291|10282|10333|10252|10264|10300|10270|10294|10279|10258|10330|10285,2.81E-14,,GO:0071363,1.027245874,0,10.27245874
5584,27,GO Biological Process,,Positive regulation of cellular process,5.52E-11,CSNK2A1|STUB1|CYP27B1|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,3.52E-14,,GO:0048522,1.025806092,0,10.25806092
5681,27,GO Biological Process,,Regulation of cellular metabolic process,7.93E-11,CSNK2A1|STUB1|CYP27B1|RBL2|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10276|10267|10324|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,5.56E-14,,GO:0031323,1.010072681,0,10.10072681
5734,27,GO Biological Process,,Regulation of nitrogen compound metabolic process,9.30E-11,CSNK2A1|STUB1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,7.11E-14,,GO:0051171,1.003151705,0,10.03151705
1103,16,GO Biological Process,,Cellular response to endogenous stimulus,1.73E-10,SMAD2|CASP6|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10267|10309|10291|10312|10282|10261|10333|10252|10264|10300|10270|10294|10279|10258|10330|10285,1.65E-13,,GO:0071495,0.97619539,0,9.761953897
206,10,GO Biological Process,,Transmembrane receptor protein serine/threonine kinase signaling pathway,2.10E-10,STUB1|SMAD2|TP53|SMAD1|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|SMAD5,10163,10315|10267|10291|10282|10252|10300|10270|10294|10279|10258,2.22E-13,,GO:0007178,0.967778071,0,9.677780705
1363,17,GO Biological Process,,Response to endogenous stimulus,2.10E-10,CYP27B1|SMAD2|CASP6|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10255|10267|10309|10291|10312|10282|10261|10333|10252|10264|10300|10270|10294|10279|10258|10330|10285,2.15E-13,,GO:0009719,0.967778071,0,9.677780705
1669,18,GO Biological Process,,Regulation of cell population proliferation,2.73E-10,CSNK2A1|CYP27B1|SMAD2|CDK2|TP53|CEBPB|SMAD1|CASP3|SMAD3|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|AKT1|MYC|CTNNB1,10163,10306|10255|10267|10303|10291|10312|10282|10333|10252|10264|10300|10270|10321|10327|10294|10330|10318|10285,3.13E-13,,GO:0042127,0.956383735,0,9.563837353
3114,22,GO Biological Process,,Positive regulation of cellular metabolic process,2.94E-10,STUB1|SMAD2|CDK2|TP53|PLK1|CEBPB|SMAD1|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10315|10267|10303|10291|10297|10312|10282|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,3.56E-13,,GO:0031325,0.953165267,0,9.53165267
4736,25,GO Biological Process,,Negative regulation of cellular process,4.10E-10,CSNK2A1|STUB1|CYP27B1|RBL2|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10276|10267|10324|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10327|10294|10279|10258|10330|10318|10285,5.23E-13,,GO:0048523,0.938721614,0,9.387216143
2056,19,GO Biological Process,,Positive regulation of nucleobase-containing compound metabolic process,4.68E-10,SMAD2|CDK2|TP53|CEBPB|SMAD1|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10267|10303|10291|10312|10282|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10258|10330|10318|10285,6.56E-13,,GO:0045935,0.932975415,0,9.329754147
6249,27,GO Biological Process,,Regulation of macromolecule metabolic process,4.75E-10,CSNK2A1|STUB1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,6.96E-13,,GO:0060255,0.932330639,0,9.32330639
4169,24,GO Cellular Component,,Nucleoplasm,5.80E-10,CSNK2A1|STUB1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|SKI|E2F4|CDK1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10270|10321|10327|10273|10258|10330|10318|10285,5.67E-13,,GO:0005654,0.923657201,0,9.236572006
5506,26,GO Cellular Component,,Protein-containing complex,5.81E-10,CSNK2A1|STUB1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10258|10330|10318|10285,8.52E-13,,GO:0032991,0.923582387,0,9.235823868
1250,16,GO Biological Process,,Positive regulation of transcription by RNA polymerase II,7.20E-10,SMAD2|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10267|10291|10312|10282|10252|10288|10264|10300|10270|10321|10294|10279|10258|10330|10318|10285,1.10E-12,,GO:0045944,0.91426675,0,9.142667504
114,8,WikiPathways,,CKAP4 signaling pathway map,7.42E-10,TP53|CASP3|SMAD3|E2F1|CDK1|AKT1|MYC|CTNNB1,10163,10291|10333|10252|10264|10327|10330|10318|10285,4.75E-12,,WP5322,0.912959609,0,9.129596095
641,13,GO Biological Process,,Enzyme-linked receptor protein signaling pathway,7.72E-10,STUB1|SMAD2|TP53|SMAD1|CASP3|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10315|10267|10291|10282|10333|10252|10300|10270|10294|10279|10258|10330|10285,1.23E-12,,GO:0007167,0.91123827,0,9.1123827
96,8,GO Biological Process,,Transforming growth factor beta receptor signaling pathway,7.80E-10,SMAD2|TP53|SMAD1|SMAD3|BMPR1A|SKI|ACVR1|SMAD5,10163,10267|10291|10282|10252|10300|10270|10279|10258,1.29E-12,,GO:0007179,0.91079054,0,9.107905397
256,10,GO Cellular Component,,RNA polymerase II transcription regulator complex,9.10E-10,SMAD2|CEBPB|SMAD1|SMAD3|MYB|E2F1|E2F4|SMAD5|MYC|CTNNB1,10163,10267|10312|10282|10252|10288|10264|10321|10258|10318|10285,1.78E-12,,GO:0090575,0.904095861,0,9.040958608
69,7,WikiPathways,,DNA damage response,1.37E-09,CDK2|TP53|CASP3|E2F1|CDK1|AKT1|MYC,10163,10303|10291|10333|10264|10327|10330|10318,1.05E-11,,WP707,0.886327943,0,8.863279433
2586,20,GO Biological Process,,Regulation of transcription by RNA polymerase II,1.48E-09,RBL2|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|SMAD1|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10276|10267|10324|10303|10291|10297|10312|10282|10252|10288|10264|10300|10270|10321|10294|10279|10258|10330|10318|10285,2.63E-12,,GO:0006357,0.882973828,0,8.829738285
2982,21,GO Biological Process,,Negative regulation of metabolic process,1.48E-09,CSNK2A1|CYP27B1|RBL2|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|SMAD1|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|CDK1|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10255|10276|10267|10324|10303|10291|10297|10312|10282|10333|10252|10288|10264|10300|10270|10327|10258|10330|10318|10285,2.55E-12,,GO:0009892,0.882973828,0,8.829738285
72,7,WikiPathways,,Chromosomal and microsatellite instability in colorectal cancer ,1.55E-09,SMAD2|TP53|CASP3|SMAD3|AKT1|MYC|CTNNB1,10163,10267|10291|10333|10252|10330|10318|10285,1.39E-11,,WP4216,0.88096683,0,8.809668302
876,14,GO Biological Process,,Positive regulation of cell differentiation,1.56E-09,CYP27B1|SMAD2|RCOR1|CEBPB|SMAD1|SMAD3|MYB|E2F1|BMPR1A|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10255|10267|10324|10312|10282|10252|10288|10264|10300|10294|10279|10258|10330|10285,2.91E-12,,GO:0045597,0.88068754,0,8.806875402
1332,16,GO Biological Process,,Positive regulation of developmental process,1.56E-09,CYP27B1|SMAD2|RCOR1|CEBPB|SMAD1|SMAD3|MYB|E2F1|BMPR1A|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10255|10267|10324|10312|10282|10252|10288|10264|10300|10327|10294|10279|10258|10330|10318|10285,2.88E-12,,GO:0051094,0.88068754,0,8.806875402
2609,20,GO Biological Process,,Cellular response to chemical stimulus,1.57E-09,STUB1|SMAD2|CASP6|CDK2|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10315|10267|10309|10303|10291|10312|10282|10261|10333|10252|10264|10300|10270|10327|10294|10279|10258|10330|10318|10285,3.11E-12,,GO:0070887,0.880410035,0,8.804100348
27,6,Reactome Pathways,,G0 and Early G1,1.89E-09,RBL2|CDK2|E2F1|E2F4|CDK1|MYC,10163,10276|10303|10264|10321|10327|10318,4.97E-12,,HSA-1538133,0.87235382,0,8.723538196
82,7,KEGG Pathways,,Colorectal cancer,2.10E-09,SMAD2|TP53|CASP3|SMAD3|AKT1|MYC|CTNNB1,10163,10267|10291|10333|10252|10330|10318|10285,3.28E-11,,hsa05210,0.867778071,0,8.677780705
146,8,KEGG Pathways,,Gastric cancer,2.10E-09,SMAD2|CDK2|TP53|SMAD3|E2F1|AKT1|MYC|CTNNB1,10163,10267|10303|10291|10252|10264|10330|10318|10285,3.13E-11,,hsa05226,0.867778071,0,8.677780705
2692,20,GO Biological Process,,Response to organic substance,2.65E-09,STUB1|CYP27B1|SMAD2|CASP6|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10315|10255|10267|10309|10291|10312|10282|10261|10333|10252|10264|10300|10270|10327|10294|10279|10258|10330|10318|10285,5.59E-12,,GO:0010033,0.857675413,0,8.576754126
1389,16,GO Biological Process,,Regulation of multicellular organismal development,2.65E-09,CYP27B1|RCOR1|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|AKT1|MYC|CTNNB1,10163,10255|10324|10291|10312|10282|10252|10288|10264|10300|10270|10327|10294|10279|10330|10318|10285,5.41E-12,,GO:2000026,0.857675413,0,8.576754126
5325,25,COMPARTMENTS,,Protein-containing complex,3.32E-09,CSNK2A1|STUB1|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10327|10294|10279|10273|10258|10330|10318|10285,8.67E-12,,GOCC:0032991,0.847886192,0,8.478861916
2019,18,GO Biological Process,,Cellular response to organic substance,3.64E-09,STUB1|SMAD2|CASP6|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10315|10267|10309|10291|10312|10282|10261|10333|10252|10264|10300|10270|10327|10294|10279|10258|10330|10285,7.88E-12,,GO:0071310,0.843889862,0,8.438898616
2760,20,GO Biological Process,,Negative regulation of macromolecule metabolic process,3.65E-09,CSNK2A1|RBL2|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|SMAD1|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|CDK1|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10276|10267|10324|10303|10291|10297|10312|10282|10333|10252|10288|10264|10300|10270|10327|10258|10330|10318|10285,8.91E-12,,GO:0010605,0.843770714,0,8.437707136
1710,17,GO Biological Process,,"Positive regulation of transcription, DNA-templated",3.65E-09,SMAD2|CDK2|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10267|10303|10291|10312|10282|10252|10288|10264|10300|10270|10321|10294|10279|10258|10330|10318|10285,8.14E-12,,GO:0045893,0.843770714,0,8.437707136
68,7,GO Biological Process,,Positive regulation of osteoblast differentiation,3.75E-09,CEBPB|SMAD1|BMPR1A|BMPR1B|ACVR1|SMAD5|CTNNB1,10163,10312|10282|10300|10294|10279|10258|10285,9.57E-12,,GO:0045669,0.842596873,0,8.425968732
4787,24,COMPARTMENTS,,Nucleus,4.37E-09,CSNK2A1|STUB1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|SKI|E2F4|CDK1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10270|10321|10327|10273|10258|10330|10318|10285,1.33E-11,,GOCC:0005634,0.835951856,0,8.359518563
442,11,TISSUES,,Bone marrow cancer cell,7.60E-09,STUB1|SMAD2|RCOR1|PLK1|CASP3|SMAD3|MYB|E2F4|CDK1|AKT1|MYC,10163,10315|10267|10324|10297|10333|10252|10288|10321|10327|10330|10318,1.25E-11,,BTO:0000583,0.811918641,0,8.119186408
67,7,STRING Clusters,,"Mixed, incl. G1 Phase, and G0 and Early G1",7.95E-09,RBL2|CDK2|TP53|E2F1|E2F4|CDK1|MYC,10163,10276|10303|10291|10264|10321|10327|10318,8.69E-12,,CL:6897,0.809963287,0,8.099632871
54,6,WikiPathways,,TGF-beta receptor signaling,2.14E-08,SMAD2|SMAD1|SMAD3|SKI|SMAD5|CTNNB1,10163,10267|10282|10252|10270|10258|10285,2.19E-10,,WP560,0.766958623,0,7.669586227
244,9,TISSUES,,Erythroleukemia cell,2.21E-08,STUB1|RCOR1|PLK1|CASP3|MYB|E2F4|CDK1|AKT1|MYC,10163,10315|10324|10297|10333|10288|10321|10327|10330|10318,4.55E-11,,BTO:0000426,0.765560773,0,7.655607726
92,7,GO Biological Process,,BMP signaling pathway,2.39E-08,SMAD2|SMAD1|SMAD3|BMPR1A|BMPR1B|ACVR1|SMAD5,10163,10267|10282|10252|10300|10294|10279|10258,7.02E-11,,GO:0030509,0.76216021,0,7.621602099
210,8,KEGG Pathways,,Human T-cell leukemia virus 1 infection,2.41E-08,SMAD2|CDK2|TP53|PRKACA|SMAD3|E2F1|AKT1|MYC,10163,10267|10303|10291|10261|10252|10264|10330|10318,5.03E-10,,hsa05166,0.761798296,0,7.617982957
526,11,Reactome Pathways,,"Cell Cycle, Mitotic",2.53E-08,CSNK2A1|RBL2|CDK2|TP53|PLK1|PRKACA|E2F1|E2F4|CDK1|AKT1|MYC,10163,10306|10276|10303|10291|10297|10261|10264|10321|10327|10330|10318,7.76E-11,,HSA-69278,0.759687948,0,7.596879479
129,7,KEGG Pathways,,Fluid shear stress and atherosclerosis,2.79E-08,TP53|BMPR1A|BMPR1B|ACVR1|SUMO2|AKT1|CTNNB1,10163,10291|10300|10294|10279|10273|10330|10285,6.65E-10,,hsa05418,0.75543958,0,7.554395797
116,7,WikiPathways,,Embryonic stem cell pluripotency pathways,2.83E-08,SMAD1|BMPR1A|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10282|10300|10294|10279|10258|10330|10285,3.27E-10,,WP3931,0.754821356,0,7.548213564
58,6,WikiPathways,,TGF-beta receptor signaling in skeletal dysplasias,2.83E-08,SMAD2|SMAD1|SMAD3|SKI|SMAD5|CTNNB1,10163,10267|10282|10252|10270|10258|10285,3.27E-10,,WP4816,0.754821356,0,7.548213564
167,8,GO Biological Process,,Gastrulation,2.91E-08,SMAD2|TP53|SMAD1|PRKACA|SMAD3|BMPR1A|ACVR1|CTNNB1,10163,10267|10291|10282|10261|10252|10300|10279|10285,8.73E-11,,GO:0007369,0.753610701,0,7.536107011
4074,22,GO Biological Process,,Regulation of nucleobase-containing compound metabolic process,3.01E-08,RBL2|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|SMAD1|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10276|10267|10324|10303|10291|10297|10312|10282|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10258|10330|10318|10285,9.20E-11,,GO:0019219,0.75214335,0,7.521433504
713,12,GO Biological Process,,Negative regulation of cell population proliferation,3.15E-08,CYP27B1|SMAD2|TP53|CEBPB|SMAD1|CASP3|SMAD3|E2F1|SKI|BMPR1B|MYC|CTNNB1,10163,10255|10267|10291|10312|10282|10333|10252|10264|10270|10294|10318|10285,9.83E-11,,GO:0008285,0.750168945,0,7.501689446
48,6,GO Biological Process,,Positive regulation of miRNA transcription,3.56E-08,TP53|SMAD1|SMAD3|MYB|BMPR1A|MYC,10163,10291|10282|10252|10288|10300|10318,1.14E-10,,GO:1902895,0.744855,0,7.448550002
49,6,Reactome Pathways,,TP53 Regulates Transcription of Cell Cycle Genes,3.64E-08,RBL2|CDK2|TP53|E2F1|E2F4|CDK1,10163,10276|10303|10291|10264|10321|10327,1.27E-10,,HSA-6791312,0.743889862,0,7.438898616
736,12,GO Biological Process,,Protein phosphorylation,4.25E-08,CSNK2A1|SMAD2|CDK2|PLK1|SMAD1|PRKACA|BMPR1A|CDK1|BMPR1B|ACVR1|SMAD5|AKT1,10163,10306|10267|10303|10297|10282|10261|10300|10327|10294|10279|10258|10330,1.41E-10,,GO:0006468,0.737161107,0,7.37161107
515,10,KEGG Pathways,,Pathways in cancer,5.21E-08,SMAD2|CDK2|TP53|PRKACA|CASP3|SMAD3|E2F1|AKT1|MYC|CTNNB1,10163,10267|10303|10291|10261|10333|10252|10264|10330|10318|10285,1.40E-09,,hsa05200,0.728316228,0,7.283162277
3246,20,GO Biological Process,,Animal organ development,5.32E-08,CYP27B1|SMAD2|RCOR1|TP53|CEBPB|SMAD1|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10255|10267|10324|10291|10312|10282|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10258|10330|10318|10285,1.81E-10,,GO:0048513,0.727408837,0,7.274088368
16,5,STRING Clusters,,"Dwarfin, and E3 ubiquitin-protein ligase, SMURF1 type",6.03E-08,SMAD2|SMAD1|SMAD3|SKI|SMAD5,10163,10267|10282|10252|10270|10258,7.91E-11,,CL:21327,0.721968269,0,7.219682688
1504,15,GO Biological Process,,Reproductive process,7.19E-08,CYP27B1|CDK2|PLK1|CEBPB|SMAD1|PRKACA|CASP3|E2F1|BMPR1A|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10255|10303|10297|10312|10282|10261|10333|10264|10300|10327|10294|10279|10258|10330|10285,2.66E-10,,GO:0022414,0.714327111,0,7.14327111
71,6,WikiPathways,,miRNA regulation of DNA damage response,7.24E-08,CDK2|TP53|CASP3|E2F1|CDK1|MYC,10163,10303|10291|10333|10264|10327|10318,1.02E-09,,WP1530,0.714026143,0,7.140261434
154,7,KEGG Pathways,,Hippo signaling pathway,7.29E-08,SMAD2|SMAD1|SMAD3|BMPR1A|BMPR1B|MYC|CTNNB1,10163,10267|10282|10252|10300|10294|10318|10285,2.17E-09,,hsa04390,0.713727247,0,7.137272472
157,7,KEGG Pathways,,Hepatitis C,7.54E-08,CDK2|TP53|CASP3|E2F1|AKT1|MYC|CTNNB1,10163,10303|10291|10333|10264|10330|10318|10285,2.47E-09,,hsa05160,0.712262865,0,7.122628654
158,7,KEGG Pathways,,Hepatitis B,7.54E-08,CDK2|TP53|CASP3|SMAD3|E2F1|AKT1|MYC,10163,10303|10291|10333|10252|10264|10330|10318,2.57E-09,,hsa05161,0.712262865,0,7.122628654
161,7,KEGG Pathways,,Hepatocellular carcinoma,7.54E-08,SMAD2|TP53|SMAD3|E2F1|AKT1|MYC|CTNNB1,10163,10267|10291|10252|10264|10330|10318|10285,2.92E-09,,hsa05225,0.712262865,0,7.122628654
1512,15,GO Biological Process,,Positive regulation of protein metabolic process,7.61E-08,CSNK2A1|STUB1|CASP6|TP53|PLK1|CASP3|SMAD3|MYB|BMPR1A|BMPR1B|ACVR1|SUMO2|AKT1|MYC|CTNNB1,10163,10306|10315|10309|10291|10297|10333|10252|10288|10300|10294|10279|10273|10330|10318|10285,2.86E-10,,GO:0051247,0.711861534,0,7.118615343
1518,15,GO Biological Process,,Intracellular signal transduction,7.78E-08,SMAD2|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|CDK1|AKT1|MYC|CTNNB1,10163,10267|10309|10303|10291|10297|10312|10282|10261|10333|10252|10264|10327|10330|10318|10285,3.02E-10,,GO:0035556,0.71090204,0,7.109020403
419,10,TISSUES,,Lymphocytic leukemia cell,7.97E-08,STUB1|RBL2|RCOR1|CDK2|TP53|PRKACA|E2F1|CDK1|AKT1|CTNNB1,10163,10315|10276|10324|10303|10291|10261|10264|10327|10330|10285,1.97E-10,,BTO:0000744,0.709854168,0,7.098541679
119,7,GO Biological Process,,Formation of primary germ layer,9.82E-08,SMAD2|SMAD1|PRKACA|SMAD3|BMPR1A|ACVR1|CTNNB1,10163,10267|10282|10261|10252|10300|10279|10285,3.88E-10,,GO:0001704,0.700788851,0,7.007888512
455,10,GO Biological Process,,Pattern specification process,1.07E-07,SMAD2|TP53|SMAD1|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|SMAD5|CTNNB1,10163,10267|10291|10282|10252|10300|10270|10294|10279|10258|10285,4.32E-10,,GO:0007389,0.697061622,0,6.970616222
92,6,KEGG Pathways,,Small cell lung cancer,1.07E-07,CDK2|TP53|CASP3|E2F1|AKT1|MYC,10163,10303|10291|10333|10264|10330|10318,4.44E-09,,hsa05222,0.697061622,0,6.970616222
14,5,GO Molecular Function,,I-SMAD binding,1.12E-07,SMAD2|SMAD1|SMAD3|SMAD5|CTNNB1,10163,10267|10282|10252|10258|10285,4.53E-11,,GO:0070411,0.695078198,0,6.950781977
1049,13,GO Biological Process,,Embryo development,1.26E-07,SMAD2|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|BMPR1A|SKI|ACVR1|SMAD5|AKT1|CTNNB1,10163,10267|10291|10312|10282|10261|10333|10252|10300|10270|10279|10258|10330|10285,5.22E-10,,GO:0009790,0.689962945,0,6.899629455
2622,18,GO Biological Process,,Regulation of protein metabolic process,1.42E-07,CSNK2A1|STUB1|CASP6|CDK2|TP53|PLK1|PRKACA|CASP3|SMAD3|MYB|BMPR1A|SKI|BMPR1B|ACVR1|SUMO2|AKT1|MYC|CTNNB1,10163,10306|10315|10309|10303|10291|10297|10261|10333|10252|10288|10300|10270|10294|10279|10273|10330|10318|10285,6.17E-10,,GO:0051246,0.684771166,0,6.847711656
2265,17,GO Biological Process,,Negative regulation of cellular metabolic process,1.54E-07,CSNK2A1|CYP27B1|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|CASP3|SMAD3|MYB|E2F1|SKI|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10255|10267|10324|10303|10291|10297|10312|10333|10252|10288|10264|10270|10258|10330|10318|10285,6.86E-10,,GO:0031324,0.681247928,0,6.812479279
3507,20,GO Biological Process,,Cell differentiation,1.66E-07,RBL2|SMAD2|RCOR1|CASP6|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10276|10267|10324|10309|10291|10312|10282|10261|10333|10252|10288|10300|10270|10321|10327|10294|10279|10258|10330|10285,7.52E-10,,GO:0030154,0.677989191,0,6.779891912
654,11,GO Biological Process,,Chordate embryonic development,1.66E-07,SMAD2|TP53|CEBPB|PRKACA|CASP3|SMAD3|BMPR1A|SKI|ACVR1|AKT1|CTNNB1,10163,10267|10291|10312|10261|10333|10252|10300|10270|10279|10330|10285,7.49E-10,,GO:0043009,0.677989191,0,6.779891912
4010,21,GO Biological Process,,Response to chemical,1.78E-07,STUB1|CYP27B1|SMAD2|CASP6|CDK2|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10315|10255|10267|10309|10303|10291|10312|10282|10261|10333|10252|10264|10300|10270|10327|10294|10279|10258|10330|10318|10285,8.26E-10,,GO:0042221,0.674958,0,6.749579998
27,5,Reactome Pathways,,Signaling by BMP,1.78E-07,SMAD1|BMPR1A|SKI|BMPR1B|SMAD5,10163,10282|10300|10270|10294|10258,7.75E-10,,HSA-201451,0.674958,0,6.749579998
130,7,Reactome Pathways,,G1/S Transition,1.78E-07,RBL2|CDK2|E2F1|E2F4|CDK1|AKT1|MYC,10163,10276|10303|10264|10321|10327|10330|10318,7.00E-10,,HSA-69206,0.674958,0,6.749579998
70,6,GO Biological Process,,Mesoderm formation,1.97E-07,SMAD2|SMAD1|PRKACA|SMAD3|BMPR1A|ACVR1,10163,10267|10282|10261|10252|10300|10279,9.42E-10,,GO:0001707,0.670553377,0,6.705533774
1108,13,GO Biological Process,,Regulation of cell cycle,2.09E-07,CSNK2A1|RBL2|CDK2|TP53|PLK1|PRKACA|CASP3|E2F1|CDK1|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10276|10303|10291|10297|10261|10333|10264|10327|10279|10330|10318|10285,1.01E-09,,GO:0051726,0.667985371,0,6.679853714
37,5,WikiPathways,,Neovascularisation processes,2.11E-07,SMAD2|SMAD1|SMAD3|SMAD5|AKT1,10163,10267|10282|10252|10258|10330,3.24E-09,,WP4331,0.667571754,0,6.675717545
880,12,GO Biological Process,,Tube development,2.15E-07,SMAD2|SMAD1|PRKACA|CASP3|SMAD3|BMPR1A|SKI|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10267|10282|10261|10333|10252|10300|10270|10279|10258|10330|10318|10285,1.06E-09,,GO:0035295,0.666756154,0,6.66756154
194,7,KEGG Pathways,,Proteoglycans in cancer,2.27E-07,SMAD2|TP53|PRKACA|CASP3|AKT1|MYC|CTNNB1,10163,10267|10291|10261|10333|10330|10318|10285,1.01E-08,,hsa05205,0.664397414,0,6.643974143
141,7,GO Biological Process,,Osteoblast differentiation,2.34E-07,SMAD1|SMAD3|BMPR1A|BMPR1B|SMAD5|AKT1|CTNNB1,10163,10282|10252|10300|10294|10258|10330|10285,1.20E-09,,GO:0001649,0.663078414,0,6.630784143
359,9,GO Biological Process,,Negative regulation of cell cycle,2.40E-07,RBL2|CDK2|TP53|PLK1|CASP3|E2F1|CDK1|ACVR1|CTNNB1,10163,10276|10303|10291|10297|10333|10264|10327|10279|10285,1.25E-09,,GO:0045786,0.661978876,0,6.619788758
361,9,Reactome Pathways,,Transcriptional Regulation by TP53,2.50E-07,CSNK2A1|RBL2|CASP6|CDK2|TP53|E2F1|E2F4|CDK1|AKT1,10163,10306|10276|10309|10303|10291|10264|10321|10327|10330,1.31E-09,,HSA-3700989,0.660205999,0,6.602059991
2749,18,GO Biological Process,,Regulation of multicellular organismal process,2.54E-07,CYP27B1|SMAD2|RCOR1|TP53|CEBPB|SMAD1|PRKACA|SMAD3|MYB|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|AKT1|MYC|CTNNB1,10163,10255|10267|10324|10291|10312|10282|10261|10252|10288|10264|10300|10270|10327|10294|10279|10330|10318|10285,1.34E-09,,GO:0051239,0.659516628,0,6.595166283
27,5,TISSUES,,Colonic adenocarcinoma cell line,2.69E-07,TP53|CASP3|AKT1|MYC|CTNNB1,10163,10291|10333|10330|10318|10285,7.75E-10,,BTO:0001913,0.657024772,0,6.57024772
324,8,KEGG Pathways,,Human papillomavirus infection,2.88E-07,RBL2|CDK2|TP53|PRKACA|CASP3|E2F1|AKT1|CTNNB1,10163,10276|10303|10291|10261|10333|10264|10330|10285,1.37E-08,,hsa05165,0.654060751,0,6.540607512
4143,21,GO Biological Process,,Regulation of cellular biosynthetic process,2.89E-07,CYP27B1|RBL2|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|SMAD1|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10255|10276|10267|10324|10303|10291|10297|10312|10282|10252|10288|10264|10300|10270|10321|10294|10279|10258|10330|10318|10285,1.55E-09,,GO:0031326,0.653910216,0,6.539102157
2084,17,GO Molecular Function,,Enzyme binding,3.06E-07,STUB1|SMAD2|RCOR1|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|SKI|ACVR1|SUMO2|SMAD5|AKT1|CTNNB1,10163,10315|10267|10324|10291|10297|10312|10282|10261|10333|10252|10264|10270|10279|10273|10258|10330|10285,1.86E-10,,GO:0019899,0.651427857,0,6.514278574
95,6,WikiPathways,,Small cell lung cancer,3.20E-07,CDK2|TP53|CASP3|E2F1|AKT1|MYC,10163,10303|10291|10333|10264|10330|10318,5.33E-09,,WP4658,0.649485002,0,6.494850022
7,4,TISSUES,,Colorectal cancer cell,3.23E-07,TP53|AKT1|MYC|CTNNB1,10163,10291|10330|10318|10285,1.06E-09,,BTO:0001615,0.649079748,0,6.490797478
4714,22,GO Biological Process,,Signal transduction,3.29E-07,CSNK2A1|STUB1|SMAD2|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10267|10309|10303|10291|10297|10312|10282|10261|10333|10252|10264|10300|10270|10327|10294|10279|10258|10330|10318|10285,1.78E-09,,GO:0007165,0.64828041,0,6.482804102
375,9,GO Biological Process,,Regulation of binding,3.32E-07,STUB1|SMAD2|PLK1|PRKACA|SMAD3|E2F1|SKI|AKT1|CTNNB1,10163,10315|10267|10297|10261|10252|10264|10270|10330|10285,1.82E-09,,GO:0051098,0.647886192,0,6.478861916
716,11,GO Biological Process,,Regulation of cell cycle process,3.45E-07,CSNK2A1|RBL2|CDK2|TP53|PLK1|E2F1|CDK1|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10276|10303|10291|10297|10264|10327|10279|10330|10318|10285,1.91E-09,,GO:0010564,0.64621809,0,6.462180905
785,12,GO Molecular Function,,Kinase binding,3.60E-07,STUB1|TP53|PLK1|CEBPB|SMAD1|PRKACA|SMAD3|E2F1|SKI|ACVR1|AKT1|CTNNB1,10163,10315|10291|10297|10312|10282|10261|10252|10264|10270|10279|10330|10285,2.92E-10,,GO:0019900,0.64436975,0,6.443697499
8,4,GO Cellular Component,,Heteromeric SMAD protein complex,3.63E-07,SMAD2|SMAD1|SMAD3|SMAD5,10163,10267|10282|10252|10258,1.59E-09,,GO:0071144,0.644009337,0,6.440093375
82,6,Reactome Pathways,,Cyclin E associated events during G1/S transition,3.76E-07,RBL2|CDK2|E2F1|E2F4|AKT1|MYC,10163,10276|10303|10264|10321|10330|10318,2.31E-09,,HSA-69202,0.642481216,0,6.424812155
84,6,Reactome Pathways,,Cyclin A:Cdk2-associated events at S phase entry,4.03E-07,RBL2|CDK2|E2F1|E2F4|AKT1|MYC,10163,10276|10303|10264|10321|10330|10318,2.65E-09,,HSA-69656,0.639469495,0,6.394694954
1462,14,GO Biological Process,,Regulation of apoptotic process,4.22E-07,CSNK2A1|CASP6|TP53|PLK1|CEBPB|CASP3|SMAD3|E2F1|CDK1|BMPR1B|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10309|10291|10297|10312|10333|10252|10264|10327|10294|10279|10330|10318|10285,2.40E-09,,GO:0042981,0.637468755,0,6.374687549
217,7,KEGG Pathways,,Human cytomegalovirus infection,4.23E-07,TP53|PRKACA|CASP3|E2F1|AKT1|MYC|CTNNB1,10163,10291|10261|10333|10264|10330|10318|10285,2.14E-08,,hsa05163,0.637365963,0,6.373659633
317,9,GO Molecular Function,,Ubiquitin-like protein ligase binding,4.26E-07,STUB1|SMAD2|TP53|CEBPB|PRKACA|SMAD3|SKI|SUMO2|SMAD5,10163,10315|10267|10291|10312|10261|10252|10270|10273|10258,4.31E-10,,GO:0044389,0.63705904,0,6.370590401
548,10,GO Biological Process,,Heart development,4.37E-07,SMAD2|TP53|SMAD1|CASP3|SMAD3|BMPR1A|CDK1|ACVR1|SMAD5|CTNNB1,10163,10267|10291|10282|10333|10252|10300|10327|10279|10258|10285,2.51E-09,,GO:0007507,0.635951856,0,6.359518563
739,11,GO Biological Process,,Regulation of proteolysis,4.57E-07,CSNK2A1|STUB1|CASP6|CDK2|TP53|PLK1|PRKACA|SMAD3|SUMO2|AKT1|MYC,10163,10306|10315|10309|10303|10291|10297|10261|10252|10273|10330|10318,2.65E-09,,GO:0030162,0.63400838,0,6.3400838
87,6,GO Biological Process,,Ureteric bud development,5.33E-07,SMAD2|SMAD1|SMAD3|SMAD5|MYC|CTNNB1,10163,10267|10282|10252|10258|10318|10285,3.23E-09,,GO:0001657,0.627327279,0,6.273272791
565,10,GO Biological Process,,Tissue morphogenesis,5.47E-07,SMAD2|SMAD1|PRKACA|CASP3|SMAD3|BMPR1A|SKI|ACVR1|MYC|CTNNB1,10163,10267|10282|10261|10333|10252|10300|10270|10279|10318|10285,3.35E-09,,GO:0048729,0.626201267,0,6.262012674
1505,14,GO Biological Process,,Positive regulation of multicellular organismal process,5.57E-07,CYP27B1|SMAD2|CEBPB|SMAD1|SMAD3|MYB|E2F1|BMPR1A|CDK1|BMPR1B|ACVR1|AKT1|MYC|CTNNB1,10163,10255|10267|10312|10282|10252|10288|10264|10300|10327|10294|10279|10330|10318|10285,3.48E-09,,GO:0051240,0.62541448,0,6.254144805
48,5,WikiPathways,,Hepatitis C and hepatocellular carcinoma,6.03E-07,TP53|CASP3|SMAD3|AKT1|MYC,10163,10291|10333|10252|10330|10318,1.08E-08,,WP3646,0.621968269,0,6.219682688
4899,22,GO Biological Process,,Regulation of gene expression,6.07E-07,RBL2|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10276|10267|10324|10303|10291|10297|10312|10282|10261|10252|10288|10264|10300|10270|10321|10327|10294|10279|10258|10330|10318|10285,3.87E-09,,GO:0010468,0.621681131,0,6.216811309
109,6,WikiPathways,,DNA damage response (only ATM dependent),6.08E-07,RBL2|TP53|SMAD3|AKT1|MYC|CTNNB1,10163,10276|10291|10252|10330|10318|10285,1.17E-08,,WP710,0.621609642,0,6.216096421
92,6,Reactome Pathways,,Signaling by TGF-beta Receptor Complex,6.33E-07,STUB1|SMAD2|SMAD3|SKI|E2F4|MYC,10163,10315|10267|10252|10270|10321|10318,4.44E-09,,HSA-170834,0.619859629,0,6.19859629
3867,20,GO Biological Process,,System development,6.89E-07,CYP27B1|SMAD2|RCOR1|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10255|10267|10324|10291|10312|10282|10261|10333|10252|10288|10264|10300|10270|10327|10294|10279|10258|10330|10318|10285,4.46E-09,,GO:0048731,0.616178078,0,6.161780778
951,12,COMPARTMENTS,,Chromosome,7.25E-07,CSNK2A1|RBL2|SMAD2|TP53|PLK1|SMAD3|MYB|E2F1|E2F4|CDK1|MYC|CTNNB1,10163,10306|10276|10267|10291|10297|10252|10288|10264|10321|10327|10318|10285,2.52E-09,,GOCC:0005694,0.613966199,0,6.139661993
590,10,GO Biological Process,,Embryonic morphogenesis,7.67E-07,SMAD2|TP53|SMAD1|PRKACA|CASP3|SMAD3|BMPR1A|SKI|ACVR1|CTNNB1,10163,10267|10291|10282|10261|10333|10252|10300|10270|10279|10285,5.03E-09,,GO:0048598,0.611520464,0,6.115204636
115,6,WikiPathways,,Spinal cord injury,7.74E-07,CDK2|TP53|CASP3|E2F1|CDK1|MYC,10163,10303|10291|10333|10264|10327|10318,1.59E-08,,WP2431,0.611125904,0,6.111259039
287,8,GO Biological Process,,Ossification,8.22E-07,CYP27B1|SMAD1|SMAD3|BMPR1A|BMPR1B|SMAD5|AKT1|CTNNB1,10163,10255|10282|10252|10300|10294|10258|10330|10285,5.45E-09,,GO:0001503,0.608512818,0,6.085128182
1850,15,GO Cellular Component,,Chromosome,8.64E-07,CSNK2A1|RBL2|SMAD2|CDK2|TP53|PLK1|CEBPB|SMAD1|SMAD3|E2F1|E2F4|CDK1|SMAD5|MYC|CTNNB1,10163,10306|10276|10267|10303|10291|10297|10312|10282|10252|10264|10321|10327|10258|10318|10285,4.64E-09,,GO:0005694,0.606348626,0,6.063486258
2229,16,GO Biological Process,,Anatomical structure morphogenesis,8.92E-07,SMAD2|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|BMPR1A|SKI|E2F4|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10267|10291|10312|10282|10261|10333|10252|10300|10270|10321|10294|10279|10258|10330|10318|10285,5.97E-09,,GO:0009653,0.604963515,0,6.049635146
55,5,WikiPathways,,Overlap between signal transduction pathways contributing to LMNA laminopathies,9.39E-07,SMAD2|CEBPB|SMAD3|E2F1|CTNNB1,10163,10267|10312|10252|10264|10285,2.04E-08,,WP4879,0.602733441,0,6.027334408
5657,23,GO Biological Process,,Developmental process,1.03E-06,CYP27B1|RBL2|SMAD2|RCOR1|CASP6|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10255|10276|10267|10324|10309|10291|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10258|10330|10318|10285,6.99E-09,,GO:0032502,0.598716278,0,5.987162775
1285,13,GO Cellular Component,,Chromatin,1.03E-06,CSNK2A1|RBL2|SMAD2|TP53|PLK1|CEBPB|SMAD1|SMAD3|E2F1|E2F4|SMAD5|MYC|CTNNB1,10163,10306|10276|10267|10291|10297|10312|10282|10252|10264|10321|10258|10318|10285,6.02E-09,,GO:0000785,0.598716278,0,5.987162775
1592,14,GO Biological Process,,Negative regulation of cellular biosynthetic process,1.05E-06,CYP27B1|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|SMAD3|MYB|E2F1|SKI|SMAD5|MYC|CTNNB1,10163,10255|10267|10324|10303|10291|10297|10312|10252|10288|10264|10270|10258|10318|10285,7.16E-09,,GO:0031327,0.59788107,0,5.978810701
100,6,GO Biological Process,,Regulation of biomineral tissue development,1.05E-06,CYP27B1|CEBPB|SMAD3|BMPR1A|BMPR1B|ACVR1,10163,10255|10312|10252|10300|10294|10279,7.14E-09,,GO:0070167,0.59788107,0,5.978810701
21,5,DISEASES,,Liver cancer,1.17E-06,TP53|CASP3|AKT1|MYC|CTNNB1,10163,10291|10333|10330|10318|10285,2.55E-10,,DOID:3571,0.593181414,0,5.931814138
1322,13,GO Biological Process,,"Negative regulation of transcription, DNA-templated",1.18E-06,SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|SMAD3|MYB|E2F1|SKI|SMAD5|MYC|CTNNB1,10163,10267|10324|10303|10291|10297|10312|10252|10288|10264|10270|10258|10318|10285,8.46E-09,,GO:0045892,0.592811799,0,5.928117993
3085,18,GO Biological Process,,Regulation of molecular function,1.21E-06,CSNK2A1|STUB1|CYP27B1|RBL2|SMAD2|CASP6|TP53|PLK1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|BMPR1B|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10276|10267|10309|10291|10297|10261|10333|10252|10264|10300|10270|10294|10330|10318|10285,8.82E-09,,GO:0065009,0.591721463,0,5.91721463
5117,22,GO Biological Process,,Anatomical structure development,1.24E-06,CYP27B1|SMAD2|RCOR1|CASP6|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10255|10267|10324|10309|10291|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10258|10330|10318|10285,9.26E-09,,GO:0048856,0.590657831,0,5.906578315
71,5,KEGG Pathways,,Pancreatic cancer,1.27E-06,SMAD2|TP53|SMAD3|E2F1|AKT1,10163,10267|10291|10252|10264|10330,6.81E-08,,hsa05212,0.589619628,0,5.896196279
8,4,SMART Domains,,Domain B in dwarfin family proteins,1.31E-06,SMAD2|SMAD1|SMAD3|SMAD5,10163,10267|10282|10252|10258,1.59E-09,,SM00524,0.58827287,0,5.882728704
130,6,WikiPathways,,Adipogenesis,1.39E-06,RBL2|CEBPB|SMAD3|E2F1|E2F4|CTNNB1,10163,10276|10312|10252|10264|10321|10285,3.20E-08,,WP236,0.58569852,0,5.8569852
5781,23,GO Biological Process,,Macromolecule metabolic process,1.47E-06,CSNK2A1|STUB1|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|CTNNB1,10163,10306|10315|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10264|10300|10270|10327|10294|10279|10273|10258|10330|10285,1.10E-08,,GO:0043170,0.583268267,0,5.832682665
12,4,COMPARTMENTS,,SMAD protein complex,1.49E-06,SMAD2|SMAD1|SMAD3|SMAD5,10163,10267|10282|10252|10258,5.84E-09,,GOCC:0071141,0.582681373,0,5.826813732
154,6,KEGG Pathways,,Wnt signaling pathway,1.49E-06,CSNK2A1|TP53|PRKACA|SMAD3|MYC|CTNNB1,10163,10306|10291|10261|10252|10318|10285,8.42E-08,,hsa04310,0.582681373,0,5.826813732
75,5,KEGG Pathways,,Chronic myeloid leukemia,1.49E-06,TP53|SMAD3|E2F1|AKT1|MYC,10163,10291|10252|10264|10330|10318,8.83E-08,,hsa05220,0.582681373,0,5.826813732
861,11,GO Biological Process,,Response to organic cyclic compound,1.65E-06,CYP27B1|SMAD2|CASP6|CEBPB|SMAD1|PRKACA|CASP3|CDK1|ACVR1|SMAD5|CTNNB1,10163,10255|10267|10309|10312|10282|10261|10333|10327|10279|10258|10285,1.27E-08,,GO:0014070,0.578251606,0,5.782516056
390,9,UniProt Keywords,,Serine/threonine-protein kinase,1.71E-06,CSNK2A1|CDK2|PLK1|PRKACA|BMPR1A|CDK1|BMPR1B|ACVR1|AKT1,10163,10306|10303|10297|10261|10300|10327|10294|10279|10330,2.55E-09,,KW-0723,0.576700389,0,5.76700389
64,5,WikiPathways,,Oncostatin M signaling pathway,1.71E-06,CDK2|TP53|CEBPB|CASP3|AKT1,10163,10303|10291|10312|10333|10330,4.17E-08,,WP2374,0.576700389,0,5.76700389
64,5,WikiPathways,,G1 to S cell cycle control,1.71E-06,CDK2|TP53|E2F1|CDK1|MYC,10163,10303|10291|10264|10327|10318,4.17E-08,,WP45,0.576700389,0,5.76700389
50,5,Reactome Pathways,,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,1.76E-06,SMAD2|SMAD3|SKI|E2F4|MYC,10163,10267|10252|10270|10321|10318,1.31E-08,,HSA-2173793,0.575448733,0,5.754487332
66,5,WikiPathways,,Thyroid stimulating hormone (TSH) signaling pathway,1.79E-06,RBL2|CDK2|E2F1|AKT1|MYC,10163,10276|10303|10264|10330|10318,4.82E-08,,WP2032,0.574714697,0,5.747146969
16,4,Reactome Pathways,,Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1,1.92E-06,RBL2|E2F1|E2F4|CDK1,10163,10276|10264|10321|10327,1.55E-08,,HSA-1362300,0.571669877,0,5.716698771
206,7,Reactome Pathways,,Programmed Cell Death,1.92E-06,STUB1|CASP6|TP53|CASP3|E2F1|AKT1|CTNNB1,10163,10315|10309|10291|10333|10264|10330|10285,1.51E-08,,HSA-5357801,0.571669877,0,5.716698771
3654,19,GO Biological Process,,Regulation of biological quality,2.02E-06,STUB1|CYP27B1|SMAD2|RCOR1|CASP6|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|E2F4|SMAD5|AKT1|MYC|CTNNB1,10163,10315|10255|10267|10324|10309|10291|10297|10312|10282|10261|10333|10252|10288|10264|10321|10258|10330|10318|10285,1.57E-08,,GO:0065008,0.569464863,0,5.694648631
669,10,GO Biological Process,,Tube morphogenesis,2.09E-06,SMAD2|PRKACA|CASP3|SMAD3|BMPR1A|SKI|ACVR1|AKT1|MYC|CTNNB1,10163,10267|10261|10333|10252|10300|10270|10279|10330|10318|10285,1.64E-08,,GO:0035239,0.567985371,0,5.679853714
883,11,GO Biological Process,,Multicellular organismal reproductive process,2.09E-06,CYP27B1|PLK1|SMAD1|PRKACA|CASP3|E2F1|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10255|10297|10282|10261|10333|10264|10294|10279|10258|10330|10285,1.65E-08,,GO:0048609,0.567985371,0,5.679853714
332,8,GO Biological Process,,Regulation of mitotic cell cycle phase transition,2.09E-06,RBL2|CDK2|TP53|PLK1|E2F1|CDK1|ACVR1|AKT1,10163,10276|10303|10291|10297|10264|10327|10279|10330,1.65E-08,,GO:1901990,0.567985371,0,5.679853714
2040,15,GO Biological Process,,Cell surface receptor signaling pathway,2.19E-06,CSNK2A1|STUB1|SMAD2|TP53|SMAD1|PRKACA|CASP3|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10306|10315|10267|10291|10282|10261|10333|10252|10300|10270|10294|10279|10258|10330|10285,1.76E-08,,GO:0007166,0.565955589,0,5.659555885
2403,16,GO Biological Process,,Negative regulation of nitrogen compound metabolic process,2.19E-06,CSNK2A1|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|CASP3|SMAD3|MYB|E2F1|SKI|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10267|10324|10303|10291|10297|10312|10333|10252|10288|10264|10270|10258|10330|10318|10285,1.77E-08,,GO:0051172,0.565955589,0,5.659555885
146,6,WikiPathways,,Mesodermal commitment pathway,2.20E-06,SMAD2|SMAD1|PRKACA|SMAD3|BMPR1A|ACVR1,10163,10267|10282|10261|10252|10300|10279,6.21E-08,,WP2857,0.565757732,0,5.657577319
891,11,GO Biological Process,,Negative regulation of apoptotic process,2.21E-06,CSNK2A1|TP53|PLK1|CEBPB|CASP3|SMAD3|CDK1|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10291|10297|10312|10333|10252|10327|10279|10330|10318|10285,1.80E-08,,GO:0043066,0.565560773,0,5.655607726
493,9,GO Biological Process,,Regulation of mitotic cell cycle,2.27E-06,RBL2|CDK2|TP53|PLK1|E2F1|CDK1|ACVR1|AKT1|CTNNB1,10163,10276|10303|10291|10297|10264|10327|10279|10330|10285,1.87E-08,,GO:0007346,0.564397414,0,5.643974143
54,5,GO Biological Process,,Positive regulation of biomineral tissue development,2.27E-06,CEBPB|SMAD3|BMPR1A|BMPR1B|ACVR1,10163,10312|10252|10300|10294|10279,1.88E-08,,GO:0070169,0.564397414,0,5.643974143
1719,14,GO Biological Process,,Cell development,2.28E-06,CEBPB|PRKACA|CASP3|SMAD3|MYB|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10312|10261|10333|10252|10288|10300|10270|10321|10327|10294|10279|10258|10330|10285,1.91E-08,,GO:0048468,0.564206515,0,5.642065153
214,7,GO Biological Process,,Negative regulation of mitotic cell cycle,2.32E-06,RBL2|CDK2|TP53|PLK1|CDK1|ACVR1|CTNNB1,10163,10276|10303|10291|10297|10327|10279|10285,1.95E-08,,GO:0045930,0.563451202,0,5.634512015
341,8,GO Biological Process,,Regionalization,2.38E-06,SMAD2|TP53|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|CTNNB1,10163,10267|10291|10252|10300|10270|10294|10279|10285,2.02E-08,,GO:0003002,0.562342304,0,5.623423043
901,11,GO Biological Process,,Circulatory system development,2.38E-06,SMAD2|TP53|SMAD1|CASP3|SMAD3|BMPR1A|CDK1|ACVR1|SMAD5|AKT1|CTNNB1,10163,10267|10291|10282|10333|10252|10300|10327|10279|10258|10330|10285,2.02E-08,,GO:0072359,0.562342304,0,5.623423043
12,4,SMART Domains,,Domain A in dwarfin family proteins,2.40E-06,SMAD2|SMAD1|SMAD3|SMAD5,10163,10267|10282|10252|10258,5.84E-09,,SM00523,0.561978876,0,5.619788758
310,9,InterPro Domains,,"Serine/threonine-protein kinase, active site",2.56E-06,CSNK2A1|CDK2|PLK1|PRKACA|BMPR1A|CDK1|BMPR1B|ACVR1|AKT1,10163,10306|10303|10297|10261|10300|10327|10294|10279|10330,3.56E-10,,IPR008271,0.559176003,0,5.591760035
18,4,Reactome Pathways,,TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,2.66E-06,RBL2|TP53|E2F4|CDK1,10163,10276|10291|10321|10327,2.33E-08,,HSA-6804114,0.557511836,0,5.575118363
508,9,GO Biological Process,,Cellular response to organic cyclic compound,2.70E-06,CASP6|CEBPB|SMAD1|PRKACA|CASP3|CDK1|ACVR1|SMAD5|CTNNB1,10163,10309|10312|10282|10261|10333|10327|10279|10258|10285,2.41E-08,,GO:0071407,0.556863624,0,5.568636236
154,6,WikiPathways,,Breast cancer pathway,2.86E-06,CSNK2A1|TP53|E2F1|AKT1|MYC|CTNNB1,10163,10306|10291|10264|10330|10318|10285,8.42E-08,,WP4262,0.554363397,0,5.543633967
513,9,GO Biological Process,,Skeletal system development,2.91E-06,SMAD2|TP53|SMAD1|SMAD3|BMPR1A|SKI|BMPR1B|SMAD5|CTNNB1,10163,10267|10291|10282|10252|10300|10270|10294|10258|10285,2.62E-08,,GO:0001501,0.553610701,0,5.536107011
225,7,GO Biological Process,,Negative regulation of cell cycle phase transition,3.01E-06,RBL2|CDK2|TP53|PLK1|E2F1|CDK1|ACVR1,10163,10276|10303|10291|10297|10264|10327|10279,2.73E-08,,GO:1901988,0.55214335,0,5.521433504
19,4,Reactome Pathways,,Transcription of E2F targets under negative control by DREAM complex,3.07E-06,RBL2|E2F1|E2F4|MYC,10163,10276|10264|10321|10318,2.82E-08,,HSA-1362277,0.551286162,0,5.512861625
59,5,Reactome Pathways,,Transcriptional regulation of granulopoiesis,3.07E-06,CDK2|CEBPB|MYB|E2F1|MYC,10163,10303|10312|10288|10264|10318,2.84E-08,,HSA-9616222,0.551286162,0,5.512861625
938,11,GO Biological Process,,Anatomical structure formation involved in morphogenesis,3.32E-06,SMAD2|TP53|SMAD1|PRKACA|CASP3|SMAD3|BMPR1A|SKI|ACVR1|AKT1|CTNNB1,10163,10267|10291|10282|10261|10333|10252|10300|10270|10279|10330|10285,3.05E-08,,GO:0048646,0.547886192,0,5.478861916
230,7,GO Biological Process,,Regulation of proteolysis involved in protein catabolic process,3.42E-06,CSNK2A1|STUB1|CDK2|PLK1|PRKACA|SUMO2|AKT1,10163,10306|10315|10303|10297|10261|10273|10330,3.16E-08,,GO:1903050,0.546597389,0,5.465973894
183,6,KEGG Pathways,,Viral carcinogenesis,3.61E-06,RBL2|CDK2|TP53|PRKACA|CASP3|CDK1,10163,10276|10303|10291|10261|10333|10327,2.26E-07,,hsa05203,0.54424928,0,5.442492798
44,5,STRING Clusters,,"G1 Phase, and Polo-like kinase mediated events",3.67E-06,RBL2|CDK2|E2F1|E2F4|CDK1,10163,10276|10303|10264|10321|10327,7.22E-09,,CL:6900,0.543533394,0,5.435333936
367,8,GO Biological Process,,Regulation of protein catabolic process,3.79E-06,CSNK2A1|STUB1|CDK2|PLK1|PRKACA|SMAD3|SUMO2|AKT1,10163,10306|10315|10303|10297|10261|10252|10273|10330,3.53E-08,,GO:0042176,0.542136079,0,5.42136079
187,6,KEGG Pathways,,Kaposi sarcoma-associated herpesvirus infection,3.90E-06,TP53|CASP3|E2F1|AKT1|MYC|CTNNB1,10163,10291|10333|10264|10330|10318|10285,2.56E-07,,hsa05167,0.540893539,0,5.408935393
95,5,KEGG Pathways,,Progesterone-mediated oocyte maturation,3.96E-06,CDK2|PLK1|PRKACA|CDK1|AKT1,10163,10303|10297|10261|10327|10330,2.71E-07,,hsa04914,0.540230481,0,5.402304814
81,5,WikiPathways,,DNA IR-damage and cellular response via ATR,4.14E-06,CDK2|TP53|PLK1|E2F1|CDK1,10163,10303|10291|10297|10264|10327,1.27E-07,,WP4016,0.538299966,0,5.382999659
192,6,KEGG Pathways,,Epstein-Barr virus infection,4.16E-06,CDK2|TP53|CASP3|E2F1|AKT1|MYC,10163,10303|10291|10333|10264|10330|10318,2.97E-07,,hsa05169,0.538090667,0,5.380906669
97,5,KEGG Pathways,,Prostate cancer,4.16E-06,CDK2|TP53|E2F1|AKT1|CTNNB1,10163,10303|10291|10264|10330|10285,2.99E-07,,hsa05215,0.538090667,0,5.380906669
64,5,GO Biological Process,,SMAD protein signal transduction,4.42E-06,SMAD2|SMAD1|SMAD3|SKI|SMAD5,10163,10267|10282|10252|10270|10258,4.17E-08,,GO:0060395,0.535457773,0,5.354577731
83,5,WikiPathways,,Apoptosis,4.46E-06,CASP6|TP53|CASP3|AKT1|MYC,10163,10309|10291|10333|10330|10318,1.43E-07,,WP254,0.535066514,0,5.350665141
30,4,WikiPathways,,Extracellular vesicle-mediated signaling in recipient cells,4.46E-06,SMAD2|SMAD3|AKT1|CTNNB1,10163,10267|10252|10330|10285,1.46E-07,,WP2870,0.535066514,0,5.350665141
971,11,GO Biological Process,,Negative regulation of transcription by RNA polymerase II,4.55E-06,CDK2|TP53|PLK1|CEBPB|SMAD3|MYB|E2F1|SKI|SMAD5|MYC|CTNNB1,10163,10303|10291|10297|10312|10252|10288|10264|10270|10258|10318|10285,4.33E-08,,GO:0000122,0.53419886,0,5.341988603
86,5,WikiPathways,,Pancreatic adenocarcinoma pathway,4.89E-06,SMAD2|TP53|SMAD3|E2F1|AKT1,10163,10267|10291|10252|10264|10330,1.69E-07,,WP4263,0.531069114,0,5.310691141
87,5,WikiPathways,,Retinoblastoma gene in cancer,4.98E-06,CDK2|TP53|E2F1|CDK1|MYC,10163,10303|10291|10264|10327|10318,1.78E-07,,WP2446,0.530277066,0,5.302770657
1246,12,GO Biological Process,,Cell cycle,5.21E-06,CSNK2A1|CYP27B1|RBL2|CDK2|TP53|PLK1|MYB|E2F1|E2F4|CDK1|MYC|CTNNB1,10163,10306|10255|10276|10303|10291|10297|10288|10264|10321|10327|10318|10285,5.02E-08,,GO:0007049,0.528316228,0,5.283162277
434,9,GO Molecular Function,,Protein serine/threonine kinase activity,5.21E-06,CSNK2A1|CDK2|PLK1|PRKACA|BMPR1A|CDK1|BMPR1B|ACVR1|AKT1,10163,10306|10303|10297|10261|10300|10327|10294|10279|10330,6.34E-09,,GO:0004674,0.528316228,0,5.283162277
299,8,GO Molecular Function,,Ubiquitin protein ligase binding,5.25E-06,STUB1|SMAD2|TP53|PRKACA|SMAD3|SKI|SUMO2|SMAD5,10163,10315|10267|10291|10261|10252|10270|10273|10258,7.45E-09,,GO:0031625,0.52798407,0,5.279840697
988,11,GO Biological Process,,Regulation of catabolic process,5.32E-06,CSNK2A1|STUB1|CDK2|TP53|PLK1|PRKACA|CASP3|SMAD3|E2F1|SUMO2|AKT1,10163,10306|10315|10303|10291|10297|10261|10333|10252|10264|10273|10330,5.16E-08,,GO:0009894,0.527408837,0,5.274088368
250,7,GO Biological Process,,Cell fate commitment,5.64E-06,SMAD2|TP53|SMAD1|CASP3|ACVR1|SMAD5|CTNNB1,10163,10267|10291|10282|10333|10279|10258|10285,5.50E-08,,GO:0045165,0.52487209,0,5.248720896
2542,16,TISSUES,,Organism form,5.66E-06,STUB1|RBL2|SMAD2|CDK2|TP53|PLK1|CEBPB|CASP3|SMAD3|MYB|BMPR1A|CDK1|ACVR1|AKT1|MYC|CTNNB1,10163,10315|10276|10267|10303|10291|10297|10312|10333|10252|10288|10300|10327|10279|10330|10318|10285,3.97E-08,,BTO:0000284,0.524718357,0,5.247183569
8,4,InterPro Domains,,"SMAD domain, Dwarfin-type",5.72E-06,SMAD2|SMAD1|SMAD3|SMAD5,10163,10267|10282|10252|10258,1.59E-09,,IPR001132,0.524260397,0,5.242603971
8,4,InterPro Domains,,"MAD homology, MH1",5.72E-06,SMAD2|SMAD1|SMAD3|SMAD5,10163,10267|10282|10252|10258,1.59E-09,,IPR013019,0.524260397,0,5.242603971
8,4,InterPro Domains,,Dwarfin,5.72E-06,SMAD2|SMAD1|SMAD3|SMAD5,10163,10267|10282|10252|10258,1.59E-09,,IPR013790,0.524260397,0,5.242603971
382,9,InterPro Domains,,"Protein kinase, ATP binding site",5.72E-06,CSNK2A1|CDK2|PLK1|PRKACA|BMPR1A|CDK1|BMPR1B|ACVR1|AKT1,10163,10306|10303|10297|10261|10300|10327|10294|10279|10330,2.13E-09,,IPR017441,0.524260397,0,5.242603971
8,4,InterPro Domains,,SMAD MH1 domain superfamily,5.72E-06,SMAD2|SMAD1|SMAD3|SMAD5,10163,10267|10282|10252|10258,1.59E-09,,IPR036578,0.524260397,0,5.242603971
997,11,GO Biological Process,,Animal organ morphogenesis,5.76E-06,SMAD2|TP53|CEBPB|SMAD3|BMPR1A|SKI|E2F4|BMPR1B|ACVR1|MYC|CTNNB1,10163,10267|10291|10312|10252|10300|10270|10321|10294|10279|10318|10285,5.65E-08,,GO:0009887,0.523957752,0,5.239577517
5278,22,UniProt Keywords,,Nucleus,5.77E-06,CSNK2A1|STUB1|RBL2|SMAD2|RCOR1|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|SMAD3|MYB|E2F1|SKI|E2F4|CDK1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10276|10267|10324|10303|10291|10297|10312|10282|10261|10252|10288|10264|10270|10321|10327|10273|10258|10330|10318|10285,1.72E-08,,KW-0539,0.523882419,0,5.238824187
393,8,GO Biological Process,,In utero embryonic development,5.99E-06,SMAD2|TP53|CEBPB|SMAD3|BMPR1A|ACVR1|AKT1|CTNNB1,10163,10267|10291|10312|10252|10300|10279|10330|10285,5.92E-08,,GO:0001701,0.522257318,0,5.222573178
12,4,InterPro Domains,,"MAD homology 1, Dwarfin-type",5.99E-06,SMAD2|SMAD1|SMAD3|SMAD5,10163,10267|10282|10252|10258,5.84E-09,,IPR003619,0.522257318,0,5.222573178
3309,18,COMPARTMENTS,,Intracellular non-membrane-bounded organelle,6.29E-06,CSNK2A1|RBL2|SMAD2|CASP6|CDK2|TP53|PLK1|PRKACA|CASP3|SMAD3|MYB|E2F1|SKI|E2F4|CDK1|AKT1|MYC|CTNNB1,10163,10306|10276|10267|10309|10303|10291|10297|10261|10333|10252|10288|10264|10270|10321|10327|10330|10318|10285,2.73E-08,,GOCC:0043232,0.520134935,0,5.201349355
462,9,GO Molecular Function,,DNA-binding transcription activator activity,6.65E-06,SMAD2|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F1|E2F4|MYC,10163,10267|10291|10312|10282|10252|10288|10264|10321|10318,1.08E-08,,GO:0001216,0.517717835,0,5.177178355
7242,25,GO Molecular Function,,Protein binding,6.80E-06,CSNK2A1|STUB1|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,1.24E-08,,GO:0005515,0.516749109,0,5.167491087
1023,11,GO Biological Process,,Developmental process involved in reproduction,7.28E-06,CYP27B1|CEBPB|PRKACA|CASP3|E2F1|BMPR1A|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10255|10312|10261|10333|10264|10300|10294|10279|10258|10330|10285,7.33E-08,,GO:0003006,0.513786862,0,5.137868621
789,10,GO Biological Process,,Regulation of cellular catabolic process,7.49E-06,CSNK2A1|STUB1|CDK2|TP53|PLK1|PRKACA|CASP3|E2F1|SUMO2|AKT1,10163,10306|10315|10303|10291|10297|10261|10333|10264|10273|10330,7.59E-08,,GO:0031329,0.512551818,0,5.125518182
36,4,WikiPathways,,Ovarian infertility,7.71E-06,CEBPB|SMAD3|BMPR1B|AKT1,10163,10312|10252|10294|10330,2.86E-07,,WP34,0.511294562,0,5.112945622
2674,16,GO Biological Process,,Protein modification process,8.00E-06,CSNK2A1|STUB1|SMAD2|RCOR1|CDK2|PLK1|SMAD1|PRKACA|BMPR1A|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|CTNNB1,10163,10306|10315|10267|10324|10303|10297|10282|10261|10300|10327|10294|10279|10273|10258|10330|10285,8.16E-08,,GO:0036211,0.509691001,0,5.096910013
1041,11,GO Biological Process,,Apoptotic process,8.51E-06,CSNK2A1|CASP6|TP53|CEBPB|CASP3|SMAD3|E2F1|CDK1|AKT1|MYC|CTNNB1,10163,10306|10309|10291|10312|10333|10252|10264|10327|10330|10318|10285,8.74E-08,,GO:0006915,0.507007044,0,5.07007044
11025,28,GO Biological Process,,Regulation of cellular process,8.61E-06,CSNK2A1|STUB1|CYP27B1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,8.90E-08,,GO:0050794,0.506499685,0,5.064996849
269,7,GO Biological Process,,Muscle cell differentiation,8.62E-06,CASP3|BMPR1A|SKI|CDK1|ACVR1|AKT1|CTNNB1,10163,10333|10300|10270|10327|10279|10330|10285,8.96E-08,,GO:0042692,0.506449273,0,5.064492734
76,5,GO Biological Process,,Embryonic pattern specification,8.99E-06,SMAD2|SMAD1|SMAD3|SMAD5|CTNNB1,10163,10267|10282|10252|10258|10285,9.40E-08,,GO:0009880,0.504624031,0,5.046240308
275,7,GO Biological Process,,Regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,9.80E-06,STUB1|SMAD2|TP53|SMAD3|BMPR1A|SKI|ACVR1,10163,10315|10267|10291|10252|10300|10270|10279,1.04E-07,,GO:0090092,0.500877392,0,5.008773924
7156,24,GO Biological Process,,Primary metabolic process,9.89E-06,CSNK2A1|STUB1|CYP27B1|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|CTNNB1,10163,10306|10315|10255|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10264|10300|10270|10327|10294|10279|10273|10258|10330|10285,1.05E-07,,GO:0044238,0.500480371,0,5.004803708
78,5,GO Biological Process,,Peptidyl-threonine phosphorylation,9.92E-06,CSNK2A1|PRKACA|CDK1|ACVR1|AKT1,10163,10306|10261|10327|10279|10330,1.06E-07,,GO:0018107,0.500348833,0,5.003488328
120,5,KEGG Pathways,,Thyroid hormone signaling pathway,1.07E-05,TP53|PRKACA|AKT1|MYC|CTNNB1,10163,10291|10261|10330|10318|10285,8.24E-07,,hsa04919,0.497061622,0,4.970616222
5977,23,GO Molecular Function,,Heterocyclic compound binding,1.09E-05,CSNK2A1|CYP27B1|RBL2|SMAD2|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC,10163,10306|10255|10276|10267|10303|10291|10297|10312|10282|10261|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318,2.22E-08,,GO:1901363,0.49625735,0,4.962573502
7988,25,GO Biological Process,,Metabolic process,1.11E-05,CSNK2A1|STUB1|CYP27B1|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10264|10300|10270|10327|10294|10279|10273|10258|10330|10318|10285,1.21E-07,,GO:0008152,0.495467702,0,4.954677021
80,5,GO Biological Process,,Regulation of bone mineralization,1.11E-05,CYP27B1|SMAD3|BMPR1A|BMPR1B|ACVR1,10163,10255|10252|10300|10294|10279,1.20E-07,,GO:0030500,0.495467702,0,4.954677021
164,6,GO Biological Process,,Regulation of G1/S transition of mitotic cell cycle,1.11E-05,RBL2|CDK2|TP53|E2F1|ACVR1|AKT1,10163,10276|10303|10291|10264|10279|10330,1.21E-07,,GO:2000045,0.495467702,0,4.954677021
15,4,InterPro Domains,,SMAD-like domain superfamily,1.11E-05,SMAD2|SMAD1|SMAD3|SMAD5,10163,10267|10282|10252|10258,1.24E-08,,IPR017855,0.495467702,0,4.954677021
617,9,GO Biological Process,,Epithelial cell differentiation,1.12E-05,CASP6|CEBPB|CASP3|SMAD3|E2F4|CDK1|ACVR1|AKT1|CTNNB1,10163,10309|10312|10333|10252|10321|10327|10279|10330|10285,1.24E-07,,GO:0030855,0.495078198,0,4.950781977
28,4,Reactome Pathways,,G1/S-Specific Transcription,1.12E-05,RBL2|E2F1|E2F4|CDK1,10163,10276|10264|10321|10327,1.14E-07,,HSA-69205,0.495078198,0,4.950781977
702,10,GO Molecular Function,,Protein kinase binding,1.15E-05,TP53|PLK1|SMAD1|PRKACA|SMAD3|E2F1|SKI|ACVR1|AKT1|CTNNB1,10163,10291|10297|10282|10261|10252|10264|10270|10279|10330|10285,2.56E-08,,GO:0019901,0.493930216,0,4.93930216
1290,12,GO Cellular Component,,Nuclear protein-containing complex,1.16E-05,CSNK2A1|SMAD2|RCOR1|CEBPB|SMAD1|SMAD3|MYB|E2F1|E2F4|SMAD5|MYC|CTNNB1,10163,10306|10267|10324|10312|10282|10252|10288|10264|10321|10258|10318|10285,7.34E-08,,GO:0140513,0.493554201,0,4.935542011
2370,15,GO Biological Process,,Regulation of catalytic activity,1.18E-05,CSNK2A1|STUB1|CYP27B1|RBL2|CASP6|TP53|PLK1|CASP3|SMAD3|BMPR1A|SKI|BMPR1B|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10276|10309|10291|10297|10333|10252|10300|10270|10294|10330|10318|10285,1.32E-07,,GO:0050790,0.492811799,0,4.928117993
6050,23,GO Molecular Function,,Organic cyclic compound binding,1.18E-05,CSNK2A1|CYP27B1|RBL2|SMAD2|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC,10163,10306|10255|10276|10267|10303|10291|10297|10312|10282|10261|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318,2.86E-08,,GO:0097159,0.492811799,0,4.928117993
167,6,GO Biological Process,,Negative regulation of mitotic cell cycle phase transition,1.19E-05,RBL2|CDK2|TP53|PLK1|CDK1|ACVR1,10163,10276|10303|10291|10297|10327|10279,1.34E-07,,GO:1901991,0.492445304,0,4.924453039
83,5,GO Biological Process,,Dorsal/ventral pattern formation,1.26E-05,SMAD2|BMPR1A|BMPR1B|ACVR1|CTNNB1,10163,10267|10300|10294|10279|10285,1.43E-07,,GO:0009953,0.489962945,0,4.899629455
126,5,KEGG Pathways,,FoxO signaling pathway,1.29E-05,RBL2|CDK2|PLK1|SMAD3|AKT1,10163,10276|10303|10297|10252|10330,1.04E-06,,hsa04068,0.488941029,0,4.88941029
486,9,InterPro Domains,,Protein kinase domain,1.32E-05,CSNK2A1|CDK2|PLK1|PRKACA|BMPR1A|CDK1|BMPR1B|ACVR1|AKT1,10163,10306|10303|10297|10261|10300|10327|10294|10279|10330,1.66E-08,,IPR000719,0.487942607,0,4.879426069
291,7,GO Biological Process,,Response to decreased oxygen levels,1.33E-05,STUB1|TP53|CASP3|SMAD3|E2F1|AKT1|MYC,10163,10315|10291|10333|10252|10264|10330|10318,1.51E-07,,GO:0036293,0.487614836,0,4.876148359
173,6,GO Biological Process,,Mitotic cell cycle phase transition,1.44E-05,CDK2|PLK1|E2F1|E2F4|CDK1|MYC,10163,10303|10297|10264|10321|10327|10318,1.64E-07,,GO:0044772,0.484163751,0,4.841637508
173,6,GO Biological Process,,Regulation of ubiquitin-dependent protein catabolic process,1.44E-05,CSNK2A1|STUB1|CDK2|PLK1|SUMO2|AKT1,10163,10306|10315|10303|10297|10273|10330,1.64E-07,,GO:2000058,0.484163751,0,4.841637508
77,5,GO Cellular Component,,Transcription repressor complex,1.46E-05,RCOR1|TP53|SKI|MYC|CTNNB1,10163,10324|10291|10270|10318|10285,1.00E-07,,GO:0017053,0.483564714,0,4.835647144
1108,11,Reactome Pathways,,Developmental Biology,1.49E-05,CSNK2A1|SMAD2|CDK2|CEBPB|PRKACA|SMAD3|MYB|E2F1|AKT1|MYC|CTNNB1,10163,10306|10267|10303|10312|10261|10252|10288|10264|10330|10318|10285,1.64E-07,,HSA-1266738,0.482681373,0,4.826813732
454,8,GO Biological Process,,Embryonic organ development,1.52E-05,SMAD2|TP53|CEBPB|SMAD3|BMPR1A|ACVR1|AKT1|CTNNB1,10163,10267|10291|10312|10252|10300|10279|10330|10285,1.75E-07,,GO:0048568,0.481815641,0,4.818156412
175,6,Reactome Pathways,,Apoptosis,1.54E-05,CASP6|TP53|CASP3|E2F1|AKT1|CTNNB1,10163,10309|10291|10333|10264|10330|10285,1.75E-07,,HSA-109581,0.481247928,0,4.812479279
113,5,WikiPathways,,Gastrin signaling pathway,1.60E-05,PRKACA|CASP3|AKT1|MYC|CTNNB1,10163,10261|10333|10330|10318|10285,6.19E-07,,WP4659,0.479588002,0,4.795880017
218,6,WikiPathways,,Network map of SARS-CoV-2 signaling pathway,1.60E-05,CEBPB|SMAD1|CASP3|CDK1|SMAD5|AKT1,10163,10312|10282|10333|10327|10258|10330,6.13E-07,,WP5115,0.479588002,0,4.795880017
6643,23,GO Biological Process,,Nitrogen compound metabolic process,1.69E-05,CSNK2A1|STUB1|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|CTNNB1,10163,10306|10315|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10264|10300|10270|10327|10294|10279|10273|10258|10330|10285,1.99E-07,,GO:0006807,0.47721133,0,4.772113295
89,5,GO Biological Process,,Regulation of fibroblast proliferation,1.69E-05,TP53|E2F1|SKI|MYC|CTNNB1,10163,10291|10264|10270|10318|10285,1.99E-07,,GO:0048145,0.47721133,0,4.772113295
4,3,COMPARTMENTS,,Homomeric SMAD protein complex,1.71E-05,SMAD2|SMAD1|SMAD3,10163,10267|10282|10252,8.93E-08,,GOCC:0071142,0.476700389,0,4.76700389
10,3,WikiPathways,,Mammary gland development pathway - Involution (Stage 4 of 4),1.77E-05,TP53|E2F1|MYC,10163,10291|10264|10318,7.25E-07,,WP2815,0.475202673,0,4.752026734
117,5,WikiPathways,,Osteoblast differentiation and related diseases,1.77E-05,SMAD1|BMPR1A|BMPR1B|SMAD5|CTNNB1,10163,10282|10300|10294|10258|10285,7.31E-07,,WP4787,0.475202673,0,4.752026734
885,10,GO Biological Process,,Sexual reproduction,1.84E-05,PLK1|SMAD1|PRKACA|E2F1|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10297|10282|10261|10264|10327|10294|10279|10258|10330|10285,2.19E-07,,GO:0019953,0.473518218,0,4.735182177
137,5,KEGG Pathways,,Measles,1.86E-05,CSNK2A1|CDK2|TP53|CASP3|AKT1,10163,10306|10303|10291|10333|10330,1.55E-06,,hsa05162,0.473048706,0,4.730487056
1146,11,GO Biological Process,,Positive regulation of gene expression,1.91E-05,SMAD2|TP53|CEBPB|SMAD1|SMAD3|E2F1|BMPR1A|CDK1|AKT1|MYC|CTNNB1,10163,10267|10291|10312|10282|10252|10264|10300|10327|10330|10318|10285,2.29E-07,,GO:0010628,0.471896663,0,4.718966633
5,3,TISSUES,,HT-29 cell,1.92E-05,TP53|CASP3|AKT1,10163,10291|10333|10330,1.43E-07,,BTO:0000182,0.471669877,0,4.716698771
5,3,TISSUES,,Vas efferens,1.92E-05,TP53|CASP3|MYC,10163,10291|10333|10318,1.43E-07,,BTO:0002254,0.471669877,0,4.716698771
2101,14,GO Biological Process,,Gene expression,1.97E-05,STUB1|SMAD2|CASP6|CDK2|TP53|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|SKI|AKT1|CTNNB1,10163,10315|10267|10309|10303|10291|10312|10282|10261|10333|10252|10264|10270|10330|10285,2.37E-07,,GO:0010467,0.470553377,0,4.705533774
58,4,KEGG Pathways,,Endometrial cancer,1.98E-05,TP53|AKT1|MYC|CTNNB1,10163,10291|10330|10318|10285,1.71E-06,,hsa05213,0.470333481,0,4.70333481
899,10,GO Biological Process,,Negative regulation of gene expression,2.09E-05,RBL2|SMAD2|RCOR1|TP53|SMAD1|SMAD3|BMPR1A|CDK1|AKT1|CTNNB1,10163,10276|10267|10324|10291|10282|10252|10300|10327|10330|10285,2.53E-07,,GO:0010629,0.467985371,0,4.679853714
315,7,GO Biological Process,,Epithelial tube morphogenesis,2.09E-05,PRKACA|CASP3|SMAD3|SKI|ACVR1|MYC|CTNNB1,10163,10261|10333|10252|10270|10279|10318|10285,2.55E-07,,GO:0060562,0.467985371,0,4.679853714
35,4,Reactome Pathways,,Regulation of TP53 Degradation,2.18E-05,CDK2|TP53|CDK1|AKT1,10163,10303|10291|10327|10330,2.58E-07,,HSA-6804757,0.466154351,0,4.661543506
318,7,GO Biological Process,,Apoptotic signaling pathway,2.21E-05,CASP6|TP53|CEBPB|CASP3|SMAD3|E2F1|CTNNB1,10163,10309|10291|10312|10333|10252|10264|10285,2.72E-07,,GO:0097190,0.465560773,0,4.655607726
3358,17,GO Biological Process,,Response to stress,2.25E-05,STUB1|CYP27B1|SMAD2|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|CDK1|BMPR1B|ACVR1|AKT1|MYC,10163,10315|10255|10267|10303|10291|10297|10312|10282|10261|10333|10252|10264|10327|10294|10279|10330|10318,2.80E-07,,GO:0006950,0.464781748,0,4.647817482
2131,14,GO Biological Process,,Positive regulation of response to stimulus,2.26E-05,CSNK2A1|CYP27B1|SMAD2|CASP6|TP53|CEBPB|SMAD3|MYB|BMPR1A|SKI|BMPR1B|ACVR1|MYC|CTNNB1,10163,10306|10255|10267|10309|10291|10312|10252|10288|10300|10270|10294|10279|10318|10285,2.83E-07,,GO:0048584,0.464589156,0,4.645891561
912,10,GO Biological Process,,Regulation of transferase activity,2.29E-05,STUB1|RBL2|TP53|PLK1|CASP3|BMPR1A|BMPR1B|AKT1|MYC|CTNNB1,10163,10315|10276|10291|10297|10333|10300|10294|10330|10318|10285,2.88E-07,,GO:0051338,0.464016452,0,4.640164518
36,4,Reactome Pathways,,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,2.34E-05,SMAD2|SMAD3|E2F4|MYC,10163,10267|10252|10321|10318,2.86E-07,,HSA-2173796,0.463078414,0,4.630784143
685,9,GO Biological Process,,Negative regulation of cell differentiation,2.35E-05,TP53|SMAD1|SMAD3|MYB|E2F1|BMPR1A|SKI|MYC|CTNNB1,10163,10291|10282|10252|10288|10264|10300|10270|10318|10285,2.97E-07,,GO:0045596,0.462893214,0,4.628932138
146,5,KEGG Pathways,,Breast cancer,2.35E-05,TP53|E2F1|AKT1|MYC|CTNNB1,10163,10291|10264|10330|10318|10285,2.10E-06,,hsa05224,0.462893214,0,4.628932138
7,3,GO Biological Process,,SMAD protein complex assembly,2.39E-05,SMAD2|SMAD1|SMAD3,10163,10267|10282|10252,3.05E-07,,GO:0007183,0.46216021,0,4.621602099
193,6,GO Biological Process,,Peptidyl-serine phosphorylation,2.39E-05,CSNK2A1|CDK2|PLK1|PRKACA|CDK1|AKT1,10163,10306|10303|10297|10261|10327|10330,3.06E-07,,GO:0018105,0.46216021,0,4.621602099
7522,24,GO Biological Process,,Organic substance metabolic process,2.42E-05,CSNK2A1|STUB1|CYP27B1|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|CTNNB1,10163,10306|10315|10255|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10264|10300|10270|10327|10294|10279|10273|10258|10330|10285,3.12E-07,,GO:0071704,0.461618463,0,4.616184634
530,9,InterPro Domains,,Protein kinase-like domain superfamily,2.48E-05,CSNK2A1|CDK2|PLK1|PRKACA|BMPR1A|CDK1|BMPR1B|ACVR1|AKT1,10163,10306|10303|10297|10261|10300|10327|10294|10279|10330,3.45E-08,,IPR011009,0.460554832,0,4.605548319
196,6,GO Biological Process,,Regulation of proteasomal protein catabolic process,2.58E-05,STUB1|CDK2|PLK1|PRKACA|SUMO2|AKT1,10163,10315|10303|10297|10261|10273|10330,3.34E-07,,GO:0061136,0.458838029,0,4.588380294
6,3,TISSUES,,HeLa cell,2.59E-05,TP53|CASP3|MYC,10163,10291|10333|10318,2.14E-07,,BTO:0000567,0.458670024,0,4.586700236
12,3,WikiPathways,,Bone morphogenic protein signaling and regulation,2.60E-05,SMAD1|BMPR1A|BMPR1B,10163,10282|10300|10294,1.15E-06,,WP1425,0.458502665,0,4.585026652
52,4,WikiPathways,,NRP1-triggered signaling pathways in pancreatic cancer ,2.60E-05,SMAD2|CDK2|SMAD3|AKT1,10163,10267|10303|10252|10330,1.13E-06,,WP5144,0.458502665,0,4.585026652
197,6,Reactome Pathways,,Mitotic G2-G2/M phases,2.62E-05,CDK2|TP53|PLK1|PRKACA|E2F1|CDK1,10163,10303|10291|10297|10261|10264|10327,3.44E-07,,HSA-453274,0.458169871,0,4.581698709
102,5,GO Biological Process,,Microtubule organizing center organization,2.92E-05,CDK2|PLK1|E2F4|CDK1|CTNNB1,10163,10303|10297|10321|10327|10285,3.80E-07,,GO:0031023,0.453461715,0,4.534617149
584,9,GO Molecular Function,,Chromatin binding,2.92E-05,RBL2|SMAD2|RCOR1|TP53|CEBPB|SMAD3|E2F4|CDK1|CTNNB1,10163,10276|10267|10324|10291|10312|10252|10321|10327|10285,7.82E-08,,GO:0003682,0.453461715,0,4.534617149
3910,18,GO Biological Process,,Protein metabolic process,2.96E-05,CSNK2A1|STUB1|SMAD2|RCOR1|CASP6|CDK2|PLK1|SMAD1|PRKACA|CASP3|BMPR1A|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|CTNNB1,10163,10306|10315|10267|10324|10309|10303|10297|10282|10261|10333|10300|10327|10294|10279|10273|10258|10330|10285,3.87E-07,,GO:0019538,0.452870829,0,4.528708289
13,3,WikiPathways,,BMP2-WNT4-FOXO1 pathway in primary endometrial stromal cell differentiation,3.07E-05,SMAD1|SMAD5|CTNNB1,10163,10282|10258|10285,1.42E-06,,WP3876,0.451286162,0,4.512861625
204,6,GO Biological Process,,Striated muscle cell differentiation,3.20E-05,CASP3|BMPR1A|SKI|CDK1|ACVR1|AKT1,10163,10333|10300|10270|10327|10279|10330,4.20E-07,,GO:0051146,0.449485002,0,4.494850022
105,5,GO Biological Process,,DNA damage checkpoint signaling,3.29E-05,CDK2|TP53|PLK1|E2F1|CDK1,10163,10303|10291|10297|10264|10327,4.36E-07,,GO:0000077,0.44828041,0,4.482804102
7,3,TISSUES,,A-549 cell,3.37E-05,TP53|CASP3|AKT1,10163,10291|10333|10330,3.05E-07,,BTO:0000018,0.44723701,0,4.472370099
7,3,TISSUES,,Hep-G2 cell,3.37E-05,TP53|CASP3|AKT1,10163,10291|10333|10330,3.05E-07,,BTO:0000599,0.44723701,0,4.472370099
2399,15,UniProt Keywords,,Ubl conjugation,3.47E-05,STUB1|SMAD2|RCOR1|TP53|PLK1|CEBPB|SMAD1|SMAD3|MYB|SKI|CDK1|SUMO2|AKT1|MYC|CTNNB1,10163,10315|10267|10324|10291|10297|10312|10282|10252|10288|10270|10327|10273|10330|10318|10285,1.55E-07,,KW-0832,0.445967053,0,4.459670525
8162,25,COMPARTMENTS,,Intracellular membrane-bounded organelle,3.50E-05,CSNK2A1|STUB1|CYP27B1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|SKI|E2F4|CDK1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10270|10321|10327|10273|10258|10330|10318|10285,1.98E-07,,GOCC:0043231,0.445593196,0,4.455931956
518,8,GO Biological Process,,"Transcription, DNA-templated",3.53E-05,SMAD2|CDK2|TP53|CEBPB|SMAD1|E2F1|SKI|CTNNB1,10163,10267|10303|10291|10312|10282|10264|10270|10285,4.71E-07,,GO:0006351,0.445222529,0,4.452225295
347,7,GO Biological Process,,Urogenital system development,3.59E-05,SMAD2|SMAD1|SMAD3|ACVR1|SMAD5|MYC|CTNNB1,10163,10267|10282|10252|10279|10258|10318|10285,4.83E-07,,GO:0001655,0.444490555,0,4.444905551
470,8,COMPARTMENTS,,Centrosome,3.74E-05,CDK2|TP53|PLK1|PRKACA|E2F1|SKI|CDK1|CTNNB1,10163,10303|10291|10297|10261|10264|10270|10327|10285,2.27E-07,,GOCC:0005813,0.44271284,0,4.427128398
3362,17,UniProt Keywords,,Acetylation,3.83E-05,SMAD2|CDK2|TP53|PLK1|CEBPB|SMAD1|CASP3|SMAD3|MYB|E2F1|E2F4|CDK1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10267|10303|10291|10297|10312|10282|10333|10252|10288|10264|10321|10327|10273|10258|10330|10318|10285,2.85E-07,,KW-0007,0.441680123,0,4.416801226
476,8,COMPARTMENTS,,Chromatin,3.84E-05,CSNK2A1|SMAD2|TP53|SMAD3|E2F1|E2F4|MYC|CTNNB1,10163,10306|10267|10291|10252|10264|10321|10318|10285,2.50E-07,,GOCC:0000785,0.441566878,0,4.415668776
9,3,GO Biological Process,,Embryonic foregut morphogenesis,4.11E-05,SMAD2|SMAD3|CTNNB1,10163,10267|10252|10285,5.59E-07,,GO:0048617,0.438615818,0,4.386158178
72,4,KEGG Pathways,,p53 signaling pathway,4.21E-05,CDK2|TP53|CASP3|CDK1,10163,10303|10291|10333|10327,3.88E-06,,hsa04115,0.43757179,0,4.375717904
216,6,GO Biological Process,,Anterior/posterior pattern specification,4.24E-05,SMAD2|TP53|SMAD3|BMPR1A|SKI|CTNNB1,10163,10267|10291|10252|10300|10270|10285,5.82E-07,,GO:0009952,0.437263414,0,4.372634143
15,3,WikiPathways,,miRNAs involved in DNA damage response,4.35E-05,TP53|E2F1|MYC,10163,10291|10264|10318,2.06E-06,,WP1545,0.436151074,0,4.361510743
434,7,WikiPathways,,Malignant pleural mesothelioma,4.35E-05,CSNK2A1|CDK2|TP53|E2F1|AKT1|MYC|CTNNB1,10163,10306|10303|10291|10264|10330|10318|10285,2.10E-06,,WP5087,0.436151074,0,4.361510743
44,4,GO Biological Process,,Positive regulation of bone mineralization,4.39E-05,SMAD3|BMPR1A|BMPR1B|ACVR1,10163,10252|10300|10294|10279,6.05E-07,,GO:0030501,0.435753548,0,4.35753548
17,4,DISEASES,,Colon cancer,4.39E-05,TP53|AKT1|MYC|CTNNB1,10163,10291|10330|10318|10285,1.91E-08,,DOID:219,0.435753548,0,4.35753548
17,4,DISEASES,,Hepatocellular carcinoma,4.39E-05,TP53|AKT1|MYC|CTNNB1,10163,10291|10330|10318|10285,1.91E-08,,DOID:684,0.435753548,0,4.35753548
62,4,WikiPathways,,DYRK1A,4.41E-05,RBL2|TP53|CASP3|E2F4,10163,10276|10291|10333|10321,2.20E-06,,WP5180,0.435556141,0,4.355561411
1572,12,GO Biological Process,,Cellular response to stress,4.47E-05,STUB1|CDK2|TP53|PLK1|CEBPB|PRKACA|CASP3|SMAD3|E2F1|CDK1|AKT1|MYC,10163,10315|10303|10291|10297|10312|10261|10333|10252|10264|10327|10330|10318,6.22E-07,,GO:0033554,0.434969248,0,4.349692477
63,4,WikiPathways,,Endometrial cancer,4.57E-05,TP53|AKT1|MYC|CTNNB1,10163,10291|10330|10318|10285,2.34E-06,,WP4155,0.43400838,0,4.3400838
150,5,WikiPathways,,Hepatitis B infection,4.57E-05,SMAD2|CASP3|SMAD3|AKT1|MYC,10163,10267|10333|10252|10330|10318,2.38E-06,,WP4666,0.43400838,0,4.3400838
5,3,GO Molecular Function,,"Transforming growth factor beta receptor activity, type I",4.69E-05,BMPR1A|BMPR1B|ACVR1,10163,10300|10294|10279,1.43E-07,,GO:0005025,0.432882716,0,4.328827157
756,9,GO Biological Process,,Gamete generation,4.80E-05,PLK1|SMAD1|PRKACA|E2F1|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10297|10282|10261|10264|10294|10279|10258|10330|10285,6.73E-07,,GO:0007276,0.431875876,0,4.318758763
365,7,GO Biological Process,,Regulation of apoptotic signaling pathway,4.80E-05,CSNK2A1|TP53|BMPR1B|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10291|10294|10279|10330|10318|10285,6.74E-07,,GO:2001233,0.431875876,0,4.318758763
108,5,TISSUES,,Leukemia cell line,4.84E-05,RBL2|CASP3|E2F4|AKT1|MYC,10163,10276|10333|10321|10330|10318,4.99E-07,,BTO:0000737,0.431515464,0,4.315154638
65,4,WikiPathways,,Pathways affected in adenoid cystic carcinoma,4.90E-05,TP53|MYB|AKT1|MYC,10163,10291|10288|10330|10318,2.63E-06,,WP3651,0.430980392,0,4.30980392
154,5,WikiPathways,,Sudden infant death syndrome (SIDS) susceptibility pathways,4.91E-05,CEBPB|PRKACA|CASP3|MYB|CTNNB1,10163,10312|10261|10333|10288|10285,2.70E-06,,WP706,0.430891851,0,4.308918508
66,4,WikiPathways,,AGE/RAGE pathway,4.95E-05,SMAD2|CASP3|SMAD3|AKT1,10163,10267|10333|10252|10330,2.79E-06,,WP2324,0.43053948,0,4.305394801
17,3,WikiPathways,,TGF-beta signaling in thyroid cells for epithelial-mesenchymal transition,4.99E-05,SMAD2|SMAD3|AKT1,10163,10267|10252|10330,2.87E-06,,WP3859,0.430189945,0,4.301899454
17,3,WikiPathways,,Canonical and non-canonical TGF-B signaling,4.99E-05,SMAD2|SMAD3|BMPR1A,10163,10267|10252|10300,2.87E-06,,WP3874,0.430189945,0,4.301899454
68,4,WikiPathways,,RAC1/PAK1/p38/MMP2 pathway,5.19E-05,TP53|AKT1|MYC|CTNNB1,10163,10291|10330|10318|10285,3.13E-06,,WP3303,0.428483264,0,4.284832642
9,3,TISSUES,,MDA-MB-231 cell,5.21E-05,TP53|CASP3|AKT1,10163,10291|10333|10330,5.59E-07,,BTO:0000815,0.428316228,0,4.283162277
160,5,WikiPathways,,Epithelial to mesenchymal transition in colorectal cancer,5.27E-05,SMAD2|TP53|SMAD3|AKT1|CTNNB1,10163,10267|10291|10252|10330|10285,3.24E-06,,WP4239,0.427818938,0,4.278189385
375,7,GO Biological Process,,Positive regulation of proteolysis,5.67E-05,STUB1|CASP6|PLK1|SMAD3|SUMO2|AKT1|MYC,10163,10315|10309|10297|10252|10273|10330|10318,8.06E-07,,GO:0045862,0.424641694,0,4.246416941
47,4,Reactome Pathways,,Cyclin D associated events in G1,5.71E-05,RBL2|CDK2|E2F1|E2F4,10163,10276|10303|10264|10321,7.75E-07,,HSA-69231,0.424336389,0,4.243363892
1409,12,GO Molecular Function,,RNA polymerase II transcription regulatory region sequence-specific DNA binding,5.78E-05,RBL2|SMAD2|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F1|SKI|E2F4|SMAD5|MYC,10163,10276|10267|10291|10312|10282|10252|10288|10264|10270|10321|10258|10318,1.91E-07,,GO:0000977,0.423807216,0,4.238072162
458,8,GO Molecular Function,,"DNA-binding transcription activator activity, RNA polymerase II-specific",5.78E-05,SMAD2|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F4|MYC,10163,10267|10291|10312|10282|10252|10288|10321|10318,1.87E-07,,GO:0001228,0.423807216,0,4.238072162
5,3,STRING Clusters,,Activin types I and II receptor domain,5.94E-05,BMPR1A|BMPR1B|ACVR1,10163,10300|10294|10279,1.43E-07,,CL:21282,0.422621356,0,4.226213555
8,3,COMPARTMENTS,,PCNA complex,6.03E-05,CDK2|TP53|CASP3,10163,10303|10291|10333,4.19E-07,,GOCC:0043626,0.421968269,0,4.219682688
72,4,WikiPathways,,Non-small cell lung cancer,6.19E-05,TP53|CASP3|E2F1|AKT1,10163,10291|10333|10264|10330,3.88E-06,,WP4255,0.420830935,0,4.208309351
72,4,WikiPathways,,Head and neck squamous cell carcinoma,6.19E-05,TP53|E2F1|AKT1|CTNNB1,10163,10291|10264|10330|10285,3.88E-06,,WP4674,0.420830935,0,4.208309351
11,3,GO Biological Process,,Dorsal/ventral axis specification,6.43E-05,SMAD2|BMPR1A|CTNNB1,10163,10267|10300|10285,9.22E-07,,GO:0009950,0.419178903,0,4.191789027
11,3,GO Biological Process,,Paraxial mesoderm morphogenesis,6.43E-05,SMAD2|SMAD3|BMPR1A,10163,10267|10252|10300,9.22E-07,,GO:0048340,0.419178903,0,4.191789027
6490,22,GO Biological Process,,Multicellular organismal process,6.79E-05,CYP27B1|SMAD2|RCOR1|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10255|10267|10324|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10258|10330|10318|10285,9.83E-07,,GO:0032501,0.416813023,0,4.168130226
4,3,DISEASES,,Nasopharynx carcinoma,6.84E-05,TP53|AKT1|MYC,10163,10291|10330|10318,8.93E-08,,DOID:9261,0.41649439,0,4.164943898
9,3,COMPARTMENTS,,BMP receptor complex,7.14E-05,BMPR1A|BMPR1B|ACVR1,10163,10300|10294|10279,5.59E-07,,GOCC:0070724,0.414630179,0,4.146301788
51,4,GO Biological Process,,Positive regulation of epithelial to mesenchymal transition,7.25E-05,SMAD2|SMAD3|ACVR1|CTNNB1,10163,10267|10252|10279|10285,1.05E-06,,GO:0010718,0.413966199,0,4.139661993
1058,10,GO Biological Process,,Response to nitrogen compound,7.62E-05,STUB1|CASP6|CDK2|TP53|CEBPB|PRKACA|CASP3|CDK1|AKT1|CTNNB1,10163,10315|10309|10303|10291|10312|10261|10333|10327|10330|10285,1.11E-06,,GO:1901698,0.411804503,0,4.118045029
11,3,TISSUES,,MCF-7 cell,7.72E-05,TP53|CASP3|AKT1,10163,10291|10333|10330,9.22E-07,,BTO:0000093,0.41123827,0,4.1123827
484,8,GO Molecular Function,,DNA-binding transcription factor binding,7.76E-05,SMAD2|TP53|CEBPB|SMAD3|E2F1|SKI|MYC|CTNNB1,10163,10267|10291|10312|10252|10264|10270|10318|10285,2.83E-07,,GO:0140297,0.411013828,0,4.110138279
52,4,Reactome Pathways,,Intrinsic Pathway for Apoptosis,7.84E-05,TP53|CASP3|E2F1|AKT1,10163,10291|10333|10264|10330,1.13E-06,,HSA-109606,0.410568394,0,4.105683937
2299,14,UniProt Keywords,,Transcription regulation,8.07E-05,CSNK2A1|RBL2|SMAD2|RCOR1|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F1|E2F4|SMAD5|MYC|CTNNB1,10163,10306|10276|10267|10324|10291|10312|10282|10252|10288|10264|10321|10258|10318|10285,7.21E-07,,KW-0805,0.409312647,0,4.093126465
2369,14,TISSUES,,Embryonic structure,8.14E-05,STUB1|RBL2|SMAD2|CDK2|TP53|PLK1|CEBPB|CASP3|SMAD3|MYB|BMPR1A|ACVR1|MYC|CTNNB1,10163,10315|10276|10267|10303|10291|10297|10312|10333|10252|10288|10300|10279|10318|10285,1.04E-06,,BTO:0000174,0.40893756,0,4.089375595
7,3,SMART Domains,,GS motif,8.35E-05,BMPR1A|BMPR1B|ACVR1,10163,10300|10294|10279,3.05E-07,,SM00467,0.407831352,0,4.078313525
29,4,DISEASES,,Pancreatic cancer,8.48E-05,TP53|AKT1|MYC|CTNNB1,10163,10291|10330|10318|10285,1.29E-07,,DOID:1793,0.407160415,0,4.071604148
1196,11,GO Molecular Function,,RNA polymerase II cis-regulatory region sequence-specific DNA binding,8.66E-05,SMAD2|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F1|SKI|E2F4|SMAD5|MYC,10163,10267|10291|10312|10282|10252|10288|10264|10270|10321|10258|10318,3.51E-07,,GO:0000978,0.406248211,0,4.062482108
10,3,COMPARTMENTS,,Tubulin complex,8.79E-05,CASP3|AKT1|MYC,10163,10333|10330|10318,7.25E-07,,GOCC:0045298,0.405601112,0,4.056011125
2804,15,TISSUES,,Internal female genital organ,8.84E-05,CSNK2A1|RBL2|SMAD2|CDK2|TP53|PLK1|CEBPB|SMAD3|BMPR1A|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10276|10267|10303|10291|10297|10312|10252|10300|10294|10279|10258|10330|10318|10285,1.20E-06,,BTO:0003099,0.405354773,0,4.053547735
54,4,GO Biological Process,,Mesenchyme morphogenesis,8.91E-05,SMAD2|SMAD3|BMPR1A|ACVR1,10163,10267|10252|10300|10279,1.31E-06,,GO:0072132,0.40501223,0,4.050122296
8,3,GO Molecular Function,,DEAD/H-box RNA helicase binding,9.22E-05,SMAD1|SMAD3|SMAD5,10163,10282|10252|10258,4.19E-07,,GO:0017151,0.403526908,0,4.035269079
31,4,DISEASES,,Stomach cancer,9.47E-05,TP53|AKT1|MYC|CTNNB1,10163,10291|10330|10318|10285,1.65E-07,,DOID:10534,0.402365002,0,4.023650021
13,3,GO Biological Process,,Primary miRNA processing,9.57E-05,SMAD2|SMAD1|SMAD3,10163,10267|10282|10252,1.42E-06,,GO:0031053,0.401908806,0,4.019088062
1702,12,Reactome Pathways,,Disease,9.72E-05,CYP27B1|SMAD2|RCOR1|CDK2|TP53|CEBPB|PRKACA|SMAD3|E2F1|AKT1|MYC|CTNNB1,10163,10255|10267|10324|10303|10291|10312|10261|10252|10264|10330|10318|10285,1.45E-06,,HSA-1643685,0.401233374,0,4.012333735
82,4,WikiPathways,,Glioblastoma signaling pathways,9.74E-05,CDK2|TP53|E2F1|AKT1,10163,10303|10291|10264|10330,6.36E-06,,WP2261,0.401144104,0,4.011441043
835,9,GO Biological Process,,Cell cycle process,1.00E-04,CYP27B1|CDK2|TP53|PLK1|E2F1|E2F4|CDK1|MYC|CTNNB1,10163,10255|10303|10291|10297|10264|10321|10327|10318|10285,1.53E-06,,GO:0022402,0.4,0,4
136,5,GO Biological Process,,Cellular response to decreased oxygen levels,1.00E-04,STUB1|TP53|E2F1|AKT1|MYC,10163,10315|10291|10264|10330|10318,1.50E-06,,GO:0036294,0.4,0,4
412,7,GO Biological Process,,Developmental growth,1.00E-04,SMAD2|TP53|SMAD1|SMAD3|BMPR1A|BMPR1B|CTNNB1,10163,10267|10291|10282|10252|10300|10294|10285,1.49E-06,,GO:0048589,0.4,0,4
138,5,Reactome Pathways,,PTEN Regulation,1.00E-04,CSNK2A1|STUB1|RCOR1|TP53|AKT1,10163,10306|10315|10324|10291|10330,1.60E-06,,HSA-6807070,0.4,0,4
140,5,GO Biological Process,,Regulation of transforming growth factor beta receptor signaling pathway,1.10E-04,STUB1|SMAD2|TP53|SMAD3|SKI,10163,10315|10267|10291|10252|10270,1.72E-06,,GO:0017015,0.395860731,0,3.958607315
417,7,GO Biological Process,,Cellular process involved in reproduction in multicellular organism,1.10E-04,PLK1|PRKACA|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10297|10261|10294|10279|10258|10330|10285,1.62E-06,,GO:0022412,0.395860731,0,3.958607315
1406,11,GO Biological Process,,Homeostatic process,1.10E-04,CYP27B1|RCOR1|SMAD1|PRKACA|CASP3|MYB|E2F4|SMAD5|AKT1|MYC|CTNNB1,10163,10255|10324|10282|10261|10333|10288|10321|10258|10330|10318|10285,1.73E-06,,GO:0042592,0.395860731,0,3.958607315
5191,20,GO Cellular Component,,Intracellular non-membrane-bounded organelle,1.10E-04,CSNK2A1|STUB1|RBL2|SMAD2|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|SMAD3|E2F1|SKI|E2F4|CDK1|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10276|10267|10309|10303|10291|10297|10312|10282|10261|10252|10264|10270|10321|10327|10258|10330|10318|10285,8.27E-07,,GO:0043232,0.395860731,0,3.958607315
94,4,KEGG Pathways,,Endocrine resistance,1.10E-04,TP53|PRKACA|E2F1|AKT1,10163,10291|10261|10264|10330,1.07E-05,,hsa01522,0.395860731,0,3.958607315
14,3,Reactome Pathways,,TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,1.10E-04,CDK2|TP53|E2F1,10163,10303|10291|10264,1.72E-06,,HSA-6804116,0.395860731,0,3.958607315
14,3,Reactome Pathways,,Formation of axial mesoderm,1.10E-04,SMAD2|SMAD3|CTNNB1,10163,10267|10252|10285,1.72E-06,,HSA-9796292,0.395860731,0,3.958607315
336,6,WikiPathways,,PI3K-Akt signaling pathway,1.10E-04,RBL2|CDK2|TP53|MYB|AKT1|MYC,10163,10276|10303|10291|10288|10330|10318,7.09E-06,,WP4172,0.395860731,0,3.958607315
263,6,GO Biological Process,,Myeloid cell differentiation,1.20E-04,RCOR1|CEBPB|CASP3|MYB|SMAD5|CTNNB1,10163,10324|10312|10333|10288|10258|10285,1.78E-06,,GO:0030099,0.392081875,0,3.920818754
143,5,GO Biological Process,,Regulation of proteasomal ubiquitin-dependent protein catabolic process,1.20E-04,STUB1|CDK2|PLK1|SUMO2|AKT1,10163,10315|10303|10297|10273|10330,1.90E-06,,GO:0032434,0.392081875,0,3.920818754
96,4,KEGG Pathways,,AGE-RAGE signaling pathway in diabetic complications,1.20E-04,SMAD2|CASP3|SMAD3|AKT1,10163,10267|10333|10252|10330,1.16E-05,,hsa04933,0.392081875,0,3.920818754
25,3,WikiPathways,,Differentiation of white and brown adipocyte,1.20E-04,CEBPB|SMAD1|SMAD5,10163,10312|10282|10258,8.19E-06,,WP2895,0.392081875,0,3.920818754
631,8,GO Biological Process,,Mitotic cell cycle,1.30E-04,CDK2|TP53|PLK1|MYB|E2F1|E2F4|CDK1|MYC,10163,10303|10291|10297|10288|10264|10321|10327|10318,2.03E-06,,GO:0000278,0.388605665,0,3.886056648
90,4,WikiPathways,,Androgen receptor signaling pathway,1.30E-04,STUB1|SMAD3|AKT1|CTNNB1,10163,10315|10252|10330|10285,9.07E-06,,WP138,0.388605665,0,3.886056648
26,3,WikiPathways,,Wnt/beta-catenin signaling pathway in leukemia,1.30E-04,AKT1|MYC|CTNNB1,10163,10330|10318|10285,9.13E-06,,WP3658,0.388605665,0,3.886056648
637,8,GO Biological Process,,Cellular response to nitrogen compound,1.40E-04,CASP6|CDK2|TP53|CEBPB|PRKACA|CASP3|AKT1|CTNNB1,10163,10309|10303|10291|10312|10261|10333|10330|10285,2.18E-06,,GO:1901699,0.385387196,0,3.853871964
1931,13,GO Molecular Function,,Transcription regulator activity,1.40E-04,SMAD2|RCOR1|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F1|SKI|E2F4|SMAD5|MYC|CTNNB1,10163,10267|10324|10291|10312|10282|10252|10288|10264|10270|10321|10258|10318|10285,7.18E-07,,GO:0140110,0.385387196,0,3.853871964
8122,24,UniProt Keywords,,Phosphoprotein,1.40E-04,CSNK2A1|STUB1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|SKI|E2F4|CDK1|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10270|10321|10327|10279|10258|10330|10318|10285,1.62E-06,,KW-0597,0.385387196,0,3.853871964
92,4,WikiPathways,,TNF-alpha signaling pathway,1.40E-04,CSNK2A1|PLK1|CASP3|AKT1,10163,10306|10297|10333|10330,9.86E-06,,WP231,0.385387196,0,3.853871964
278,6,GO Biological Process,,Response to hypoxia,1.50E-04,STUB1|TP53|CASP3|SMAD3|E2F1|MYC,10163,10315|10291|10333|10252|10264|10318,2.44E-06,,GO:0001666,0.382390874,0,3.823908741
280,6,Reactome Pathways,,Deubiquitination,1.50E-04,SMAD2|TP53|SMAD1|SMAD3|CDK1|MYC,10163,10267|10291|10282|10252|10327|10318,2.54E-06,,HSA-5688426,0.382390874,0,3.823908741
65,4,Reactome Pathways,,FOXO-mediated transcription,1.50E-04,RBL2|SMAD2|SMAD3|AKT1,10163,10276|10267|10252|10330,2.63E-06,,HSA-9614085,0.382390874,0,3.823908741
825,9,GO Cellular Component,,Microtubule organizing center,1.60E-04,CDK2|TP53|PLK1|PRKACA|E2F1|SKI|CDK1|AKT1|CTNNB1,10163,10303|10291|10297|10261|10264|10270|10327|10330|10285,1.38E-06,,GO:0005815,0.379588002,0,3.795880017
17,3,Reactome Pathways,,FOXO-mediated transcription of cell cycle genes,1.60E-04,RBL2|SMAD2|SMAD3,10163,10276|10267|10252,2.87E-06,,HSA-9617828,0.379588002,0,3.795880017
17,3,Reactome Pathways,,Germ layer formation at gastrulation,1.60E-04,SMAD2|SMAD3|CTNNB1,10163,10267|10252|10285,2.87E-06,,HSA-9754189,0.379588002,0,3.795880017
155,5,Reactome Pathways,,Factors involved in megakaryocyte development and platelet production,1.60E-04,RCOR1|CDK2|TP53|PRKACA|MYB,10163,10324|10303|10291|10261|10288,2.79E-06,,HSA-983231,0.379588002,0,3.795880017
1710,12,COMPARTMENTS,,Catalytic complex,1.70E-04,CSNK2A1|STUB1|RCOR1|CASP6|CDK2|TP53|PRKACA|CASP3|CDK1|ACVR1|SUMO2|AKT1,10163,10306|10315|10324|10309|10303|10291|10261|10333|10327|10279|10273|10330,1.52E-06,,GOCC:1902494,0.376955108,0,3.769551079
282,6,GO Biological Process,,Sex differentiation,1.70E-04,CEBPB|CASP3|BMPR1A|BMPR1B|SMAD5|CTNNB1,10163,10312|10333|10300|10294|10258|10285,2.64E-06,,GO:0007548,0.376955108,0,3.769551079
609,8,GO Cellular Component,,Centrosome,1.70E-04,CDK2|TP53|PLK1|PRKACA|E2F1|SKI|CDK1|CTNNB1,10163,10303|10291|10297|10261|10264|10270|10327|10285,1.56E-06,,GO:0005813,0.376955108,0,3.769551079
11,3,GO Molecular Function,,co-SMAD binding,1.70E-04,SMAD2|SMAD1|SMAD3,10163,10267|10282|10252,9.22E-07,,GO:0070410,0.376955108,0,3.769551079
16,3,TISSUES,,Ovary adenocarcinoma cell line,1.70E-04,TP53|CASP3|AKT1,10163,10291|10333|10330,2.44E-06,,BTO:0001882,0.376955108,0,3.769551079
159,5,Reactome Pathways,,Regulation of TP53 Activity,1.70E-04,CSNK2A1|CDK2|TP53|CDK1|AKT1,10163,10306|10303|10291|10327|10330,3.15E-06,,HSA-5633007,0.376955108,0,3.769551079
98,4,WikiPathways,,Hippo signaling regulation pathways,1.70E-04,SMAD2|PRKACA|SMAD3|CTNNB1,10163,10267|10261|10252|10285,1.25E-05,,WP4540,0.376955108,0,3.769551079
3931,17,GO Biological Process,,Regulation of response to stimulus,1.80E-04,CSNK2A1|STUB1|CYP27B1|SMAD2|CASP6|TP53|CEBPB|PRKACA|SMAD3|MYB|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10267|10309|10291|10312|10261|10252|10288|10300|10270|10294|10279|10330|10318|10285,2.81E-06,,GO:0048583,0.374472749,0,3.744727495
100,4,WikiPathways,,Neural crest differentiation,1.80E-04,SMAD1|MYB|MYC|CTNNB1,10163,10282|10288|10318|10285,1.35E-05,,WP2064,0.374472749,0,3.744727495
100,4,WikiPathways,,Burn wound healing,1.80E-04,TP53|CASP3|SMAD3|AKT1,10163,10291|10333|10252|10330,1.35E-05,,WP5055,0.374472749,0,3.744727495
651,8,UniProt Keywords,,Cell cycle,1.90E-04,CSNK2A1|RBL2|CDK2|TP53|PLK1|E2F1|E2F4|CDK1,10163,10306|10276|10303|10291|10297|10264|10321|10327,2.55E-06,,KW-0131,0.37212464,0,3.721246399
31,3,WikiPathways,,Gastric cancer network 2,1.90E-04,TP53|MYC|CTNNB1,10163,10291|10318|10285,1.49E-05,,WP2363,0.37212464,0,3.721246399
31,3,WikiPathways,,Regucalcin in proximal tubule epithelial kidney cells,1.90E-04,SMAD2|CASP3|AKT1,10163,10267|10333|10330,1.49E-05,,WP4838,0.37212464,0,3.721246399
1191,10,GO Biological Process,,Positive regulation of catalytic activity,2.00E-04,STUB1|CYP27B1|CASP6|PLK1|SMAD3|BMPR1A|BMPR1B|AKT1|MYC|CTNNB1,10163,10315|10255|10309|10297|10252|10300|10294|10330|10318|10285,3.22E-06,,GO:0043085,0.369897,0,3.698970004
1368,11,GO Molecular Function,,"DNA-binding transcription factor activity, RNA polymerase II-specific",2.00E-04,SMAD2|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F1|SKI|E2F4|SMAD5|MYC,10163,10267|10291|10312|10282|10252|10288|10264|10270|10321|10258|10318,1.32E-06,,GO:0000981,0.369897,0,3.698970004
7,3,InterPro Domains,,GS domain,2.00E-04,BMPR1A|BMPR1B|ACVR1,10163,10300|10294|10279,3.05E-07,,IPR003605,0.369897,0,3.698970004
1094,10,GO Molecular Function,,Protein dimerization activity,2.20E-04,STUB1|TP53|CEBPB|SMAD3|E2F1|BMPR1A|E2F4|ACVR1|AKT1|MYC,10163,10315|10291|10312|10252|10264|10300|10321|10279|10330|10318,1.50E-06,,GO:0046983,0.365757732,0,3.657577319
306,6,Reactome Pathways,,Intracellular signaling by second messengers,2.20E-04,CSNK2A1|STUB1|RCOR1|TP53|PRKACA|AKT1,10163,10306|10315|10324|10291|10261|10330,4.19E-06,,HSA-9006925,0.365757732,0,3.657577319
1525,11,GO Biological Process,,Positive regulation of signal transduction,2.30E-04,CSNK2A1|CYP27B1|SMAD2|TP53|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|MYC|CTNNB1,10163,10306|10255|10267|10291|10252|10300|10270|10294|10279|10318|10285,3.82E-06,,GO:0009967,0.363827216,0,3.638272164
304,6,GO Biological Process,,Positive regulation of DNA metabolic process,2.40E-04,CDK2|CASP3|CDK1|AKT1|MYC|CTNNB1,10163,10303|10333|10327|10330|10318|10285,4.04E-06,,GO:0051054,0.361978876,0,3.619788758
167,5,GO Biological Process,,Cartilage development,2.40E-04,SMAD1|BMPR1A|BMPR1B|SMAD5|CTNNB1,10163,10282|10300|10294|10258|10285,3.97E-06,,GO:0051216,0.361978876,0,3.619788758
72,4,GO Biological Process,,Regulation of cartilage development,2.40E-04,SMAD1|SMAD3|BMPR1B|CTNNB1,10163,10282|10252|10294|10285,3.88E-06,,GO:0061035,0.361978876,0,3.619788758
166,5,GO Biological Process,,Intrinsic apoptotic signaling pathway,2.40E-04,CASP6|TP53|CEBPB|CASP3|E2F1,10163,10309|10291|10312|10333|10264,3.86E-06,,GO:0097193,0.361978876,0,3.619788758
37,3,KEGG Pathways,,Thyroid cancer,2.40E-04,TP53|MYC|CTNNB1,10163,10291|10318|10285,2.44E-05,,hsa05216,0.361978876,0,3.619788758
307,6,GO Biological Process,,Germ cell development,2.50E-04,PRKACA|BMPR1B|ACVR1|SMAD5|AKT1|CTNNB1,10163,10261|10294|10279|10258|10330|10285,4.27E-06,,GO:0007281,0.360205999,0,3.602059991
1547,11,GO Biological Process,,Response to oxygen-containing compound,2.60E-04,CYP27B1|SMAD2|CDK2|TP53|CEBPB|PRKACA|CASP3|E2F1|CDK1|AKT1|CTNNB1,10163,10255|10267|10303|10291|10312|10261|10333|10264|10327|10330|10285,4.38E-06,,GO:1901700,0.358502665,0,3.585026652
75,4,GO Biological Process,,Negative regulation of G1/S transition of mitotic cell cycle,2.70E-04,RBL2|CDK2|TP53|ACVR1,10163,10276|10303|10291|10279,4.53E-06,,GO:2000134,0.356863624,0,3.568636236
121,4,KEGG Pathways,,Oocyte meiosis,2.70E-04,CDK2|PLK1|PRKACA|CDK1,10163,10303|10297|10261|10327,2.80E-05,,hsa04114,0.356863624,0,3.568636236
963,9,GO Biological Process,,Response to organonitrogen compound,2.80E-04,STUB1|CASP6|TP53|CEBPB|PRKACA|CASP3|CDK1|AKT1|CTNNB1,10163,10315|10309|10291|10312|10261|10333|10327|10330|10285,4.88E-06,,GO:0010243,0.355284197,0,3.552841969
1560,11,GO Biological Process,,Regulation of protein modification process,2.80E-04,STUB1|TP53|PLK1|CASP3|MYB|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10315|10291|10297|10333|10288|10300|10270|10294|10279|10330|10285,4.75E-06,,GO:0031399,0.355284197,0,3.552841969
314,6,GO Biological Process,,Regulation of cellular response to growth factor stimulus,2.80E-04,STUB1|SMAD2|TP53|SMAD3|SKI|CTNNB1,10163,10315|10267|10291|10252|10270|10285,4.85E-06,,GO:0090287,0.355284197,0,3.552841969
40,3,KEGG Pathways,,Bladder cancer,2.80E-04,TP53|E2F1|MYC,10163,10291|10264|10318,3.04E-05,,hsa05219,0.355284197,0,3.552841969
36,3,WikiPathways,,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling,2.80E-04,SMAD2|SMAD3|AKT1,10163,10267|10252|10330,2.26E-05,,WP3850,0.355284197,0,3.552841969
17,3,COMPARTMENTS,,BAX complex,2.90E-04,TP53|CASP3|AKT1,10163,10291|10333|10330,2.87E-06,,GOCC:0097144,0.3537602,0,3.537602002
20,3,TISSUES,,Glioblastoma cell line,3.00E-04,TP53|CASP3|AKT1,10163,10291|10333|10330,4.45E-06,,BTO:0001530,0.352287875,0,3.522878745
245,5,WikiPathways,,MAPK signaling pathway,3.00E-04,TP53|PRKACA|CASP3|AKT1|MYC,10163,10291|10261|10333|10330|10318,2.43E-05,,WP382,0.352287875,0,3.522878745
160,5,COMPARTMENTS,,Protein kinase complex,3.10E-04,CDK2|PRKACA|CDK1|ACVR1|AKT1,10163,10303|10261|10327|10279|10330,3.24E-06,,GOCC:1902911,0.350863831,0,3.508638306
1587,11,GO Biological Process,,Positive regulation of molecular function,3.20E-04,STUB1|CYP27B1|CASP6|PLK1|SMAD3|BMPR1A|SKI|BMPR1B|AKT1|MYC|CTNNB1,10163,10315|10255|10309|10297|10252|10300|10270|10294|10330|10318|10285,5.60E-06,,GO:0044093,0.349485002,0,3.494850022
179,5,GO Biological Process,,Cardiac muscle tissue development,3.20E-04,SMAD1|BMPR1A|CDK1|ACVR1|SMAD5,10163,10282|10300|10327|10279|10258,5.52E-06,,GO:0048738,0.349485002,0,3.494850022
7835,23,GO Biological Process,,Response to stimulus,3.20E-04,CSNK2A1|STUB1|CYP27B1|SMAD2|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10267|10309|10303|10291|10297|10312|10282|10261|10333|10252|10264|10300|10270|10327|10294|10279|10258|10330|10318|10285,5.64E-06,,GO:0050896,0.349485002,0,3.494850022
323,6,GO Biological Process,,Muscle tissue development,3.20E-04,SMAD1|BMPR1A|SKI|CDK1|ACVR1|SMAD5,10163,10282|10300|10270|10327|10279|10258,5.68E-06,,GO:0060537,0.349485002,0,3.494850022
2144,13,GO Molecular Function,,Identical protein binding,3.20E-04,CSNK2A1|STUB1|SMAD2|CASP6|TP53|PLK1|CEBPB|SMAD1|SMAD3|BMPR1A|SKI|ACVR1|AKT1,10163,10306|10315|10267|10309|10291|10297|10312|10282|10252|10300|10270|10279|10330,2.36E-06,,GO:0042802,0.349485002,0,3.494850022
63,4,GO Molecular Function,,Promoter-specific chromatin binding,3.20E-04,RBL2|TP53|SMAD3|E2F4,10163,10276|10291|10252|10321,2.34E-06,,GO:1990841,0.349485002,0,3.494850022
21,3,TISSUES,,Glioma cell line,3.20E-04,TP53|CASP3|AKT1,10163,10291|10333|10330,5.08E-06,,BTO:0000711,0.349485002,0,3.494850022
3054,15,COMPARTMENTS,,Cytosol,3.30E-04,STUB1|RBL2|SMAD2|CASP6|CDK2|TP53|PLK1|SMAD1|PRKACA|CASP3|SMAD3|CDK1|SMAD5|AKT1|CTNNB1,10163,10315|10276|10267|10309|10303|10291|10297|10282|10261|10333|10252|10327|10258|10330|10285,3.61E-06,,GOCC:0005829,0.348148606,0,3.48148606
507,7,GO Biological Process,,Positive regulation of apoptotic process,3.30E-04,CASP6|TP53|CASP3|E2F1|BMPR1B|MYC|CTNNB1,10163,10309|10291|10333|10264|10294|10318|10285,5.76E-06,,GO:0043065,0.348148606,0,3.48148606
7090,22,TISSUES,,Urogenital system,3.30E-04,CSNK2A1|CYP27B1|RBL2|SMAD2|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|BMPR1A|E2F4|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10255|10276|10267|10303|10291|10297|10312|10282|10261|10333|10252|10288|10300|10321|10294|10279|10273|10258|10330|10318|10285,5.29E-06,,BTO:0003091,0.348148606,0,3.48148606
130,5,DISEASES,,Nervous system cancer,3.30E-04,CDK2|TP53|E2F1|ACVR1|AKT1,10163,10303|10291|10264|10279|10330,1.21E-06,,DOID:3093,0.348148606,0,3.48148606
81,4,GO Biological Process,,Endoderm development,3.40E-04,SMAD2|SMAD3|BMPR1A|CTNNB1,10163,10267|10252|10300|10285,6.07E-06,,GO:0007492,0.346852108,0,3.468521083
81,4,GO Biological Process,,Mitotic DNA damage checkpoint signaling,3.40E-04,CDK2|TP53|PLK1|CDK1,10163,10303|10291|10297|10327,6.07E-06,,GO:0044773,0.346852108,0,3.468521083
131,4,KEGG Pathways,,Apoptosis,3.40E-04,CASP6|TP53|CASP3|AKT1,10163,10309|10291|10333|10330,3.78E-05,,hsa04210,0.346852108,0,3.468521083
259,6,SMART Domains,,"Serine/Threonine protein kinases, catalytic domain",3.40E-04,CSNK2A1|CDK2|PLK1|PRKACA|CDK1|AKT1,10163,10306|10303|10297|10261|10327|10330,1.63E-06,,SM00220,0.346852108,0,3.468521083
133,4,KEGG Pathways,,Apelin signaling pathway,3.50E-04,SMAD2|PRKACA|SMAD3|AKT1,10163,10267|10261|10252|10330,4.00E-05,,hsa04371,0.345593196,0,3.455931956
39,3,WikiPathways,,Bladder cancer,3.50E-04,TP53|E2F1|MYC,10163,10291|10264|10318,2.83E-05,,WP2828,0.345593196,0,3.455931956
11,3,STRING Clusters,,"Dwarfin, and E3 ubiquitin-protein ligase, SMURF1 type",3.50E-04,SMAD2|SMAD3|SMAD5,10163,10267|10252|10258,9.22E-07,,CL:21329,0.345593196,0,3.455931956
23,3,GO Biological Process,,Positive regulation of mesenchymal cell proliferation,3.60E-04,BMPR1A|MYC|CTNNB1,10163,10300|10318|10285,6.51E-06,,GO:0002053,0.34436975,0,3.443697499
23,3,GO Biological Process,,Positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus,3.60E-04,TP53|SMAD1|SMAD5,10163,10291|10282|10258,6.51E-06,,GO:1901522,0.34436975,0,3.443697499
55,4,DISEASES,,Ovarian cancer,3.60E-04,TP53|AKT1|MYC|CTNNB1,10163,10291|10330|10318|10285,1.40E-06,,DOID:2394,0.34436975,0,3.443697499
40,3,WikiPathways,,ATM signaling pathway,3.70E-04,CDK2|TP53|CDK1,10163,10303|10291|10327,3.04E-05,,WP2516,0.343179828,0,3.431798276
744,8,GO Biological Process,,Cellular response to DNA damage stimulus,3.80E-04,STUB1|CDK2|TP53|PLK1|CASP3|E2F1|CDK1|MYC,10163,10315|10303|10291|10297|10333|10264|10327|10318,6.78E-06,,GO:0006974,0.34202164,0,3.420216403
749,8,GO Biological Process,,Immune system development,3.90E-04,RCOR1|TP53|CEBPB|CASP3|SMAD3|MYB|SMAD5|CTNNB1,10163,10324|10291|10312|10333|10252|10288|10258|10285,7.11E-06,,GO:0002520,0.340893539,0,3.408935393
24,3,GO Biological Process,,Cell surface receptor signaling pathway involved in heart development,4.00E-04,BMPR1A|ACVR1|CTNNB1,10163,10300|10279|10285,7.32E-06,,GO:0061311,0.339794001,0,3.397940009
42,3,WikiPathways,,TNF-related weak inducer of apoptosis (TWEAK) signaling pathway,4.10E-04,CASP3|AKT1|CTNNB1,10163,10333|10330|10285,3.49E-05,,WP2036,0.338721614,0,3.387216143
86,4,GO Biological Process,,G1/S transition of mitotic cell cycle,4.20E-04,CDK2|E2F1|E2F4|MYC,10163,10303|10264|10321|10318,7.63E-06,,GO:0000082,0.337675071,0,3.37675071
1018,9,GO Biological Process,,Positive regulation of protein modification process,4.20E-04,STUB1|TP53|PLK1|MYB|BMPR1A|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10315|10291|10297|10288|10300|10294|10279|10330|10285,7.63E-06,,GO:0031401,0.337675071,0,3.37675071
25,3,Reactome Pathways,,Cyclin A/B1/B2 associated events during G2/M transition,4.20E-04,CDK2|PLK1|CDK1,10163,10303|10297|10327,8.19E-06,,HSA-69273,0.337675071,0,3.37675071
195,5,Reactome Pathways,,G2/M Transition,4.20E-04,CDK2|TP53|PLK1|PRKACA|CDK1,10163,10303|10291|10297|10261|10327,8.28E-06,,HSA-69275,0.337675071,0,3.37675071
6568,21,GO Biological Process,,Cellular metabolic process,4.30E-04,CSNK2A1|STUB1|CYP27B1|SMAD2|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|SMAD3|E2F1|BMPR1A|SKI|CDK1|BMPR1B|ACVR1|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10267|10303|10291|10297|10312|10282|10261|10252|10264|10300|10270|10327|10294|10279|10258|10330|10318|10285,8.00E-06,,GO:0044237,0.336653154,0,3.366531544
286,5,KEGG Pathways,,MAPK signaling pathway,4.30E-04,TP53|PRKACA|CASP3|AKT1|MYC,10163,10291|10261|10333|10330|10318,5.02E-05,,hsa04010,0.336653154,0,3.366531544
10,3,InterPro Domains,,Activin types I and II receptor domain,4.30E-04,BMPR1A|BMPR1B|ACVR1,10163,10300|10294|10279,7.25E-07,,IPR000472,0.336653154,0,3.366531544
43,3,WikiPathways,,Heart development,4.30E-04,SMAD1|BMPR1A|CTNNB1,10163,10282|10300|10285,3.73E-05,,WP1591,0.336653154,0,3.366531544
25,3,GO Biological Process,,Regulation of activin receptor signaling pathway,4.40E-04,SMAD2|SKI|ACVR1,10163,10267|10270|10279,8.19E-06,,GO:0032925,0.335654732,0,3.356547324
26,3,Reactome Pathways,,Downregulation of TGF-beta receptor signaling,4.40E-04,STUB1|SMAD2|SMAD3,10163,10315|10267|10252,9.13E-06,,HSA-2173788,0.335654732,0,3.356547324
88,4,GO Biological Process,,Centrosome cycle,4.50E-04,CDK2|PLK1|CDK1|CTNNB1,10163,10303|10297|10327|10285,8.32E-06,,GO:0007098,0.334678749,0,3.346787486
537,7,GO Biological Process,,Mitotic cell cycle process,4.50E-04,CDK2|TP53|PLK1|E2F1|E2F4|CDK1|MYC,10163,10303|10291|10297|10264|10321|10327|10318,8.35E-06,,GO:1903047,0.334678749,0,3.346787486
1575,11,COMPARTMENTS,,Cytoskeleton,4.60E-04,CDK2|TP53|PLK1|PRKACA|CASP3|E2F1|SKI|CDK1|AKT1|MYC|CTNNB1,10163,10303|10291|10297|10261|10333|10264|10270|10327|10330|10318|10285,5.21E-06,,GOCC:0005856,0.333724217,0,3.337242168
973,9,COMPARTMENTS,,Microtubule cytoskeleton,4.60E-04,CDK2|TP53|PLK1|PRKACA|E2F1|SKI|CDK1|AKT1|CTNNB1,10163,10303|10291|10297|10261|10264|10270|10327|10330|10285,5.30E-06,,GOCC:0015630,0.333724217,0,3.337242168
541,7,GO Biological Process,,Regulation of DNA metabolic process,4.70E-04,CDK2|TP53|CASP3|CDK1|AKT1|MYC|CTNNB1,10163,10303|10291|10333|10327|10330|10318|10285,8.76E-06,,GO:0051052,0.332790214,0,3.327902142
1318,10,TISSUES,,Fetus,4.70E-04,RBL2|SMAD2|CDK2|CEBPB|SMAD3|MYB|BMPR1A|ACVR1|MYC|CTNNB1,10163,10276|10267|10303|10312|10252|10288|10300|10279|10318|10285,7.90E-06,,BTO:0000449,0.332790214,0,3.327902142
15,3,DISEASES,,Pancreatic carcinoma,4.70E-04,TP53|AKT1|MYC,10163,10291|10330|10318,2.06E-06,,DOID:4905,0.332790214,0,3.327902142
204,5,Reactome Pathways,,Signaling by NOTCH,4.80E-04,TP53|SMAD3|E2F1|AKT1|MYC,10163,10291|10252|10264|10330|10318,1.03E-05,,HSA-157118,0.331875876,0,3.318758763
203,5,Reactome Pathways,,Ub-specific processing proteases,4.80E-04,SMAD2|TP53|SMAD1|SMAD3|MYC,10163,10267|10291|10282|10252|10318,1.00E-05,,HSA-5689880,0.331875876,0,3.318758763
94,4,Reactome Pathways,,Transcriptional regulation by RUNX3,4.90E-04,TP53|SMAD3|MYC|CTNNB1,10163,10291|10252|10318|10285,1.07E-05,,HSA-8878159,0.330980392,0,3.30980392
45,3,WikiPathways,,Aryl hydrocarbon receptor pathway,4.90E-04,CDK2|E2F1|MYC,10163,10303|10264|10318,4.24E-05,,WP2586,0.330980392,0,3.30980392
45,3,WikiPathways,,Translation inhibitors in chronically activated PDGFRA cells,4.90E-04,CSNK2A1|PRKACA|AKT1,10163,10306|10261|10330,4.24E-05,,WP4566,0.330980392,0,3.30980392
135,4,WikiPathways,,Measles virus infection,4.90E-04,CSNK2A1|CDK2|TP53|CASP3,10163,10306|10303|10291|10333,4.24E-05,,WP4630,0.330980392,0,3.30980392
91,4,GO Biological Process,,Positive regulation of protein localization to nucleus,5.00E-04,PLK1|SMAD3|CDK1|AKT1,10163,10297|10252|10327|10330,9.46E-06,,GO:1900182,0.330103,0,3.301029996
46,3,WikiPathways,,Microtubule cytoskeleton regulation,5.00E-04,PRKACA|CDK1|AKT1,10163,10261|10327|10330,4.52E-05,,WP2038,0.330103,0,3.301029996
695,8,GO Molecular Function,,Protein domain specific binding,5.10E-04,STUB1|SMAD2|CDK2|TP53|PRKACA|SKI|E2F4|CTNNB1,10163,10315|10267|10303|10291|10261|10270|10321|10285,4.13E-06,,GO:0019904,0.329242982,0,3.292429824
16,3,DISEASES,,Retinoblastoma,5.30E-04,CDK2|TP53|E2F1,10163,10303|10291|10264,2.44E-06,,DOID:768,0.327572413,0,3.27572413
140,4,WikiPathways,,Endoderm differentiation,5.30E-04,SMAD2|SMAD3|BMPR1A|CTNNB1,10163,10267|10252|10300|10285,4.87E-05,,WP2853,0.327572413,0,3.27572413
140,4,WikiPathways,,Neuroinflammation and glutamatergic signaling,5.30E-04,SMAD2|PRKACA|SMAD3|AKT1,10163,10267|10261|10252|10330,4.87E-05,,WP5083,0.327572413,0,3.27572413
93,4,GO Biological Process,,Erythrocyte differentiation,5.40E-04,RCOR1|CASP3|MYB|SMAD5,10163,10324|10333|10288|10258,1.03E-05,,GO:0030218,0.326760624,0,3.26760624
534,7,UniProt Keywords,,Apoptosis,5.40E-04,CSNK2A1|CASP6|TP53|CASP3|E2F1|CDK1|AKT1,10163,10306|10309|10291|10333|10264|10327|10330,8.05E-06,,KW-0053,0.326760624,0,3.26760624
29,3,Reactome Pathways,,Activation of BH3-only proteins,5.50E-04,TP53|E2F1|AKT1,10163,10291|10264|10330,1.24E-05,,HSA-114452,0.325963731,0,3.259637311
29,3,Reactome Pathways,,Downregulation of SMAD2/3:SMAD4 transcriptional activity,5.50E-04,SMAD2|SMAD3|SKI,10163,10267|10252|10270,1.24E-05,,HSA-2173795,0.325963731,0,3.259637311
6,2,WikiPathways,,Metastatic brain tumor,5.60E-04,TP53|MYC,10163,10291|10318,5.41E-05,,WP2249,0.325181197,0,3.251811973
143,4,WikiPathways,,Brain-derived neurotrophic factor (BDNF) signaling pathway,5.60E-04,CSNK2A1|CASP3|AKT1|CTNNB1,10163,10306|10333|10330|10285,5.27E-05,,WP2380,0.325181197,0,3.251811973
17,3,DISEASES,,Tumor of exocrine pancreas,5.70E-04,TP53|AKT1|MYC,10163,10291|10330|10318,2.87E-06,,DOID:1795,0.324412514,0,3.244125144
153,4,KEGG Pathways,,Cushing syndrome,5.70E-04,CDK2|PRKACA|E2F1|CTNNB1,10163,10303|10261|10264|10285,6.81E-05,,hsa04934,0.324412514,0,3.244125144
411,8,Monarch Phenotype,,Abnormal bleeding,5.70E-04,SMAD2|TP53|PRKACA|SMAD3|BMPR1A|AKT1|MYC|CTNNB1,10163,10267|10291|10261|10252|10300|10330|10318|10285,8.30E-08,,HP:0001892,0.324412514,0,3.244125144
244,7,Monarch Phenotype,,Internal hemorrhage,5.70E-04,SMAD2|TP53|SMAD3|BMPR1A|AKT1|MYC|CTNNB1,10163,10267|10291|10252|10300|10330|10318|10285,4.68E-08,,HP:0011029,0.324412514,0,3.244125144
28,3,GO Biological Process,,Activin receptor signaling pathway,5.80E-04,SMAD2|SMAD3|ACVR1,10163,10267|10252|10279,1.12E-05,,GO:0032924,0.323657201,0,3.236572006
96,4,GO Biological Process,,Axis specification,6.00E-04,SMAD2|BMPR1A|SKI|CTNNB1,10163,10267|10300|10270|10285,1.16E-05,,GO:0009798,0.322184875,0,3.22184875
96,4,GO Biological Process,,Positive regulation of proteasomal ubiquitin-dependent protein catabolic process,6.00E-04,STUB1|PLK1|SUMO2|AKT1,10163,10315|10297|10273|10330,1.16E-05,,GO:0032436,0.322184875,0,3.22184875
2,2,GO Biological Process,,Positive regulation of determination of dorsal identity,6.00E-04,ACVR1|CTNNB1,10163,10279|10285,1.16E-05,,GO:2000017,0.322184875,0,3.22184875
51,3,WikiPathways,,Copper homeostasis,6.20E-04,TP53|CASP3|AKT1,10163,10291|10333|10330,6.05E-05,,WP3286,0.320760831,0,3.207608311
51,3,WikiPathways,,Wnt signaling pathway,6.20E-04,AKT1|MYC|CTNNB1,10163,10330|10318|10285,6.05E-05,,WP363,0.320760831,0,3.207608311
12,3,InterPro Domains,,"Ser/Thr protein kinase, TGFB receptor",6.30E-04,BMPR1A|BMPR1B|ACVR1,10163,10300|10294|10279,1.15E-06,,IPR000333,0.320065945,0,3.200659451
52,4,InterPro Domains,,SMAD/FHA domain superfamily,6.30E-04,SMAD2|SMAD1|SMAD3|SMAD5,10163,10267|10282|10252|10258,1.13E-06,,IPR008984,0.320065945,0,3.200659451
33,4,Monarch Phenotype,,Large intestinal polyposis,6.30E-04,TP53|BMPR1A|AKT1|CTNNB1,10163,10291|10300|10330|10285,2.08E-07,,HP:0030255,0.320065945,0,3.200659451
2,2,TISSUES,,HEP-3B cell,6.40E-04,TP53|CASP3,10163,10291|10333,1.16E-05,,BTO:0000972,0.319382003,0,3.193820026
2,2,TISSUES,,HCT-15 cell,6.40E-04,TP53|CASP3,10163,10291|10333,1.16E-05,,BTO:0002201,0.319382003,0,3.193820026
52,3,WikiPathways,,Netrin-UNC5B signaling pathway,6.40E-04,TP53|CASP3|AKT1,10163,10291|10333|10330,6.39E-05,,WP4747,0.319382003,0,3.193820026
159,4,KEGG Pathways,,MicroRNAs in cancer,6.50E-04,TP53|CASP3|E2F1|MYC,10163,10291|10333|10264|10318,7.88E-05,,hsa05206,0.318708664,0,3.187086643
1394,10,GO Biological Process,,Macromolecule biosynthetic process,6.60E-04,SMAD2|CDK2|TP53|CEBPB|SMAD1|E2F1|SKI|BMPR1B|AKT1|CTNNB1,10163,10267|10303|10291|10312|10282|10264|10270|10294|10330|10285,1.29E-05,,GO:0009059,0.318045606,0,3.180456064
214,5,GO Biological Process,,Regulation of myeloid cell differentiation,6.60E-04,RCOR1|CEBPB|MYB|MYC|CTNNB1,10163,10324|10312|10288|10318|10285,1.29E-05,,GO:0045637,0.318045606,0,3.180456064
214,5,GO Biological Process,,Positive regulation of protein catabolic process,6.60E-04,CSNK2A1|STUB1|PLK1|SUMO2|AKT1,10163,10306|10315|10297|10273|10330,1.29E-05,,GO:0045732,0.318045606,0,3.180456064
574,7,GO Biological Process,,Cellular response to organonitrogen compound,6.60E-04,CASP6|TP53|CEBPB|PRKACA|CASP3|AKT1|CTNNB1,10163,10309|10291|10312|10261|10333|10330|10285,1.28E-05,,GO:0071417,0.318045606,0,3.180456064
216,5,GO Biological Process,,Bone development,6.80E-04,TP53|SMAD1|SKI|BMPR1B|SMAD5,10163,10291|10282|10270|10294|10258,1.34E-05,,GO:0060348,0.316749109,0,3.167491087
1459,12,Monarch Phenotype,,Abnormality of limb bone morphology,6.80E-04,CSNK2A1|STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1,10163,10306|10315|10255|10267|10291|10261|10252|10300|10270|10294|10279|10330,2.79E-07,,HP:0002813,0.316749109,0,3.167491087
101,4,GO Biological Process,,Regulation of gliogenesis,7.10E-04,TP53|E2F1|SKI|CTNNB1,10163,10291|10264|10270|10285,1.41E-05,,GO:0014013,0.314874165,0,3.148741651
219,5,GO Biological Process,,MAPK cascade,7.20E-04,SMAD1|SMAD3|CDK1|MYC|CTNNB1,10163,10282|10252|10327|10318|10285,1.43E-05,,GO:0000165,0.31426675,0,3.142667504
2121,12,GO Biological Process,,Immune system process,7.20E-04,CYP27B1|RCOR1|CASP6|TP53|CEBPB|CASP3|SMAD3|MYB|BMPR1A|SMAD5|AKT1|CTNNB1,10163,10255|10324|10309|10291|10312|10333|10252|10288|10300|10258|10330|10285,1.43E-05,,GO:0002376,0.31426675,0,3.142667504
827,8,GO Biological Process,,Response to lipid,7.30E-04,CYP27B1|SMAD2|CEBPB|CASP3|E2F1|ACVR1|AKT1|CTNNB1,10163,10255|10267|10312|10333|10264|10279|10330|10285,1.46E-05,,GO:0033993,0.313667714,0,3.13667714
586,7,GO Biological Process,,Positive regulation of transferase activity,7.30E-04,STUB1|PLK1|BMPR1A|BMPR1B|AKT1|MYC|CTNNB1,10163,10315|10297|10300|10294|10330|10318|10285,1.46E-05,,GO:0051347,0.313667714,0,3.13667714
1717,11,UniProt Keywords,,Isopeptide bond,7.30E-04,STUB1|RCOR1|TP53|PLK1|CEBPB|SMAD3|MYB|CDK1|SUMO2|AKT1|MYC,10163,10315|10324|10291|10297|10312|10252|10288|10327|10273|10330|10318,1.19E-05,,KW-1017,0.313667714,0,3.13667714
165,4,KEGG Pathways,,Tuberculosis,7.30E-04,CYP27B1|CEBPB|CASP3|AKT1,10163,10255|10312|10333|10330,9.06E-05,,hsa05152,0.313667714,0,3.13667714
1107,9,GO Biological Process,,Response to abiotic stimulus,7.40E-04,STUB1|TP53|PRKACA|CASP3|SMAD3|E2F1|AKT1|MYC|CTNNB1,10163,10315|10291|10261|10333|10252|10264|10330|10318|10285,1.49E-05,,GO:0009628,0.313076828,0,3.13076828
55,3,WikiPathways,,DNA IR-double strand breaks and cellular response via ATM,7.40E-04,TP53|CASP3|E2F1,10163,10291|10333|10264,7.50E-05,,WP3959,0.313076828,0,3.13076828
12838,28,GO Molecular Function,,Binding,7.60E-04,CSNK2A1|STUB1|CYP27B1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,6.28E-06,,GO:0005488,0.311918641,0,3.119186408
2978,14,GO Biological Process,,Regulation of signal transduction,7.80E-04,CSNK2A1|STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10267|10291|10261|10252|10300|10270|10294|10279|10330|10318|10285,1.60E-05,,GO:0009966,0.31079054,0,3.107905397
32,3,GO Biological Process,,Positive regulation of cartilage development,7.90E-04,SMAD1|SMAD3|BMPR1B,10163,10282|10252|10294,1.63E-05,,GO:0061036,0.310237291,0,3.102372909
333,6,GO Molecular Function,,DNA-binding transcription repressor activity,7.90E-04,TP53|CEBPB|SMAD3|SKI|SMAD5|MYC,10163,10291|10312|10252|10270|10258|10318,6.74E-06,,GO:0001217,0.310237291,0,3.102372909
1121,9,GO Biological Process,,Organic cyclic compound biosynthetic process,8.00E-04,CYP27B1|SMAD2|CDK2|TP53|CEBPB|SMAD1|E2F1|SKI|CTNNB1,10163,10255|10267|10303|10291|10312|10282|10264|10270|10285,1.65E-05,,GO:1901362,0.309691001,0,3.096910013
222,5,TISSUES,,Chronic lymphocytic leukemia cell,8.10E-04,CDK2|PRKACA|E2F1|CDK1|CTNNB1,10163,10303|10261|10264|10327|10285,1.53E-05,,BTO:0001546,0.309151498,0,3.091514981
171,4,KEGG Pathways,,Transcriptional misregulation in cancer,8.10E-04,TP53|CEBPB|SMAD1|MYC,10163,10291|10312|10282|10318,1.00E-04,,hsa05202,0.309151498,0,3.091514981
3,2,Reactome Pathways,,SMAD4 MH2 Domain Mutants in Cancer,8.30E-04,SMAD2|SMAD3,10163,10267|10252,1.94E-05,,HSA-3311021,0.308092191,0,3.080921908
3,2,Reactome Pathways,,SMAD2/3 MH2 Domain Mutants in Cancer,8.30E-04,SMAD2|SMAD3,10163,10267|10252,1.94E-05,,HSA-3315487,0.308092191,0,3.080921908
8,2,WikiPathways,,Caloric restriction and aging,8.50E-04,TP53|AKT1,10163,10291|10330,8.68E-05,,WP4191,0.307058107,0,3.070581074
229,5,GO Biological Process,,Skeletal system morphogenesis,8.60E-04,SMAD2|SMAD3|SKI|BMPR1B|CTNNB1,10163,10267|10252|10270|10294|10285,1.77E-05,,GO:0048705,0.306550155,0,3.065501549
64,3,KEGG Pathways,,Mitophagy - animal,8.80E-04,CSNK2A1|TP53|E2F1,10163,10306|10291|10264,1.20E-04,,hsa04137,0.305551733,0,3.055517328
59,3,WikiPathways,,Markers of kidney cell lineage,8.80E-04,SMAD1|SMAD5|CTNNB1,10163,10282|10258|10285,9.16E-05,,WP5236,0.305551733,0,3.055517328
978,9,DISEASES,,Cancer,9.10E-04,CDK2|TP53|CASP3|MYB|E2F1|ACVR1|AKT1|MYC|CTNNB1,10163,10303|10291|10333|10288|10264|10279|10330|10318|10285,5.52E-06,,DOID:162,0.304095861,0,3.040958608
60,3,WikiPathways,,Development of ureteric collection system,9.10E-04,SMAD1|BMPR1A|CTNNB1,10163,10282|10300|10285,9.61E-05,,WP5053,0.304095861,0,3.040958608
3,2,GO Biological Process,,Osteoblast fate commitment,9.30E-04,SMAD1|SMAD5,10163,10282|10258,1.94E-05,,GO:0002051,0.303151705,0,3.031517051
1143,9,GO Biological Process,,Negative regulation of molecular function,9.30E-04,CSNK2A1|STUB1|CYP27B1|TP53|PLK1|CASP3|E2F1|SKI|AKT1,10163,10306|10315|10255|10291|10297|10333|10264|10270|10330,1.92E-05,,GO:0044092,0.303151705,0,3.031517051
34,3,GO Biological Process,,Negative regulation of fibroblast proliferation,9.30E-04,TP53|SKI|MYC,10163,10291|10270|10318,1.93E-05,,GO:0048147,0.303151705,0,3.031517051
349,5,KEGG Pathways,,PI3K-Akt signaling pathway,9.50E-04,RBL2|CDK2|TP53|AKT1|MYC,10163,10276|10303|10291|10330|10318,1.30E-04,,hsa04151,0.302227639,0,3.022276395
111,4,GO Biological Process,,Regulation of cell cycle G2/M phase transition,9.60E-04,CDK2|TP53|PLK1|CDK1,10163,10303|10291|10297|10327,2.01E-05,,GO:1902749,0.301772877,0,3.017728767
3,2,TISSUES,,DLD-1 cell,9.60E-04,TP53|CTNNB1,10163,10291|10285,1.94E-05,,BTO:0000391,0.301772877,0,3.017728767
3,2,TISSUES,,RBL-1 cell,9.60E-04,RBL2|E2F4,10163,10276|10321,1.94E-05,,BTO:0000994,0.301772877,0,3.017728767
3,2,TISSUES,,Rhizome,9.60E-04,CASP3|AKT1,10163,10333|10330,1.94E-05,,BTO:0001181,0.301772877,0,3.017728767
3,2,TISSUES,,NCI-H460 cell,9.60E-04,TP53|CASP3,10163,10291|10333,1.94E-05,,BTO:0002207,0.301772877,0,3.017728767
236,5,GO Biological Process,,Regulation of cysteine-type endopeptidase activity,9.70E-04,CSNK2A1|CASP6|SMAD3|AKT1|MYC,10163,10306|10309|10252|10330|10318,2.04E-05,,GO:2000116,0.301322827,0,3.013228266
356,7,Monarch Phenotype,,Pain,9.80E-04,SMAD2|TP53|SMAD3|BMPR1A|AKT1|MYC|CTNNB1,10163,10267|10291|10252|10300|10330|10318|10285,5.72E-07,,EFO:0003843,0.300877392,0,3.008773924
355,7,Monarch Phenotype,,Abnormal morphology of female internal genitalia,9.80E-04,TP53|SMAD3|BMPR1A|BMPR1B|AKT1|MYC|CTNNB1,10163,10291|10252|10300|10294|10330|10318|10285,5.62E-07,,HP:0000008,0.300877392,0,3.008773924
539,8,Monarch Phenotype,,Pain,9.80E-04,CYP27B1|SMAD2|TP53|SMAD3|BMPR1A|AKT1|MYC|CTNNB1,10163,10255|10267|10291|10252|10300|10330|10318|10285,6.33E-07,,HP:0012531,0.300877392,0,3.008773924
35,3,GO Biological Process,,Regulation of glial cell proliferation,9.90E-04,TP53|E2F1|SKI,10163,10291|10264|10270,2.09E-05,,GO:0060251,0.300436481,0,3.004364805
2203,12,GO Biological Process,,Nucleic acid metabolic process,9.90E-04,STUB1|SMAD2|CDK2|TP53|CEBPB|SMAD1|PRKACA|SMAD3|E2F1|SKI|CDK1|CTNNB1,10163,10315|10267|10303|10291|10312|10282|10261|10252|10264|10270|10327|10285,2.10E-05,,GO:0090304,0.300436481,0,3.004364805
62,3,WikiPathways,,Endochondral ossification,9.90E-04,PRKACA|BMPR1A|AKT1,10163,10261|10300|10330,1.10E-04,,WP474,0.300436481,0,3.004364805
62,3,WikiPathways,,Endochondral ossification with skeletal dysplasias,9.90E-04,PRKACA|BMPR1A|AKT1,10163,10261|10300|10330,1.10E-04,,WP4808,0.300436481,0,3.004364805
238,5,GO Biological Process,,Mesenchyme development,0.001,SMAD2|SMAD3|BMPR1A|ACVR1|CTNNB1,10163,10267|10252|10300|10279|10285,2.12E-05,,GO:0060485,0.3,0,3
70,3,KEGG Pathways,,Platinum drug resistance,0.001,TP53|CASP3|AKT1,10163,10291|10333|10330,1.50E-04,,hsa01524,0.3,0,3
69,3,KEGG Pathways,,Adherens junction,0.001,CSNK2A1|SMAD3|CTNNB1,10163,10306|10252|10285,1.40E-04,,hsa04520,0.3,0,3
71,3,KEGG Pathways,,Glioma,0.001,TP53|E2F1|AKT1,10163,10291|10264|10330,1.60E-04,,hsa05214,0.3,0,3
68,3,KEGG Pathways,,Non-small cell lung cancer,0.001,TP53|E2F1|AKT1,10163,10291|10264|10330,1.40E-04,,hsa05223,0.3,0,3
68,3,KEGG Pathways,,Central carbon metabolism in cancer,0.001,TP53|AKT1|MYC,10163,10291|10330|10318,1.40E-04,,hsa05230,0.3,0,3
419,6,GO Biological Process,,Gland development,0.0011,SMAD2|CEBPB|SMAD3|BMPR1A|AKT1|CTNNB1,10163,10267|10312|10252|10300|10330|10285,2.43E-05,,GO:0048732,0.295860731,0,2.958607315
72,3,KEGG Pathways,,Melanoma,0.0011,TP53|E2F1|AKT1,10163,10291|10264|10330,1.60E-04,,hsa05218,0.295860731,0,2.958607315
38,3,Reactome Pathways,,Apoptotic cleavage of cellular proteins,0.0011,CASP6|CASP3|CTNNB1,10163,10309|10333|10285,2.63E-05,,HSA-111465,0.295860731,0,2.958607315
430,6,Reactome Pathways,,Diseases of signal transduction by growth factor receptors and second messengers,0.0011,SMAD2|CEBPB|SMAD3|AKT1|MYC|CTNNB1,10163,10267|10312|10252|10330|10318|10285,2.81E-05,,HSA-5663202,0.295860731,0,2.958607315
39,3,Reactome Pathways,,Transcriptional Regulation by VENTX,0.0011,TP53|CEBPB|CTNNB1,10163,10291|10312|10285,2.83E-05,,HSA-8853884,0.295860731,0,2.958607315
119,4,Reactome Pathways,,Transcriptional regulation by RUNX2,0.0011,STUB1|SMAD1|CDK1|AKT1,10163,10315|10282|10327|10330,2.62E-05,,HSA-8878166,0.295860731,0,2.958607315
65,3,WikiPathways,,Physico-chemical features and toxicity-associated pathways,0.0011,AKT1|MYC|CTNNB1,10163,10330|10318|10285,1.20E-04,,WP3680,0.295860731,0,2.958607315
38,3,GO Biological Process,,Cardiac conduction system development,0.0012,SMAD1|BMPR1A|SMAD5,10163,10282|10300|10258,2.63E-05,,GO:0003161,0.292081875,0,2.920818754
422,6,GO Biological Process,,Response to xenobiotic stimulus,0.0012,TP53|CASP3|E2F1|CDK1|MYC|CTNNB1,10163,10291|10333|10264|10327|10318|10285,2.53E-05,,GO:0009410,0.292081875,0,2.920818754
900,8,GO Biological Process,,Peptidyl-amino acid modification,0.0012,CSNK2A1|CDK2|PLK1|PRKACA|CDK1|ACVR1|SUMO2|AKT1,10163,10306|10303|10297|10261|10327|10279|10273|10330,2.67E-05,,GO:0018193,0.292081875,0,2.920818754
2,2,GO Cellular Component,,Homomeric SMAD protein complex,0.0012,SMAD2|SMAD1,10163,10267|10282,1.16E-05,,GO:0071142,0.292081875,0,2.920818754
361,6,GO Molecular Function,,Protein serine kinase activity,0.0012,CSNK2A1|CDK2|PLK1|PRKACA|CDK1|AKT1,10163,10306|10303|10297|10261|10327|10330,1.06E-05,,GO:0106310,0.292081875,0,2.920818754
757,8,DISEASES,,Organ system cancer,0.0012,CDK2|TP53|CASP3|E2F1|ACVR1|AKT1|MYC|CTNNB1,10163,10303|10291|10333|10264|10279|10330|10318|10285,7.68E-06,,DOID:0050686,0.292081875,0,2.920818754
68,3,WikiPathways,,Melanoma,0.0012,TP53|E2F1|AKT1,10163,10291|10264|10330,1.40E-04,,WP4685,0.292081875,0,2.920818754
391,7,Monarch Phenotype,,Abnormal internal genitalia,0.0012,TP53|SMAD3|BMPR1A|BMPR1B|AKT1|MYC|CTNNB1,10163,10291|10252|10300|10294|10330|10318|10285,1.06E-06,,HP:0000812,0.292081875,0,2.920818754
821,9,Monarch Phenotype,,Generalized abnormality of skin,0.0012,STUB1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|AKT1|CTNNB1,10163,10315|10267|10291|10261|10252|10300|10270|10330|10285,1.33E-06,,HP:0011354,0.292081875,0,2.920818754
2018,13,Monarch Phenotype,,Abnormality of limbs,0.0012,CSNK2A1|STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10315|10255|10267|10291|10261|10252|10300|10270|10294|10279|10330|10285,1.19E-06,,HP:0040064,0.292081875,0,2.920818754
4,2,GO Biological Process,,Mullerian duct regression,0.0013,BMPR1A|SMAD5,10163,10300|10258,2.90E-05,,GO:0001880,0.288605665,0,2.886056648
4,2,TISSUES,,SW-480 cell,0.0013,TP53|CTNNB1,10163,10291|10285,2.90E-05,,BTO:0000038,0.288605665,0,2.886056648
6444,20,TISSUES,,Reproductive system,0.0013,CSNK2A1|RBL2|SMAD2|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|BMPR1A|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10276|10267|10303|10291|10297|10312|10282|10261|10333|10252|10288|10300|10294|10279|10273|10258|10330|10318|10285,3.18E-05,,BTO:0000081,0.288605665,0,2.886056648
40,3,TISSUES,,Intestinal epithelium,0.0013,TP53|CDK1|CTNNB1,10163,10291|10327|10285,3.04E-05,,BTO:0000781,0.288605665,0,2.886056648
4,2,TISSUES,,SKOV-3 cell,0.0013,CASP3|AKT1,10163,10333|10330,2.90E-05,,BTO:0000948,0.288605665,0,2.886056648
4,2,TISSUES,,PC-3 cell,0.0013,CASP3|AKT1,10163,10333|10330,2.90E-05,,BTO:0001061,0.288605665,0,2.886056648
4,2,TISSUES,,H9c2 cell,0.0013,CASP3|AKT1,10163,10333|10330,2.90E-05,,BTO:0001879,0.288605665,0,2.886056648
4,2,TISSUES,,U-87MG cell,0.0013,TP53|AKT1,10163,10291|10330,2.90E-05,,BTO:0002036,0.288605665,0,2.886056648
9,3,Pfam,,Activin types I and II receptor domain,0.0013,BMPR1A|BMPR1B|ACVR1,10163,10300|10294|10279,5.59E-07,,PF01064,0.288605665,0,2.886056648
60,4,Monarch Phenotype,,Neoplasm of the stomach,0.0013,TP53|BMPR1A|AKT1|CTNNB1,10163,10291|10300|10330|10285,1.95E-06,,HP:0006753,0.288605665,0,2.886056648
422,7,Monarch Phenotype,,Abnormality of the female genitalia,0.0013,TP53|SMAD3|BMPR1A|BMPR1B|AKT1|MYC|CTNNB1,10163,10291|10252|10300|10294|10330|10318|10285,1.75E-06,,HP:0010460,0.288605665,0,2.886056648
14,3,Monarch Phenotype,,Anasarca,0.0013,TP53|BMPR1A|CTNNB1,10163,10291|10300|10285,1.72E-06,,HP:0012050,0.288605665,0,2.886056648
144,5,Monarch Phenotype,,Sarcoma,0.0013,TP53|BMPR1A|BMPR1B|AKT1|CTNNB1,10163,10291|10300|10294|10330|10285,1.96E-06,,HP:0100242,0.288605665,0,2.886056648
655,7,GO Biological Process,,Hemopoiesis,0.0014,RCOR1|TP53|CEBPB|CASP3|MYB|SMAD5|CTNNB1,10163,10324|10291|10312|10333|10288|10258|10285,2.97E-05,,GO:0030097,0.285387196,0,2.853871964
436,6,GO Biological Process,,Reproductive structure development,0.0014,CYP27B1|CEBPB|CASP3|BMPR1B|AKT1|CTNNB1,10163,10255|10312|10333|10294|10330|10285,3.03E-05,,GO:0048608,0.285387196,0,2.853871964
256,5,GO Biological Process,,Homeostasis of number of cells,0.0014,RCOR1|CASP3|MYB|SMAD5|AKT1,10163,10324|10333|10288|10258|10330,2.99E-05,,GO:0048872,0.285387196,0,2.853871964
209,4,KEGG Pathways,,Salmonella infection,0.0014,CASP3|AKT1|MYC|CTNNB1,10163,10333|10330|10318|10285,2.20E-04,,hsa05132,0.285387196,0,2.853871964
453,6,Reactome Pathways,,Signaling by Interleukins,0.0014,TP53|PRKACA|CASP3|SMAD3|AKT1|MYC,10163,10291|10261|10333|10252|10330|10318,3.74E-05,,HSA-449147,0.285387196,0,2.853871964
639,8,Monarch Phenotype,,Abnormal bone structure,0.0014,CYP27B1|TP53|PRKACA|SMAD3|SKI|ACVR1|AKT1|CTNNB1,10163,10255|10291|10261|10252|10270|10279|10330|10285,2.23E-06,,HP:0003330,0.285387196,0,2.853871964
275,6,Monarch Phenotype,,Neoplasm by histology,0.0014,TP53|BMPR1A|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10291|10300|10294|10279|10330|10285,2.29E-06,,HP:0011792,0.285387196,0,2.853871964
128,4,GO Biological Process,,Embryonic epithelial tube formation,0.0015,PRKACA|CASP3|SKI|CTNNB1,10163,10261|10333|10270|10285,3.46E-05,,GO:0001838,0.282390874,0,2.823908741
41,3,GO Biological Process,,Negative regulation of gliogenesis,0.0015,TP53|SKI|CTNNB1,10163,10291|10270|10285,3.26E-05,,GO:0014014,0.282390874,0,2.823908741
1550,10,GO Biological Process,,RNA metabolic process,0.0015,SMAD2|CDK2|TP53|CEBPB|SMAD1|PRKACA|SMAD3|E2F1|SKI|CTNNB1,10163,10267|10303|10291|10312|10282|10261|10252|10264|10270|10285,3.24E-05,,GO:0016070,0.282390874,0,2.823908741
671,7,GO Biological Process,,Regulation of growth,0.0015,CSNK2A1|CYP27B1|TP53|SMAD3|BMPR1A|CDK1|AKT1,10163,10306|10255|10291|10252|10300|10327|10330,3.46E-05,,GO:0040008,0.282390874,0,2.823908741
447,6,GO Biological Process,,Regulation of nervous system development,0.0015,TP53|E2F1|BMPR1A|SKI|AKT1|CTNNB1,10163,10291|10264|10300|10270|10330|10285,3.48E-05,,GO:0051960,0.282390874,0,2.823908741
128,4,GO Biological Process,,Cellular response to hypoxia,0.0015,STUB1|TP53|E2F1|MYC,10163,10315|10291|10264|10318,3.46E-05,,GO:0071456,0.282390874,0,2.823908741
5,2,TISSUES,,NIH-3T3 cell,0.0015,TP53|AKT1,10163,10291|10330,4.06E-05,,BTO:0000944,0.282390874,0,2.823908741
5,2,TISSUES,,DU-145 cell,0.0015,TP53|AKT1,10163,10291|10330,4.06E-05,,BTO:0001332,0.282390874,0,2.823908741
5,2,TISSUES,,M cell,0.0015,TP53|CDK1,10163,10291|10327,4.06E-05,,BTO:0003600,0.282390874,0,2.823908741
5,2,Reactome Pathways,,Activation of NOXA and translocation to mitochondria,0.0015,TP53|E2F1,10163,10291|10264,4.06E-05,,HSA-111448,0.282390874,0,2.823908741
5,2,Reactome Pathways,,G2 Phase,0.0015,CDK2|E2F1,10163,10303|10264,4.06E-05,,HSA-68911,0.282390874,0,2.823908741
43,3,GO Biological Process,,Positive regulation of organ growth,0.0016,BMPR1A|CDK1|AKT1,10163,10300|10327|10330,3.73E-05,,GO:0046622,0.279588002,0,2.795880017
280,5,TISSUES,,Colonic cancer cell,0.0016,STUB1|SMAD2|SMAD3|E2F4|CTNNB1,10163,10315|10267|10252|10321|10285,4.55E-05,,BTO:0000586,0.279588002,0,2.795880017
905,9,Monarch Phenotype,,Abnormal joint morphology,0.0016,STUB1|CYP27B1|TP53|PRKACA|SMAD3|SKI|BMPR1B|ACVR1|AKT1,10163,10315|10255|10291|10261|10252|10270|10294|10279|10330,2.95E-06,,HP:0001367,0.279588002,0,2.795880017
2182,13,Monarch Phenotype,,Growth abnormality,0.0016,CSNK2A1|STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10315|10255|10267|10291|10261|10252|10300|10270|10294|10279|10330|10285,2.88E-06,,HP:0001507,0.279588002,0,2.795880017
945,8,GO Biological Process,,Positive regulation of cell population proliferation,0.0017,CSNK2A1|CDK2|E2F1|BMPR1A|CDK1|AKT1|MYC|CTNNB1,10163,10306|10303|10264|10300|10327|10330|10318|10285,3.77E-05,,GO:0008284,0.276955108,0,2.769551079
1252,9,GO Biological Process,,Negative regulation of signal transduction,0.0017,CSNK2A1|STUB1|TP53|PRKACA|SKI|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10315|10291|10261|10270|10279|10330|10318|10285,3.94E-05,,GO:0009968,0.276955108,0,2.769551079
270,5,GO Biological Process,,Rhythmic process,0.0017,CSNK2A1|TP53|CASP3|CDK1|BMPR1B,10163,10306|10291|10333|10327|10294,3.84E-05,,GO:0048511,0.276955108,0,2.769551079
76,3,WikiPathways,,Prolactin signaling pathway,0.0017,CASP3|AKT1|MYC,10163,10333|10330|10318,1.90E-04,,WP2037,0.276955108,0,2.769551079
1506,11,Monarch Phenotype,,Abnormality of the lower limb,0.0017,STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10315|10255|10267|10291|10261|10252|10270|10294|10279|10330|10285,3.38E-06,,HP:0002814,0.276955108,0,2.769551079
2206,13,Monarch Phenotype,,Abnormal axial skeleton morphology,0.0017,CSNK2A1|STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10315|10255|10267|10291|10261|10252|10300|10270|10294|10279|10330|10285,3.25E-06,,HP:0009121,0.276955108,0,2.769551079
5,2,GO Biological Process,,Glial cell apoptotic process,0.0018,TP53|CASP3,10163,10291|10333,4.06E-05,,GO:0034349,0.274472749,0,2.744727495
135,4,GO Biological Process,,Regulation of fat cell differentiation,0.0018,CEBPB|SMAD3|E2F1|AKT1,10163,10312|10252|10264|10330,4.24E-05,,GO:0045598,0.274472749,0,2.744727495
2365,12,GO Biological Process,,Regulation of cellular component organization,0.0018,CSNK2A1|STUB1|CYP27B1|CASP6|CDK2|TP53|PLK1|PRKACA|SMAD3|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10309|10303|10291|10297|10261|10252|10330|10318|10285,4.30E-05,,GO:0051128,0.274472749,0,2.744727495
5,2,GO Biological Process,,Positive regulation of programmed necrotic cell death,0.0018,CASP6|TP53,10163,10309|10291,4.06E-05,,GO:0062100,0.274472749,0,2.744727495
45,3,GO Biological Process,,Leukocyte apoptotic process,0.0018,TP53|CASP3|AKT1,10163,10291|10333|10330,4.24E-05,,GO:0071887,0.274472749,0,2.744727495
5,2,GO Biological Process,,Cellular response to staurosporine,0.0018,CASP6|CASP3,10163,10309|10333,4.06E-05,,GO:0072734,0.274472749,0,2.744727495
5,2,GO Biological Process,,Regulation of anaphase-promoting complex-dependent catabolic process,0.0018,CDK2|PLK1,10163,10303|10297,4.06E-05,,GO:1905784,0.274472749,0,2.744727495
2838,13,TISSUES,,Male reproductive system,0.0018,RBL2|TP53|PLK1|CEBPB|PRKACA|CASP3|MYB|BMPR1A|BMPR1B|SUMO2|AKT1|MYC|CTNNB1,10163,10276|10291|10297|10312|10261|10333|10288|10300|10294|10273|10330|10318|10285,5.17E-05,,BTO:0000082,0.274472749,0,2.744727495
6,2,TISSUES,,PC-12 cell,0.0018,CASP3|AKT1,10163,10333|10330,5.41E-05,,BTO:0001009,0.274472749,0,2.744727495
6,2,TISSUES,,LNCaP cell,0.0018,TP53|AKT1,10163,10291|10330,5.41E-05,,BTO:0001321,0.274472749,0,2.744727495
6,2,TISSUES,,Myofibroblast,0.0018,SMAD2|SMAD3,10163,10267|10252,5.41E-05,,BTO:0001946,0.274472749,0,2.744727495
87,3,KEGG Pathways,,Longevity regulating pathway,0.0018,TP53|PRKACA|AKT1,10163,10291|10261|10330,2.80E-04,,hsa04211,0.274472749,0,2.744727495
2641,14,Monarch Phenotype,,Abnormality of the face,0.0018,CSNK2A1|STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10267|10291|10261|10252|10300|10270|10294|10279|10330|10318|10285,3.87E-06,,HP:0000271,0.274472749,0,2.744727495
1888,12,Monarch Phenotype,,Abnormality of the skin,0.0018,STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10315|10255|10267|10291|10261|10252|10300|10270|10294|10279|10330|10285,4.30E-06,,HP:0000951,0.274472749,0,2.744727495
2266,13,Monarch Phenotype,,Abnormality of the integument,0.0018,CSNK2A1|STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10315|10255|10267|10291|10261|10252|10300|10270|10294|10279|10330|10285,4.40E-06,,HP:0001574,0.274472749,0,2.744727495
1214,10,Monarch Phenotype,,Abnormality of blood and blood-forming tissues,0.0018,CSNK2A1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10267|10291|10261|10252|10300|10279|10330|10318|10285,3.82E-06,,HP:0001871,0.274472749,0,2.744727495
303,6,Monarch Phenotype,,Increased blood pressure,0.0018,SMAD2|TP53|PRKACA|SMAD3|BMPR1A|CTNNB1,10163,10267|10291|10261|10252|10300|10285,3.96E-06,,HP:0032263,0.274472749,0,2.744727495
1612,10,GO Biological Process,,Negative regulation of response to stimulus,0.0019,CSNK2A1|STUB1|TP53|PRKACA|SMAD3|SKI|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10315|10291|10261|10252|10270|10279|10330|10318|10285,4.54E-05,,GO:0048585,0.27212464,0,2.721246399
6,2,Reactome Pathways,,Phosphorylation of Emi1,0.0019,PLK1|CDK1,10163,10297|10327,5.41E-05,,HSA-176417,0.27212464,0,2.721246399
6,2,Reactome Pathways,,SMAD2/3 Phosphorylation Motif Mutants in Cancer,0.0019,SMAD2|SMAD3,10163,10267|10252,5.41E-05,,HSA-3304356,0.27212464,0,2.721246399
6,2,Reactome Pathways,,TGFBR1 KD Mutants in Cancer,0.0019,SMAD2|SMAD3,10163,10267|10252,5.41E-05,,HSA-3656532,0.27212464,0,2.721246399
80,3,WikiPathways,,Clock-controlled autophagy in bone metabolism,0.0019,SMAD1|SMAD5|AKT1,10163,10282|10258|10330,2.20E-04,,WP5205,0.27212464,0,2.721246399
47,3,GO Biological Process,,Regulation of muscle tissue development,0.002,SMAD3|ACVR1|CTNNB1,10163,10252|10279|10285,4.80E-05,,GO:1901861,0.269897,0,2.698970004
14,2,WikiPathways,,H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity,0.002,E2F1|CTNNB1,10163,10264|10285,2.30E-04,,WP3969,0.269897,0,2.698970004
712,7,GO Biological Process,,Cell population proliferation,0.0021,TP53|CEBPB|SMAD1|BMPR1A|CDK1|AKT1|CTNNB1,10163,10291|10312|10282|10300|10327|10330|10285,5.03E-05,,GO:0008283,0.267778071,0,2.677780705
216,5,DISEASES,,Intestinal disease,0.0021,TP53|BMPR1A|AKT1|MYC|CTNNB1,10163,10291|10300|10330|10318|10285,1.34E-05,,DOID:5295,0.267778071,0,2.677780705
1263,10,Monarch Phenotype,,Abnormal digit morphology,0.0021,CSNK2A1|STUB1|SMAD2|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1,10163,10306|10315|10267|10261|10252|10300|10270|10294|10279|10330,5.42E-06,,HP:0011297,0.267778071,0,2.677780705
143,4,GO Biological Process,,Negative regulation of neurogenesis,0.0022,TP53|BMPR1A|SKI|CTNNB1,10163,10291|10300|10270|10285,5.27E-05,,GO:0050768,0.265757732,0,2.657577319
34,3,GO Molecular Function,,Disordered domain specific binding,0.0022,SMAD2|TP53|CTNNB1,10163,10267|10291|10285,1.93E-05,,GO:0097718,0.265757732,0,2.657577319
6111,19,TISSUES,,Female reproductive system,0.0022,CSNK2A1|RBL2|SMAD2|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|SMAD3|MYB|BMPR1A|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10276|10267|10303|10291|10297|10312|10282|10261|10252|10288|10300|10294|10279|10273|10258|10330|10318|10285,6.76E-05,,BTO:0000083,0.265757732,0,2.657577319
7,2,TISSUES,,Prostate gland cancer cell,0.0022,TP53|AKT1,10163,10291|10330,6.95E-05,,BTO:0001130,0.265757732,0,2.657577319
7,2,TISSUES,,Embryonic fibroblast,0.0022,TP53|MYC,10163,10291|10318,6.95E-05,,BTO:0004725,0.265757732,0,2.657577319
684,7,UniProt Keywords,,Activator,0.0022,TP53|CEBPB|MYB|E2F1|E2F4|MYC|CTNNB1,10163,10291|10312|10288|10264|10321|10318|10285,3.91E-05,,KW-0010,0.265757732,0,2.657577319
1971,11,UniProt Keywords,,DNA-binding,0.0022,RBL2|SMAD2|TP53|CEBPB|SMAD1|SMAD3|MYB|E2F1|E2F4|SMAD5|MYC,10163,10276|10267|10291|10312|10282|10252|10288|10264|10321|10258|10318,4.35E-05,,KW-0238,0.265757732,0,2.657577319
747,7,Reactome Pathways,,Cellular responses to stress,0.0022,CSNK2A1|CDK2|TP53|CEBPB|E2F1|AKT1|MYC,10163,10306|10303|10291|10312|10264|10330|10318,6.79E-05,,HSA-2262752,0.265757732,0,2.657577319
7,2,Reactome Pathways,,"Activation of NIMA Kinases NEK9, NEK6, NEK7",0.0022,PLK1|CDK1,10163,10297|10327,6.95E-05,,HSA-2980767,0.265757732,0,2.657577319
7,2,Reactome Pathways,,RUNX3 regulates CDKN1A transcription,0.0022,TP53|SMAD3,10163,10291|10252,6.95E-05,,HSA-8941855,0.265757732,0,2.657577319
15,2,WikiPathways,,Mammary gland development pathway - Embryonic development (Stage 1 of 4),0.0022,AKT1|MYC,10163,10330|10318,2.60E-04,,WP2813,0.265757732,0,2.657577319
85,3,WikiPathways,,Acute viral myocarditis,0.0022,CASP6|CASP3|AKT1,10163,10309|10333|10330,2.60E-04,,WP4298,0.265757732,0,2.657577319
85,3,WikiPathways,,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,0.0022,CSNK2A1|MYC|CTNNB1,10163,10306|10318|10285,2.60E-04,,WP4336,0.265757732,0,2.657577319
22,3,Monarch Phenotype,,Colorectal polyposis,0.0022,TP53|BMPR1A|AKT1,10163,10291|10300|10330,5.77E-06,,HP:0200063,0.265757732,0,2.657577319
5436,18,GO Biological Process,,Cellular component organization,0.0023,RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F4|CDK1|BMPR1B|AKT1|MYC|CTNNB1,10163,10276|10267|10324|10309|10303|10291|10297|10282|10261|10333|10252|10288|10321|10327|10294|10330|10318|10285,5.63E-05,,GO:0016043,0.263827216,0,2.638272164
87,3,WikiPathways,,Hair follicle development: cytodifferentiation - part 3 of 3,0.0023,SMAD1|BMPR1A|CTNNB1,10163,10282|10300|10285,2.80E-04,,WP2840,0.263827216,0,2.638272164
146,4,GO Biological Process,,Negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,0.0024,STUB1|TP53|SKI|ACVR1,10163,10315|10291|10270|10279,5.70E-05,,GO:0090101,0.261978876,0,2.619788758
50,3,GO Biological Process,,Execution phase of apoptosis,0.0024,CASP6|CASP3|AKT1,10163,10309|10333|10330,5.72E-05,,GO:0097194,0.261978876,0,2.619788758
89,3,WikiPathways,,Apoptosis modulation and signaling,0.0024,CASP6|TP53|CASP3,10163,10309|10291|10333,3.00E-04,,WP1772,0.261978876,0,2.619788758
16,2,WikiPathways,,ID signaling pathway,0.0024,RBL2|CDK2,10163,10276|10303,2.90E-04,,WP53,0.261978876,0,2.619788758
89,3,WikiPathways,,ErbB signaling pathway,0.0024,TP53|AKT1|MYC,10163,10291|10330|10318,3.00E-04,,WP673,0.261978876,0,2.619788758
51,3,GO Biological Process,,Regulation of telomerase activity,0.0025,TP53|MYC|CTNNB1,10163,10291|10318|10285,6.05E-05,,GO:0051972,0.260205999,0,2.602059991
398,6,DISEASES,,Endocrine system disease,0.0025,CYP27B1|TP53|PRKACA|AKT1|MYC|CTNNB1,10163,10255|10291|10261|10330|10318|10285,1.83E-05,,DOID:28,0.260205999,0,2.602059991
34,3,DISEASES,,B-cell lymphoma,0.0025,TP53|CASP3|MYC,10163,10291|10333|10318,1.93E-05,,DOID:707,0.260205999,0,2.602059991
150,4,GO Biological Process,,Response to UV,0.0026,TP53|CASP3|AKT1|MYC,10163,10291|10333|10330|10318,6.32E-05,,GO:0009411,0.258502665,0,2.585026652
52,3,GO Biological Process,,Epithelial cell apoptotic process,0.0026,CASP6|CASP3|E2F1,10163,10309|10333|10264,6.39E-05,,GO:1904019,0.258502665,0,2.585026652
8,2,Reactome Pathways,,Activation of PUMA and translocation to mitochondria,0.0026,TP53|E2F1,10163,10291|10264,8.68E-05,,HSA-139915,0.258502665,0,2.585026652
163,4,Reactome Pathways,,Cellular Senescence,0.0026,CDK2|TP53|CEBPB|E2F1,10163,10303|10291|10312|10264,8.66E-05,,HSA-2559583,0.258502665,0,2.585026652
8,2,Reactome Pathways,,Binding of TCF/LEF:CTNNB1 to target gene promoters,0.0026,MYC|CTNNB1,10163,10318|10285,8.68E-05,,HSA-4411364,0.258502665,0,2.585026652
58,3,Reactome Pathways,,Regulated Necrosis,0.0026,STUB1|TP53|CASP3,10163,10315|10291|10333,8.72E-05,,HSA-5218859,0.258502665,0,2.585026652
8,2,Reactome Pathways,,RUNX3 regulates WNT signaling,0.0026,MYC|CTNNB1,10163,10318|10285,8.68E-05,,HSA-8951430,0.258502665,0,2.585026652
92,3,WikiPathways,,Corticotropin-releasing hormone signaling pathway,0.0026,CASP3|AKT1|CTNNB1,10163,10333|10330|10285,3.20E-04,,WP2355,0.258502665,0,2.585026652
53,3,GO Biological Process,,Regulation of chondrocyte differentiation,0.0027,SMAD3|BMPR1B|CTNNB1,10163,10252|10294|10285,6.75E-05,,GO:0032330,0.256863624,0,2.568636236
93,3,WikiPathways,,lncRNA in canonical Wnt signaling and colorectal cancer,0.0027,CSNK2A1|MYC|CTNNB1,10163,10306|10318|10285,3.30E-04,,WP4258,0.256863624,0,2.568636236
93,3,WikiPathways,,Thyroid hormones production and peripheral downstream signaling effects,0.0027,TP53|PRKACA|CTNNB1,10163,10291|10261|10285,3.30E-04,,WP4746,0.256863624,0,2.568636236
190,5,Monarch Phenotype,,Abnormal adipose tissue morphology,0.0027,CYP27B1|PRKACA|BMPR1A|SKI|AKT1,10163,10255|10261|10300|10270|10330,7.32E-06,,HP:0009124,0.256863624,0,2.568636236
340,6,Monarch Phenotype,,Abnormal vascular physiology,0.0027,SMAD2|TP53|SMAD3|BMPR1A|AKT1|CTNNB1,10163,10267|10291|10252|10300|10330|10285,7.58E-06,,HP:0030163,0.256863624,0,2.568636236
1035,8,GO Biological Process,,Central nervous system development,0.0028,TP53|SMAD1|CASP3|E2F1|BMPR1A|SKI|BMPR1B|CTNNB1,10163,10291|10282|10333|10264|10300|10270|10294|10285,7.16E-05,,GO:0007417,0.255284197,0,2.552841969
54,3,GO Biological Process,,Positive regulation of neuron apoptotic process,0.0028,TP53|CASP3|CTNNB1,10163,10291|10333|10285,7.12E-05,,GO:0043525,0.255284197,0,2.552841969
506,6,GO Biological Process,,Regulation of cell development,0.0028,TP53|E2F1|BMPR1A|SKI|AKT1|CTNNB1,10163,10291|10264|10300|10270|10330|10285,6.88E-05,,GO:0060284,0.255284197,0,2.552841969
7,2,GO Biological Process,,BMP signaling pathway involved in heart development,0.0028,BMPR1A|ACVR1,10163,10300|10279,6.95E-05,,GO:0061312,0.255284197,0,2.552841969
18,2,WikiPathways,,Apoptosis modulation by HSP70,0.0028,CASP6|CASP3,10163,10309|10333,3.60E-04,,WP384,0.255284197,0,2.552841969
195,5,Monarch Phenotype,,Abnormality of the uterus,0.0028,SMAD3|BMPR1A|BMPR1B|AKT1|CTNNB1,10163,10252|10300|10294|10330|10285,8.28E-06,,HP:0000130,0.255284197,0,2.552841969
1648,11,Monarch Phenotype,,Abnormality of skin morphology,0.0028,STUB1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10315|10267|10291|10261|10252|10300|10270|10294|10279|10330|10285,8.05E-06,,HP:0011121,0.255284197,0,2.552841969
513,6,GO Biological Process,,Positive regulation of catabolic process,0.0029,CSNK2A1|STUB1|PLK1|CASP3|SUMO2|AKT1,10163,10306|10315|10297|10333|10273|10330,7.41E-05,,GO:0009896,0.2537602,0,2.537602002
1038,8,GO Biological Process,,Negative regulation of protein metabolic process,0.0029,CSNK2A1|TP53|PLK1|CASP3|SMAD3|SKI|AKT1|CTNNB1,10163,10306|10291|10297|10333|10252|10270|10330|10285,7.30E-05,,GO:0051248,0.2537602,0,2.537602002
5,2,COMPARTMENTS,,PTEN phosphatase complex,0.003,TP53|AKT1,10163,10291|10330,4.06E-05,,GOCC:1990455,0.252287875,0,2.522878745
90,4,Monarch Phenotype,,Neoplasm of the large intestine,0.003,TP53|BMPR1A|AKT1|CTNNB1,10163,10291|10300|10330|10285,9.07E-06,,HP:0100834,0.252287875,0,2.522878745
159,4,GO Biological Process,,Regulation of macroautophagy,0.0031,TP53|PRKACA|CASP3|AKT1,10163,10291|10261|10333|10330,7.88E-05,,GO:0016241,0.250863831,0,2.508638306
56,3,GO Biological Process,,Intrinsic apoptotic signaling pathway by p53 class mediator,0.0031,CASP6|TP53|E2F1,10163,10309|10291|10264,7.89E-05,,GO:0072332,0.250863831,0,2.508638306
19,2,WikiPathways,,TP53 network,0.0031,TP53|MYC,10163,10291|10318,4.00E-04,,WP1742,0.250863831,0,2.508638306
27,3,STRING Clusters,,"Defective binding of RB1 mutants to E2F1,(E2F2, E2F3), and Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes",0.0031,CDK2|E2F1|CDK1,10163,10303|10264|10327,1.01E-05,,CL:6903,0.250863831,0,2.508638306
771,7,GO Biological Process,,Negative regulation of catalytic activity,0.0032,CSNK2A1|CYP27B1|TP53|PLK1|CASP3|SKI|AKT1,10163,10306|10255|10291|10297|10333|10270|10330,8.28E-05,,GO:0043086,0.249485002,0,2.494850022
1057,8,GO Biological Process,,Cellular response to oxygen-containing compound,0.0032,CDK2|TP53|CEBPB|PRKACA|E2F1|CDK1|AKT1|CTNNB1,10163,10303|10291|10312|10261|10264|10327|10330|10285,8.29E-05,,GO:1901701,0.249485002,0,2.494850022
2279,12,GO Molecular Function,,"Catalytic activity, acting on a protein",0.0032,CSNK2A1|STUB1|CASP6|CDK2|PLK1|PRKACA|CASP3|BMPR1A|CDK1|BMPR1B|ACVR1|AKT1,10163,10306|10315|10309|10303|10297|10261|10333|10300|10327|10294|10279|10330,2.97E-05,,GO:0140096,0.249485002,0,2.494850022
100,3,WikiPathways,,Wnt signaling pathway and pluripotency,0.0032,TP53|MYC|CTNNB1,10163,10291|10318|10285,4.10E-04,,WP399,0.249485002,0,2.494850022
775,7,GO Biological Process,,Brain development,0.0033,TP53|SMAD1|CASP3|E2F1|BMPR1A|SKI|CTNNB1,10163,10291|10282|10333|10264|10300|10270|10285,8.55E-05,,GO:0007420,0.248148606,0,2.48148606
127,4,GO Cellular Component,,Protein kinase complex,0.0033,CDK2|PRKACA|CDK1|ACVR1,10163,10303|10261|10327|10279,3.36E-05,,GO:1902911,0.248148606,0,2.48148606
40,3,GO Molecular Function,,Core promoter sequence-specific DNA binding,0.0033,TP53|CEBPB|MYC,10163,10291|10312|10318,3.04E-05,,GO:0001046,0.248148606,0,2.48148606
9,2,TISSUES,,Acute lymphoblastic leukemia cell,0.0033,TP53|AKT1,10163,10291|10330,1.10E-04,,BTO:0000731,0.248148606,0,2.48148606
120,4,DISEASES,,Lymphatic system cancer,0.0033,TP53|CASP3|AKT1|MYC,10163,10291|10333|10330|10318,2.71E-05,,DOID:0060073,0.248148606,0,2.48148606
4,2,DISEASES,,Fibrodysplasia ossificans progressiva,0.0033,BMPR1B|ACVR1,10163,10294|10279,2.90E-05,,DOID:13374,0.248148606,0,2.48148606
20,2,WikiPathways,,Nanomaterial induced apoptosis,0.0033,CASP6|CASP3,10163,10309|10333,4.40E-04,,WP2507,0.248148606,0,2.48148606
20,2,WikiPathways,,BMP signaling in eyelid development,0.0033,SMAD1|SMAD5,10163,10282|10258,4.40E-04,,WP3927,0.248148606,0,2.48148606
204,5,Monarch Phenotype,,Abnormal metaphysis morphology,0.0033,CYP27B1|TP53|SKI|BMPR1B|ACVR1,10163,10255|10291|10270|10294|10279,1.03E-05,,HP:0000944,0.248148606,0,2.48148606
558,7,Monarch Phenotype,,Abnormality of lower limb joint,0.0033,STUB1|CYP27B1|PRKACA|SMAD3|SKI|BMPR1B|AKT1,10163,10315|10255|10261|10252|10270|10294|10330,1.07E-05,,HP:0100491,0.248148606,0,2.48148606
58,3,GO Biological Process,,G2/M transition of mitotic cell cycle,0.0034,CDK2|PLK1|CDK1,10163,10303|10297|10327,8.72E-05,,GO:0000086,0.246852108,0,2.468521083
40,3,DISEASES,,Malignant glioma,0.0034,TP53|ACVR1|AKT1,10163,10291|10279|10330,3.04E-05,,DOID:3070,0.246852108,0,2.468521083
111,3,KEGG Pathways,,TNF signaling pathway,0.0034,CEBPB|CASP3|AKT1,10163,10312|10333|10330,5.50E-04,,hsa04668,0.246852108,0,2.468521083
324,5,GO Biological Process,,Regulation of neuron death,0.0035,TP53|CEBPB|CASP3|AKT1|CTNNB1,10163,10291|10312|10333|10330|10285,8.97E-05,,GO:1901214,0.245593196,0,2.455931956
260,4,WikiPathways,,Alzheimers disease and miRNA effects,0.0036,CSNK2A1|CASP3|AKT1|CTNNB1,10163,10306|10333|10330|10285,5.00E-04,,WP2059,0.24436975,0,2.443697499
21,2,WikiPathways,,PI3K/AKT/mTOR - vitamin D3 signaling,0.0036,AKT1|MYC,10163,10330|10318,4.80E-04,,WP4141,0.24436975,0,2.443697499
21,2,WikiPathways,,Host-pathogen interaction of human coronaviruses - apoptosis,0.0036,CASP3|AKT1,10163,10333|10330,4.80E-04,,WP4864,0.24436975,0,2.443697499
260,4,WikiPathways,,Alzheimers disease,0.0036,CSNK2A1|CASP3|AKT1|CTNNB1,10163,10306|10333|10330|10285,5.00E-04,,WP5124,0.24436975,0,2.443697499
329,5,GO Biological Process,,Negative regulation of catabolic process,0.0037,CSNK2A1|TP53|SMAD3|E2F1|AKT1,10163,10306|10291|10252|10264|10330,9.63E-05,,GO:0009895,0.243179828,0,2.431798276
1405,9,GO Biological Process,,Regulation of phosphate metabolic process,0.0037,RBL2|TP53|PLK1|CASP3|SMAD3|BMPR1A|BMPR1B|ACVR1|AKT1,10163,10276|10291|10297|10333|10252|10300|10294|10279|10330,9.64E-05,,GO:0019220,0.243179828,0,2.431798276
328,5,GO Biological Process,,Regulation of protein stability,0.0037,STUB1|TP53|PLK1|CASP3|SMAD3,10163,10315|10291|10297|10333|10252,9.50E-05,,GO:0031647,0.243179828,0,2.431798276
824,7,TISSUES,,Embryo,0.0037,STUB1|TP53|CEBPB|CASP3|MYB|MYC|CTNNB1,10163,10315|10291|10312|10333|10288|10318|10285,1.30E-04,,BTO:0000379,0.243179828,0,2.431798276
1379,9,UniProt Keywords,,ATP-binding,0.0038,CSNK2A1|CDK2|PLK1|PRKACA|BMPR1A|CDK1|BMPR1B|ACVR1|AKT1,10163,10306|10303|10297|10261|10300|10327|10294|10279|10330,8.35E-05,,KW-0067,0.24202164,0,2.420216403
56,3,UniProt Keywords,,S-nitrosylation,0.0038,CDK2|CASP3|CTNNB1,10163,10303|10333|10285,7.89E-05,,KW-0702,0.24202164,0,2.420216403
68,3,Reactome Pathways,,Regulation of PTEN stability and activity,0.0038,CSNK2A1|STUB1|AKT1,10163,10306|10315|10330,1.40E-04,,HSA-8948751,0.24202164,0,2.420216403
22,2,WikiPathways,,Regulation of apoptosis by parathyroid hormone-related protein,0.0038,AKT1|MYC,10163,10330|10318,5.30E-04,,WP3872,0.24202164,0,2.420216403
22,2,WikiPathways,,Progeria-associated lipodystrophy,0.0038,SMAD2|SMAD3,10163,10267|10252,5.30E-04,,WP5103,0.24202164,0,2.420216403
69,3,Reactome Pathways,,Loss of Nlp from mitotic centrosomes,0.0039,PLK1|PRKACA|CDK1,10163,10297|10261|10327,1.40E-04,,HSA-380259,0.240893539,0,2.408935393
9,2,GO Biological Process,,Regulation of transforming growth factor beta2 production,0.004,SMAD3|BMPR1A,10163,10252|10300,1.10E-04,,GO:0032909,0.239794001,0,2.397940009
2658,12,TISSUES,,Male reproductive gland,0.004,RBL2|TP53|PLK1|CEBPB|PRKACA|MYB|BMPR1A|BMPR1B|SUMO2|AKT1|MYC|CTNNB1,10163,10276|10291|10297|10312|10261|10288|10300|10294|10273|10330|10318|10285,1.40E-04,,BTO:0000080,0.239794001,0,2.397940009
11,2,Reactome Pathways,,Vitamin D (calciferol) metabolism,0.004,CYP27B1|SUMO2,10163,10255|10273,1.50E-04,,HSA-196791,0.239794001,0,2.397940009
11,2,Reactome Pathways,,Condensation of Prometaphase Chromosomes,0.004,CSNK2A1|CDK1,10163,10306|10327,1.50E-04,,HSA-2514853,0.239794001,0,2.397940009
11,2,Reactome Pathways,,Apoptotic cleavage of cell adhesion  proteins,0.004,CASP3|CTNNB1,10163,10333|10285,1.50E-04,,HSA-351906,0.239794001,0,2.397940009
23,2,WikiPathways,,Angiogenesis,0.004,SMAD1|AKT1,10163,10282|10330,5.70E-04,,WP1539,0.239794001,0,2.397940009
271,4,WikiPathways,,IL-18 signaling pathway,0.004,TP53|CEBPB|CASP3|CTNNB1,10163,10291|10312|10333|10285,5.80E-04,,WP4754,0.239794001,0,2.397940009
23,2,WikiPathways,,Estrogen signaling pathway,0.004,PRKACA|AKT1,10163,10261|10330,5.70E-04,,WP712,0.239794001,0,2.397940009
114,3,WikiPathways,,Wnt signaling,0.0041,CSNK2A1|MYC|CTNNB1,10163,10306|10318|10285,6.00E-04,,WP428,0.238721614,0,2.387216143
72,3,Reactome Pathways,,AURKA Activation by TPX2,0.0042,PLK1|PRKACA|CDK1,10163,10297|10261|10327,1.60E-04,,HSA-8854518,0.237675071,0,2.37675071
24,2,WikiPathways,,miRNA regulation of p53 pathway in prostate cancer,0.0042,TP53|CASP3,10163,10291|10333,6.20E-04,,WP3982,0.237675071,0,2.37675071
2188,11,GO Biological Process,,Nervous system development,0.0043,TP53|CEBPB|SMAD1|PRKACA|CASP3|E2F1|BMPR1A|SKI|BMPR1B|AKT1|CTNNB1,10163,10291|10312|10282|10261|10333|10264|10300|10270|10294|10330|10285,1.10E-04,,GO:0007399,0.236653154,0,2.366531544
5,2,GO Molecular Function,,Histone deacetylase regulator activity,0.0043,TP53|SKI,10163,10291|10270,4.06E-05,,GO:0035033,0.236653154,0,2.366531544
104,4,Monarch Phenotype,,Soft tissue sarcoma,0.0043,TP53|BMPR1A|AKT1|CTNNB1,10163,10291|10300|10330|10285,1.57E-05,,HP:0030448,0.236653154,0,2.366531544
64,3,GO Biological Process,,Somitogenesis,0.0044,TP53|SMAD3|BMPR1A,10163,10291|10252|10300,1.20E-04,,GO:0001756,0.235654732,0,2.356547324
1438,9,GO Biological Process,,Regulation of immune system process,0.0044,RCOR1|CASP6|CEBPB|CASP3|SMAD3|MYB|AKT1|MYC|CTNNB1,10163,10324|10309|10312|10333|10252|10288|10330|10318|10285,1.20E-04,,GO:0002682,0.235654732,0,2.356547324
64,3,GO Biological Process,,Positive regulation of nucleocytoplasmic transport,0.0044,PRKACA|SMAD3|CDK1,10163,10261|10252|10327,1.20E-04,,GO:0046824,0.235654732,0,2.356547324
11,2,TISSUES,,Melanoma cell,0.0044,TP53|AKT1,10163,10291|10330,1.50E-04,,BTO:0000848,0.235654732,0,2.356547324
1151,8,TISSUES,,Skin,0.0044,STUB1|TP53|CEBPB|E2F1|CDK1|SUMO2|AKT1|CTNNB1,10163,10315|10291|10312|10264|10327|10273|10330|10285,1.50E-04,,BTO:0001253,0.235654732,0,2.356547324
12,2,Reactome Pathways,,Caspase-mediated cleavage of cytoskeletal proteins,0.0045,CASP6|CASP3,10163,10309|10333,1.70E-04,,HSA-264870,0.234678749,0,2.346787486
12,2,Reactome Pathways,,TP53 Regulates Transcription of Caspase Activators and Caspases,0.0045,CASP6|TP53,10163,10309|10291,1.70E-04,,HSA-6803207,0.234678749,0,2.346787486
25,2,WikiPathways,,IL-7 signaling pathway,0.0045,AKT1|MYC,10163,10330|10318,6.70E-04,,WP205,0.234678749,0,2.346787486
25,2,WikiPathways,,Hypothesized pathways in pathogenesis of cardiovascular disease,0.0045,SMAD2|SMAD3,10163,10267|10252,6.70E-04,,WP3668,0.234678749,0,2.346787486
119,3,WikiPathways,,Hippo-Merlin signaling dysregulation,0.0045,PRKACA|MYC|CTNNB1,10163,10261|10318|10285,6.80E-04,,WP4541,0.234678749,0,2.346787486
275,5,DISEASES,,Kidney disease,0.0046,CYP27B1|SMAD2|TP53|SMAD3|CTNNB1,10163,10255|10267|10291|10252|10285,4.18E-05,,DOID:557,0.233724217,0,2.337242168
607,6,Reactome Pathways,,Hemostasis,0.0046,RCOR1|CDK2|TP53|PRKACA|MYB|AKT1,10163,10324|10303|10291|10261|10288|10330,1.80E-04,,HSA-109582,0.233724217,0,2.337242168
73,3,TISSUES,,Embryonic cell line,0.0047,TP53|AKT1|MYC,10163,10291|10330|10318,1.70E-04,,BTO:0000669,0.232790214,0,2.327902142
13099,27,TISSUES,,Whole body,0.0047,CSNK2A1|STUB1|CYP27B1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10321|10327|10294|10279|10273|10258|10330|10318|10285,1.70E-04,,BTO:0001489,0.232790214,0,2.327902142
201,4,Reactome Pathways,,TCF dependent signaling in response to WNT,0.0047,CSNK2A1|AKT1|MYC|CTNNB1,10163,10306|10330|10318|10285,1.90E-04,,HSA-201681,0.232790214,0,2.327902142
201,4,Reactome Pathways,,Mitotic Prometaphase,0.0047,CSNK2A1|PLK1|PRKACA|CDK1,10163,10306|10297|10261|10327,1.90E-04,,HSA-68877,0.232790214,0,2.327902142
77,3,Reactome Pathways,,The role of GTSE1 in G2/M progression after G2 checkpoint,0.0047,TP53|PLK1|CDK1,10163,10291|10297|10327,2.00E-04,,HSA-8852276,0.232790214,0,2.327902142
26,2,WikiPathways,,PPAR-alpha pathway,0.0047,CDK1|MYC,10163,10327|10318,7.20E-04,,WP2878,0.232790214,0,2.327902142
229,5,Monarch Phenotype,,Abnormality of the calf,0.0047,CYP27B1|TP53|PRKACA|SKI|BMPR1B,10163,10255|10291|10261|10270|10294,1.77E-05,,HP:0002981,0.232790214,0,2.327902142
10,2,GO Biological Process,,Mitral valve morphogenesis,0.0048,BMPR1A|ACVR1,10163,10300|10279,1.30E-04,,GO:0003183,0.231875876,0,2.318758763
126,3,KEGG Pathways,,Relaxin signaling pathway,0.0049,SMAD2|PRKACA|AKT1,10163,10267|10261|10330,7.90E-04,,hsa04926,0.230980392,0,2.30980392
110,4,Monarch Phenotype,,Abnormal rectum morphology,0.0049,TP53|BMPR1A|AKT1|CTNNB1,10163,10291|10300|10330|10285,1.95E-05,,HP:0002034,0.230980392,0,2.30980392
183,4,GO Biological Process,,Stem cell differentiation,0.005,TP53|BMPR1A|ACVR1|CTNNB1,10163,10291|10300|10279|10285,1.30E-04,,GO:0048863,0.230103,0,2.301029996
4798,17,DISEASES,,Disease of anatomical entity,0.005,STUB1|CYP27B1|SMAD2|CDK2|TP53|PRKACA|CASP3|SMAD3|E2F1|BMPR1A|SKI|E2F4|BMPR1B|ACVR1|AKT1|MYC|CTNNB1,10163,10315|10255|10267|10303|10291|10261|10333|10252|10264|10300|10270|10321|10294|10279|10330|10318|10285,4.67E-05,,DOID:7,0.230103,0,2.301029996
27,2,WikiPathways,,Follicle stimulating hormone (FSH) signaling pathway,0.005,PRKACA|AKT1,10163,10261|10330,7.70E-04,,WP2035,0.230103,0,2.301029996
80,3,Reactome Pathways,,Regulation of APC/C activators between G1/S and early anaphase,0.0052,CDK2|PLK1|CDK1,10163,10303|10297|10327,2.20E-04,,HSA-176408,0.228399666,0,2.283996656
80,3,Reactome Pathways,,Recruitment of mitotic centrosome proteins and complexes,0.0052,PLK1|PRKACA|CDK1,10163,10297|10261|10327,2.20E-04,,HSA-380270,0.228399666,0,2.283996656
35,3,Monarch Phenotype,,Colon cancer,0.0052,TP53|BMPR1A|CTNNB1,10163,10291|10300|10285,2.09E-05,,HP:0003003,0.228399666,0,2.283996656
35,3,Monarch Phenotype,,Germ cell neoplasia,0.0052,TP53|AKT1|CTNNB1,10163,10291|10330|10285,2.09E-05,,HP:0100728,0.228399666,0,2.283996656
1820,10,UniProt Keywords,,Transferase,0.0053,CSNK2A1|STUB1|CDK2|PLK1|PRKACA|BMPR1A|CDK1|BMPR1B|ACVR1|AKT1,10163,10306|10315|10303|10297|10261|10300|10327|10294|10279|10330,1.30E-04,,KW-0808,0.227572413,0,2.27572413
28,2,WikiPathways,,Sphingolipid metabolism in senescence,0.0053,CDK2|E2F1,10163,10303|10264,8.20E-04,,WP5121,0.227572413,0,2.27572413
114,4,Monarch Phenotype,,Neoplasm of the endocrine system,0.0053,TP53|BMPR1A|AKT1|CTNNB1,10163,10291|10300|10330|10285,2.23E-05,,HP:0100568,0.227572413,0,2.27572413
14,2,Reactome Pathways,,Golgi Cisternae Pericentriolar Stack Reorganization,0.0054,PLK1|CDK1,10163,10297|10327,2.30E-04,,HSA-162658,0.226760624,0,2.26760624
14,2,Reactome Pathways,,Regulation of TP53 Activity through Association with Co-factors,0.0054,TP53|AKT1,10163,10291|10330,2.30E-04,,HSA-6804759,0.226760624,0,2.26760624
1169,9,Monarch Phenotype,,Abnormal cardiovascular system physiology,0.0054,SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|AKT1|MYC|CTNNB1,10163,10267|10291|10261|10252|10300|10270|10330|10318|10285,2.30E-05,,HP:0011025,0.226760624,0,2.26760624
188,4,GO Biological Process,,Regulation of histone modification,0.0055,TP53|MYB|SKI|CTNNB1,10163,10291|10288|10270|10285,1.50E-04,,GO:0031056,0.225963731,0,2.259637311
70,3,GO Biological Process,,Cardiac septum morphogenesis,0.0055,TP53|BMPR1A|ACVR1,10163,10291|10300|10279,1.50E-04,,GO:0060411,0.225963731,0,2.259637311
14060,28,COMPARTMENTS,,Cellular anatomical entity,0.0056,CSNK2A1|STUB1|CYP27B1|RBL2|SMAD2|RCOR1|CASP6|CDK2|TP53|PLK1|CEBPB|SMAD1|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|CDK1|BMPR1B|ACVR1|SUMO2|SMAD5|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10276|10267|10324|10309|10303|10291|10297|10312|10282|10261|10333|10252|10288|10264|10300|10270|10321|10327|10294|10279|10273|10258|10330|10318|10285,7.99E-05,,GOCC:0110165,0.225181197,0,2.251811973
11,2,GO Biological Process,,Negative regulation of activin receptor signaling pathway,0.0056,SKI|ACVR1,10163,10270|10279,1.50E-04,,GO:0032926,0.225181197,0,2.251811973
11,2,GO Biological Process,,Nodal signaling pathway,0.0056,SMAD2|SMAD3,10163,10267|10252,1.50E-04,,GO:0038092,0.225181197,0,2.251811973
11,2,GO Biological Process,,Fibroblast apoptotic process,0.0056,CASP3|MYC,10163,10333|10318,1.50E-04,,GO:0044346,0.225181197,0,2.251811973
6,2,GO Molecular Function,,BMP receptor activity,0.0056,BMPR1A|BMPR1B,10163,10300|10294,5.41E-05,,GO:0098821,0.225181197,0,2.251811973
29,2,WikiPathways,,Lipid metabolism pathway,0.0056,PRKACA|AKT1,10163,10261|10330,8.80E-04,,WP3965,0.225181197,0,2.251811973
1494,9,GO Biological Process,,Cellular nitrogen compound biosynthetic process,0.0057,SMAD2|CDK2|TP53|CEBPB|SMAD1|E2F1|SKI|AKT1|CTNNB1,10163,10267|10303|10291|10312|10282|10264|10270|10330|10285,1.50E-04,,GO:0044271,0.224412514,0,2.244125144
6,2,DISEASES,,Renal fibrosis,0.0057,SMAD2|SMAD3,10163,10267|10252,5.41E-05,,DOID:0050855,0.224412514,0,2.244125144
6,2,DISEASES,,Pancreatic ductal adenocarcinoma,0.0057,TP53|AKT1,10163,10291|10330,5.41E-05,,DOID:3498,0.224412514,0,2.244125144
118,4,Monarch Phenotype,,Genital neoplasm,0.0057,TP53|BMPR1A|AKT1|CTNNB1,10163,10291|10300|10330|10285,2.54E-05,,HP:0010787,0.224412514,0,2.244125144
366,5,GO Biological Process,,Regulation of epithelial cell proliferation,0.0058,SMAD3|BMPR1A|AKT1|MYC|CTNNB1,10163,10252|10300|10330|10318|10285,1.60E-04,,GO:0050678,0.223657201,0,2.236572006
119,4,Monarch Phenotype,,Abnormal uterus morphology,0.0058,SMAD3|BMPR1A|AKT1|CTNNB1,10163,10252|10300|10330|10285,2.62E-05,,HP:0031105,0.223657201,0,2.236572006
8,2,COMPARTMENTS,,Myb complex,0.0059,MYB|MYC,10163,10288|10318,8.68E-05,,GOCC:0031523,0.222914799,0,2.229147988
8,2,COMPARTMENTS,,Survivin complex,0.0059,TP53|CASP3,10163,10291|10333,8.68E-05,,GOCC:1990713,0.222914799,0,2.229147988
368,5,GO Biological Process,,Regulation of neurogenesis,0.0059,TP53|E2F1|BMPR1A|SKI|CTNNB1,10163,10291|10264|10300|10270|10285,1.60E-04,,GO:0050767,0.222914799,0,2.229147988
15,2,Reactome Pathways,,Signaling by Activin,0.006,SMAD2|SMAD3,10163,10267|10252,2.60E-04,,HSA-1502540,0.222184875,0,2.22184875
908,8,Monarch Phenotype,,Scoliosis,0.0061,CSNK2A1|CYP27B1|SMAD2|SMAD3|SKI|BMPR1B|ACVR1|AKT1,10163,10306|10255|10267|10252|10270|10294|10279|10330,2.84E-05,,HP:0002650,0.221467016,0,2.214670165
4,2,Monarch Phenotype,,Desmoid tumors,0.0061,BMPR1A|CTNNB1,10163,10300|10285,2.90E-05,,HP:0100245,0.221467016,0,2.214670165
4,2,Monarch Phenotype,,Vaginal hernia,0.0061,SMAD3|BMPR1A,10163,10252|10300,2.90E-05,,HP:0100672,0.221467016,0,2.214670165
12,2,GO Biological Process,,Anoikis,0.0063,E2F1|AKT1,10163,10264|10330,1.70E-04,,GO:0043276,0.220065945,0,2.200659451
3181,13,GO Biological Process,,Organic cyclic compound metabolic process,0.0063,STUB1|CYP27B1|SMAD2|CDK2|TP53|CEBPB|SMAD1|PRKACA|SMAD3|E2F1|SKI|CDK1|CTNNB1,10163,10315|10255|10267|10303|10291|10312|10282|10261|10252|10264|10270|10327|10285,1.70E-04,,GO:1901360,0.220065945,0,2.200659451
74,3,GO Biological Process,,Cranial skeletal system development,0.0063,SMAD2|SMAD3|CTNNB1,10163,10267|10252|10285,1.70E-04,,GO:1904888,0.220065945,0,2.200659451
12,2,GO Biological Process,,Positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,0.0063,TP53|CEBPB,10163,10291|10312,1.70E-04,,GO:1990440,0.220065945,0,2.200659451
87,3,Reactome Pathways,,Regulation of PLK1 Activity at G2/M Transition,0.0063,PLK1|PRKACA|CDK1,10163,10297|10261|10327,2.80E-04,,HSA-2565942,0.220065945,0,2.200659451
88,3,Reactome Pathways,,MAPK6/MAPK4 signaling,0.0063,PRKACA|CDK1|MYC,10163,10261|10327|10318,2.90E-04,,HSA-5687128,0.220065945,0,2.200659451
31,2,WikiPathways,,miRNA regulation of prostate cancer signaling pathways,0.0063,TP53|CTNNB1,10163,10291|10285,0.001,,WP3981,0.220065945,0,2.200659451
1901,11,Monarch Phenotype,,Abnormal oral cavity morphology,0.0063,CSNK2A1|CYP27B1|SMAD2|PRKACA|SMAD3|BMPR1A|SKI|ACVR1|AKT1|MYC|CTNNB1,10163,10306|10255|10267|10261|10252|10300|10270|10279|10330|10318|10285,3.10E-05,,HP:0000163,0.220065945,0,2.200659451
41,3,Monarch Phenotype,,Male reproductive system neoplasm,0.0063,TP53|BMPR1A|AKT1,10163,10291|10300|10330,3.26E-05,,HP:0033019,0.220065945,0,2.200659451
376,5,GO Biological Process,,Regulation of T cell activation,0.0064,CEBPB|CASP3|MYB|AKT1|CTNNB1,10163,10312|10333|10288|10330|10285,1.80E-04,,GO:0050863,0.219382003,0,2.193820026
127,4,Monarch Phenotype,,Abnormal metatarsal morphology,0.0064,SKI|BMPR1B|ACVR1|AKT1,10163,10270|10294|10279|10330,3.36E-05,,HP:0001832,0.219382003,0,2.193820026
138,3,WikiPathways,,Ectoderm differentiation,0.0065,BMPR1A|MYC|CTNNB1,10163,10300|10318|10285,0.001,,WP2858,0.218708664,0,2.187086643
128,4,Monarch Phenotype,,Neoplasm of the central nervous system,0.0065,TP53|BMPR1A|AKT1|CTNNB1,10163,10291|10300|10330|10285,3.46E-05,,HP:0100006,0.218708664,0,2.187086643
32,2,WikiPathways,,IL-17 signaling pathway,0.0066,CEBPB|AKT1,10163,10312|10330,0.0011,,WP2112,0.218045606,0,2.180456064
32,2,WikiPathways,,Hair follicle development: organogenesis - part 2 of 3,0.0066,MYC|CTNNB1,10163,10318|10285,0.0011,,WP2839,0.218045606,0,2.180456064
1190,8,GO Biological Process,,Regulation of organelle organization,0.0068,CASP6|CDK2|TP53|PLK1|SMAD3|AKT1|MYC|CTNNB1,10163,10309|10303|10291|10297|10252|10330|10318|10285,1.90E-04,,GO:0033043,0.216749109,0,2.167491087
201,4,GO Biological Process,,Regulation of protein binding,0.0068,STUB1|PLK1|PRKACA|AKT1,10163,10315|10297|10261|10330,1.90E-04,,GO:0043393,0.216749109,0,2.167491087
130,4,Monarch Phenotype,,Intracranial hemorrhage,0.0068,SMAD2|SMAD3|AKT1|CTNNB1,10163,10267|10252|10330|10285,3.67E-05,,HP:0002170,0.216749109,0,2.167491087
43,3,Monarch Phenotype,,Neoplasm of the lung,0.0068,TP53|AKT1|CTNNB1,10163,10291|10330|10285,3.73E-05,,HP:0100526,0.216749109,0,2.167491087
84,3,TISSUES,,Ovary cancer cell,0.0069,SMAD1|SMAD5|AKT1,10163,10282|10258|10330,2.50E-04,,BTO:0001023,0.216115091,0,2.161150909
1244,8,TISSUES,,Placenta,0.0069,RBL2|SMAD2|CDK2|CEBPB|SMAD3|BMPR1A|MYC|CTNNB1,10163,10276|10267|10303|10312|10252|10300|10318|10285,2.50E-04,,BTO:0001078,0.216115091,0,2.161150909
7,2,DISEASES,,Colon carcinoma,0.0069,TP53|CTNNB1,10163,10291|10285,6.95E-05,,DOID:1520,0.216115091,0,2.161150909
33,2,WikiPathways,,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4),0.0069,CEBPB|MYC,10163,10312|10318,0.0011,,WP2817,0.216115091,0,2.161150909
93,3,Reactome Pathways,,Recruitment of NuMA to mitotic centrosomes,0.0071,PLK1|PRKACA|CDK1,10163,10297|10261|10327,3.30E-04,,HSA-380320,0.214874165,0,2.148741651
92,3,Reactome Pathways,,Regulation of TP53 Activity through Phosphorylation,0.0071,CSNK2A1|CDK2|TP53,10163,10306|10303|10291,3.20E-04,,HSA-6804756,0.214874165,0,2.148741651
17,2,Reactome Pathways,,"Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)",0.0071,CDK2|E2F1,10163,10303|10264,3.30E-04,,HSA-9661069,0.214874165,0,2.148741651
1252,9,Monarch Phenotype,,Abnormality of the vertebral column,0.0071,CSNK2A1|CYP27B1|SMAD2|SMAD3|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10255|10267|10252|10270|10294|10279|10330|10285,3.94E-05,,HP:0000925,0.214874165,0,2.148741651
1954,11,Monarch Phenotype,,Abnormal skull morphology,0.0071,CSNK2A1|STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|AKT1|CTNNB1,10163,10306|10315|10255|10267|10291|10261|10252|10300|10270|10330|10285,4.01E-05,,HP:0000929,0.214874165,0,2.148741651
133,4,Monarch Phenotype,,Arachnodactyly,0.0071,STUB1|SMAD2|SMAD3|SKI,10163,10315|10267|10252|10270,4.00E-05,,HP:0001166,0.214874165,0,2.148741651
204,4,GO Biological Process,,Respiratory system development,0.0072,SMAD2|BMPR1A|SKI|CTNNB1,10163,10267|10300|10270|10285,2.00E-04,,GO:0060541,0.21426675,0,2.142667504
386,5,GO Biological Process,,Regulation of protein serine/threonine kinase activity,0.0072,PLK1|CASP3|BMPR1A|BMPR1B|AKT1,10163,10297|10333|10300|10294|10330,2.00E-04,,GO:0071900,0.21426675,0,2.142667504
34,2,WikiPathways,,Cohesin complex - Cornelia de Lange syndrome,0.0072,PLK1|CDK1,10163,10297|10327,0.0012,,WP5117,0.21426675,0,2.142667504
205,4,GO Biological Process,,Regulation of cysteine-type endopeptidase activity involved in apoptotic process,0.0073,CSNK2A1|SMAD3|AKT1|MYC,10163,10306|10252|10330|10318,2.10E-04,,GO:0043281,0.213667714,0,2.13667714
224,4,TISSUES,,Fibroblast,0.0075,SMAD2|TP53|SMAD3|MYC,10163,10267|10291|10252|10318,2.90E-04,,BTO:0000452,0.212493874,0,2.124938737
391,5,GO Biological Process,,Forebrain development,0.0076,CASP3|E2F1|BMPR1A|SKI|CTNNB1,10163,10333|10264|10300|10270|10285,2.10E-04,,GO:0030900,0.211918641,0,2.119186408
207,4,GO Biological Process,,Positive regulation of epithelial cell proliferation,0.0076,BMPR1A|AKT1|MYC|CTNNB1,10163,10300|10330|10318|10285,2.10E-04,,GO:0050679,0.211918641,0,2.119186408
16,2,TISSUES,,Cardiac muscle fiber,0.0076,CASP3|AKT1,10163,10333|10330,2.90E-04,,BTO:0002320,0.211918641,0,2.119186408
16,2,TISSUES,,Cancer stem cell,0.0076,TP53|CTNNB1,10163,10291|10285,2.90E-04,,BTO:0004254,0.211918641,0,2.119186408
18,2,Reactome Pathways,,SUMOylation of transcription factors,0.0076,TP53|SUMO2,10163,10291|10273,3.60E-04,,HSA-3232118,0.211918641,0,2.119186408
96,3,Reactome Pathways,,VEGFA-VEGFR2 Pathway,0.0076,PRKACA|AKT1|CTNNB1,10163,10261|10330|10285,3.70E-04,,HSA-4420097,0.211918641,0,2.119186408
35,2,WikiPathways,,Influence of laminopathies on Wnt signaling,0.0076,CEBPB|CTNNB1,10163,10312|10285,0.0013,,WP4844,0.211918641,0,2.119186408
8,2,GO Cellular Component,,HFE-transferrin receptor complex,0.0077,BMPR1A|BMPR1B,10163,10300|10294,8.68E-05,,GO:1990712,0.211350927,0,2.113509275
97,3,Reactome Pathways,,Anchoring of the basal body to the plasma membrane,0.0078,PLK1|PRKACA|CDK1,10163,10297|10261|10327,3.80E-04,,HSA-5620912,0.21079054,0,2.107905397
81,3,GO Biological Process,,Lens development in camera-type eye,0.008,SMAD3|SKI|CTNNB1,10163,10252|10270|10285,2.30E-04,,GO:0002088,0.209691001,0,2.096910013
2362,11,GO Biological Process,,Cellular biosynthetic process,0.008,CYP27B1|SMAD2|CDK2|TP53|CEBPB|SMAD1|E2F1|SKI|BMPR1B|AKT1|CTNNB1,10163,10255|10267|10303|10291|10312|10282|10264|10270|10294|10330|10285,2.30E-04,,GO:0044249,0.209691001,0,2.096910013
980,8,Monarch Phenotype,,Abnormality of finger,0.0081,STUB1|SMAD2|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1,10163,10315|10267|10252|10300|10270|10294|10279|10330,4.88E-05,,HP:0001167,0.209151498,0,2.091514981
912,7,GO Biological Process,,Positive regulation of phosphate metabolic process,0.0082,TP53|PLK1|SMAD3|BMPR1A|BMPR1B|ACVR1|AKT1,10163,10291|10297|10252|10300|10294|10279|10330,2.30E-04,,GO:0045937,0.208618615,0,2.086186148
141,4,Monarch Phenotype,,Emotional lability,0.0082,TP53|PRKACA|AKT1|CTNNB1,10163,10291|10261|10330|10285,5.00E-05,,HP:0000712,0.208618615,0,2.086186148
37,2,WikiPathways,,Amyotrophic lateral sclerosis (ALS),0.0084,TP53|CASP3,10163,10291|10333,0.0014,,WP2447,0.207572071,0,2.075720714
37,2,WikiPathways,,Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome,0.0084,TP53|E2F1,10163,10291|10264,0.0014,,WP4320,0.207572071,0,2.075720714
83,3,GO Biological Process,,Embryonic heart tube development,0.0085,SMAD3|ACVR1|CTNNB1,10163,10252|10279|10285,2.40E-04,,GO:0035050,0.207058107,0,2.070581074
216,4,GO Biological Process,,Regulation of neuron apoptotic process,0.0087,TP53|CEBPB|CASP3|CTNNB1,10163,10291|10312|10333|10285,2.50E-04,,GO:0043523,0.206048075,0,2.060480747
84,3,GO Biological Process,,Cardiac muscle cell differentiation,0.0087,BMPR1A|CDK1|ACVR1,10163,10300|10327|10279,2.50E-04,,GO:0055007,0.206048075,0,2.060480747
38,2,WikiPathways,,Parkinsons disease pathway,0.0087,CASP6|CASP3,10163,10309|10333,0.0015,,WP2371,0.206048075,0,2.060480747
49,3,Monarch Phenotype,,Abnormality of subcutaneous fat tissue,0.0087,PRKACA|SKI|AKT1,10163,10261|10270|10330,5.40E-05,,HP:0001001,0.206048075,0,2.060480747
145,4,Monarch Phenotype,,Abnormal venous morphology,0.0087,TP53|SMAD3|AKT1|CTNNB1,10163,10291|10252|10330|10285,5.56E-05,,HP:0002624,0.206048075,0,2.060480747
6,2,Monarch Phenotype,,Ovarian papillary adenocarcinoma,0.0087,AKT1|CTNNB1,10163,10330|10285,5.41E-05,,HP:0006774,0.206048075,0,2.060480747
50,3,Monarch Phenotype,,Uterine neoplasm,0.0087,BMPR1A|AKT1|CTNNB1,10163,10300|10330|10285,5.72E-05,,HP:0010784,0.206048075,0,2.060480747
292,5,Monarch Phenotype,,Abnormality of cranial sutures,0.0087,CYP27B1|SMAD3|SKI|AKT1|CTNNB1,10163,10255|10252|10270|10330|10285,5.53E-05,,HP:0011329,0.206048075,0,2.060480747
20,2,Reactome Pathways,,Phosphorylation of the APC/C,0.0089,PLK1|CDK1,10163,10297|10327,4.40E-04,,HSA-176412,0.205060999,0,2.050609993
85,3,GO Biological Process,,Chondrocyte differentiation,0.009,BMPR1A|BMPR1B|CTNNB1,10163,10300|10294|10285,2.60E-04,,GO:0002062,0.204575749,0,2.045757491
1251,8,GO Biological Process,,Regulation of phosphorylation,0.0092,RBL2|TP53|PLK1|CASP3|BMPR1A|BMPR1B|ACVR1|AKT1,10163,10276|10291|10297|10333|10300|10294|10279|10330,2.60E-04,,GO:0042325,0.203621217,0,2.036212173
354,4,KEGG Pathways,,Alzheimer disease,0.0093,CSNK2A1|CASP3|AKT1|CTNNB1,10163,10306|10333|10330|10285,0.0015,,hsa05010,0.203151705,0,2.031517051
413,5,GO Biological Process,,Positive regulation of cellular catabolic process,0.0094,STUB1|PLK1|CASP3|SUMO2|AKT1,10163,10315|10297|10333|10273|10330,2.70E-04,,GO:0031331,0.202687215,0,2.026872146
301,5,Monarch Phenotype,,Abnormality of the knee,0.0094,CYP27B1|PRKACA|SMAD3|SKI|BMPR1B,10163,10255|10261|10252|10270|10294,6.37E-05,,HP:0002815,0.202687215,0,2.026872146
52,3,Monarch Phenotype,,Thyroid carcinoma,0.0094,TP53|BMPR1A|AKT1,10163,10291|10300|10330,6.39E-05,,HP:0002890,0.202687215,0,2.026872146
1330,9,Monarch Phenotype,,Abnormal musculoskeletal physiology,0.0094,CSNK2A1|CYP27B1|TP53|SMAD3|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10255|10291|10252|10270|10294|10279|10330|10285,6.31E-05,,HP:0011843,0.202687215,0,2.026872146
52,3,Monarch Phenotype,,Ovarian neoplasm,0.0094,TP53|AKT1|CTNNB1,10163,10291|10330|10285,6.39E-05,,HP:0100615,0.202687215,0,2.026872146
329,5,GO Molecular Function,,"DNA-binding transcription repressor activity, RNA polymerase II-specific",0.0095,TP53|CEBPB|SKI|SMAD5|MYC,10163,10291|10312|10270|10258|10318,9.63E-05,,GO:0001227,0.202227639,0,2.022276395
105,3,Reactome Pathways,,KEAP1-NFE2L2 pathway,0.0095,CSNK2A1|AKT1|MYC,10163,10306|10330|10318,4.70E-04,,HSA-9755511,0.202227639,0,2.022276395
40,2,WikiPathways,,IL-5 signaling pathway,0.0095,AKT1|MYC,10163,10330|10318,0.0016,,WP127,0.202227639,0,2.022276395
107,3,Reactome Pathways,,Interleukin-4 and Interleukin-13 signaling,0.0098,TP53|AKT1|MYC,10163,10291|10330|10318,5.00E-04,,HSA-6785807,0.200877392,0,2.008773924
9,2,DISEASES,,Colorectal carcinoma,0.0099,TP53|CTNNB1,10163,10291|10285,1.10E-04,,DOID:0080199,0.200436481,0,2.004364805
62,3,DISEASES,,Breast cancer,0.0099,TP53|AKT1|MYC,10163,10291|10330|10318,1.10E-04,,DOID:1612,0.200436481,0,2.004364805
9,2,DISEASES,,Endometrial carcinoma,0.0099,TP53|AKT1,10163,10291|10330,1.10E-04,,DOID:2871,0.200436481,0,2.004364805
1358,9,Monarch Phenotype,,Abnormality of the genital system,0.0099,STUB1|TP53|SMAD3|BMPR1A|SKI|BMPR1B|AKT1|MYC|CTNNB1,10163,10315|10291|10252|10300|10270|10294|10330|10318|10285,7.42E-05,,HP:0000078,0.200436481,0,2.004364805
55,3,Monarch Phenotype,,Transient ischemic attack,0.0099,SMAD2|SMAD3|BMPR1A,10163,10267|10252|10300,7.50E-05,,HP:0002326,0.200436481,0,2.004364805
54,3,Monarch Phenotype,,Breast carcinoma,0.0099,TP53|AKT1|CTNNB1,10163,10291|10330|10285,7.12E-05,,HP:0003002,0.200436481,0,2.004364805
54,3,Monarch Phenotype,,Venous insufficiency,0.0099,TP53|SMAD3|CTNNB1,10163,10291|10252|10285,7.12E-05,,HP:0005293,0.200436481,0,2.004364805
1347,9,Monarch Phenotype,,Abnormality of immune system physiology,0.0099,CSNK2A1|STUB1|TP53|PRKACA|SMAD3|BMPR1A|AKT1|MYC|CTNNB1,10163,10306|10315|10291|10261|10252|10300|10330|10318|10285,6.96E-05,,HP:0010978,0.200436481,0,2.004364805
16,2,GO Biological Process,,Negative regulation of glial cell proliferation,0.0101,TP53|SKI,10163,10291|10270,2.90E-04,,GO:0060253,0.199567863,0,1.995678626
158,4,Monarch Phenotype,,Dolichocephaly,0.0101,CYP27B1|SMAD3|SKI|AKT1,10163,10255|10252|10270|10330,7.69E-05,,HP:0000268,0.199567863,0,1.995678626
763,7,Monarch Phenotype,,Neoplasm,0.0101,TP53|BMPR1A|BMPR1B|ACVR1|AKT1|MYC|CTNNB1,10163,10291|10300|10294|10279|10330|10318|10285,7.75E-05,,HP:0002664,0.199567863,0,1.995678626
56,3,Monarch Phenotype,,Abscess,0.0101,TP53|BMPR1A|CTNNB1,10163,10291|10300|10285,7.89E-05,,HP:0025615,0.199567863,0,1.995678626
2438,11,GO Biological Process,,Organic substance biosynthetic process,0.0102,CYP27B1|SMAD2|CDK2|TP53|CEBPB|SMAD1|E2F1|SKI|BMPR1B|AKT1|CTNNB1,10163,10255|10267|10303|10291|10312|10282|10264|10270|10294|10330|10285,3.00E-04,,GO:1901576,0.199139983,0,1.991399828
9,2,GO Molecular Function,,Cysteine-type endopeptidase activity involved in execution phase of apoptosis,0.0103,CASP6|CASP3,10163,10309|10333,1.10E-04,,GO:0097200,0.198716278,0,1.987162775
22,2,Reactome Pathways,,E2F mediated regulation of DNA replication,0.0103,E2F1|CDK1,10163,10264|10327,5.30E-04,,HSA-113510,0.198716278,0,1.987162775
22,2,Reactome Pathways,,Signaling by NODAL,0.0103,SMAD2|SMAD3,10163,10267|10252,5.30E-04,,HSA-1181150,0.198716278,0,1.987162775
42,2,WikiPathways,,IL-2 signaling pathway,0.0103,AKT1|MYC,10163,10330|10318,0.0018,,WP49,0.198716278,0,1.987162775
57,3,Monarch Phenotype,,Hemorrhoid,0.0106,TP53|SMAD3|BMPR1B,10163,10291|10252|10294,8.30E-05,,EFO:0009552,0.197469413,0,1.974694135
165,4,Monarch Phenotype,,Abnormality of the ovary,0.0106,TP53|AKT1|MYC|CTNNB1,10163,10291|10330|10318|10285,9.06E-05,,HP:0000137,0.197469413,0,1.974694135
1070,8,Monarch Phenotype,,Abnormality of the endocrine system,0.0106,STUB1|CYP27B1|TP53|PRKACA|BMPR1A|BMPR1B|AKT1|CTNNB1,10163,10315|10255|10291|10261|10300|10294|10330|10285,9.03E-05,,HP:0000818,0.197469413,0,1.974694135
58,3,Monarch Phenotype,,Papilledema,0.0106,TP53|AKT1|CTNNB1,10163,10291|10330|10285,8.72E-05,,HP:0001085,0.197469413,0,1.974694135
58,3,Monarch Phenotype,,Gastrointestinal carcinoma,0.0106,BMPR1A|AKT1|CTNNB1,10163,10300|10330|10285,8.72E-05,,HP:0002672,0.197469413,0,1.974694135
230,4,GO Biological Process,,Negative regulation of apoptotic signaling pathway,0.0107,CSNK2A1|ACVR1|AKT1|CTNNB1,10163,10306|10279|10330|10285,3.20E-04,,GO:2001234,0.197061622,0,1.970616222
1707,9,TISSUES,,Respiratory system,0.0107,CSNK2A1|RBL2|CASP6|PLK1|CEBPB|ACVR1|SUMO2|AKT1|CTNNB1,10163,10306|10276|10309|10297|10312|10279|10273|10330|10285,4.20E-04,,BTO:0000203,0.197061622,0,1.970616222
43,2,WikiPathways,,Fas ligand pathway and stress induction of heat shock proteins,0.0107,CASP6|CASP3,10163,10309|10333,0.0019,,WP314,0.197061622,0,1.970616222
10,2,DISEASES,,PTEN hamartoma tumor syndrome,0.0108,BMPR1A|AKT1,10163,10300|10330,1.30E-04,,DOID:0080191,0.196657624,0,1.966576245
10,2,DISEASES,,Cowden syndrome,0.0108,BMPR1A|AKT1,10163,10300|10330,1.30E-04,,DOID:6457,0.196657624,0,1.966576245
171,3,WikiPathways,,Primary ovarian insufficiency,0.0108,BMPR1A|BMPR1B|AKT1,10163,10300|10294|10330,0.0019,,WP5316,0.196657624,0,1.966576245
327,5,Monarch Phenotype,,Abnormality of the thyroid gland,0.0108,STUB1|TP53|BMPR1A|AKT1|CTNNB1,10163,10315|10291|10300|10330|10285,9.37E-05,,HP:0000820,0.196657624,0,1.966576245
12,2,COMPARTMENTS,,Activin complex,0.0109,SMAD2|ACVR1,10163,10267|10279,1.70E-04,,GOCC:0048180,0.19625735,0,1.962573502
428,5,GO Biological Process,,Regulation of cell growth,0.0109,CSNK2A1|CYP27B1|TP53|SMAD3|AKT1,10163,10306|10255|10291|10252|10330,3.20E-04,,GO:0001558,0.19625735,0,1.962573502
5,2,STRING Clusters,,"Rb C-terminal domain, and E2F-DP heterodimerization region",0.0109,RBL2|E2F4,10163,10276|10321,4.06E-05,,CL:6968,0.19625735,0,1.962573502
1290,8,GO Biological Process,,Neurogenesis,0.011,TP53|CEBPB|CASP3|BMPR1A|SKI|BMPR1B|AKT1|CTNNB1,10163,10291|10312|10333|10300|10270|10294|10330|10285,3.30E-04,,GO:0022008,0.195860731,0,1.958607315
92,3,GO Biological Process,,Roof of mouth development,0.011,SMAD2|BMPR1A|SKI,10163,10267|10300|10270,3.20E-04,,GO:0060021,0.195860731,0,1.958607315
576,6,DISEASES,,Gastrointestinal system disease,0.011,TP53|CASP3|BMPR1A|AKT1|MYC|CTNNB1,10163,10291|10333|10300|10330|10318|10285,1.40E-04,,DOID:77,0.195860731,0,1.958607315
169,4,Monarch Phenotype,,Abnormality of the adrenal glands,0.011,TP53|PRKACA|AKT1|CTNNB1,10163,10291|10261|10330|10285,9.92E-05,,HP:0000834,0.195860731,0,1.958607315
60,3,Monarch Phenotype,,Hallux valgus,0.011,BMPR1B|ACVR1|AKT1,10163,10294|10279|10330,9.61E-05,,HP:0001822,0.195860731,0,1.958607315
1763,10,Monarch Phenotype,,Abnormality of digestive system physiology,0.011,CSNK2A1|STUB1|CYP27B1|TP53|SMAD3|BMPR1A|SKI|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10291|10252|10300|10270|10330|10318|10285,9.68E-05,,HP:0025032,0.195860731,0,1.958607315
792,7,Monarch Phenotype,,Abnormal blood vessel morphology,0.011,SMAD2|TP53|SMAD3|BMPR1A|SKI|AKT1|CTNNB1,10163,10267|10291|10252|10300|10270|10330|10285,9.78E-05,,HP:0033353,0.195860731,0,1.958607315
61,3,Monarch Phenotype,,Subcutaneous nodule,0.0111,ACVR1|AKT1|CTNNB1,10163,10279|10330|10285,1.00E-04,,HP:0001482,0.195467702,0,1.954677021
93,3,GO Biological Process,,Neural tube closure,0.0112,PRKACA|CASP3|SKI,10163,10261|10333|10270,3.30E-04,,GO:0001843,0.195078198,0,1.950781977
968,7,GO Biological Process,,Chromosome organization,0.0112,RBL2|RCOR1|TP53|PLK1|MYB|CDK1|MYC,10163,10276|10324|10291|10297|10288|10327|10318,3.30E-04,,GO:0051276,0.195078198,0,1.950781977
433,5,GO Biological Process,,Negative regulation of immune system process,0.0113,CEBPB|CASP3|AKT1|MYC|CTNNB1,10163,10312|10333|10330|10318|10285,3.40E-04,,GO:0002683,0.194692156,0,1.946921557
272,4,Reactome Pathways,,Cell Cycle Checkpoints,0.0113,CDK2|TP53|PLK1|CDK1,10163,10303|10291|10297|10327,5.90E-04,,HSA-69620,0.194692156,0,1.946921557
381,5,COMPARTMENTS,,Nuclear body,0.0115,CDK2|TP53|PRKACA|SKI|SUMO2,10163,10303|10291|10261|10270|10273,1.90E-04,,GOCC:0016604,0.193930216,0,
225,4,UniProt Keywords,,Proto-oncogene,0.0115,MYB|SKI|AKT1|MYC,10163,10288|10270|10330|10318,2.90E-04,,KW-0656,0.193930216,0,
63,3,Monarch Phenotype,,Portal hypertension,0.0115,TP53|BMPR1A|CTNNB1,10163,10291|10300|10285,1.10E-04,,HP:0001409,0.193930216,0,
172,4,Monarch Phenotype,,Abdominal pain,0.0115,TP53|BMPR1A|MYC|CTNNB1,10163,10291|10300|10318|10285,1.10E-04,,HP:0002027,0.193930216,0,
1426,9,Monarch Phenotype,,Abnormality of the upper limb,0.0115,STUB1|CYP27B1|SMAD2|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1,10163,10315|10255|10267|10252|10300|10270|10294|10279|10330,1.10E-04,,HP:0002817,0.193930216,0,
9,2,Monarch Phenotype,,Subacute progressive viral hepatitis,0.0115,TP53|CTNNB1,10163,10291|10285,1.10E-04,,HP:0006572,0.193930216,0,
9,2,Monarch Phenotype,,Dysgerminoma,0.0115,AKT1|CTNNB1,10163,10330|10285,1.10E-04,,HP:0100621,0.193930216,0,
9,2,Monarch Phenotype,,Hemobilia,0.0115,TP53|CTNNB1,10163,10291|10285,1.10E-04,,HP:0100762,0.193930216,0,
3017,12,TISSUES,,Female reproductive gland,0.0116,RBL2|TP53|PLK1|CEBPB|PRKACA|MYB|BMPR1A|BMPR1B|SUMO2|AKT1|MYC|CTNNB1,10163,10276|10291|10297|10312|10261|10288|10300|10294|10273|10330|10318|10285,4.60E-04,,BTO:0000254,0.193554201,0,
95,3,GO Biological Process,,Female gonad development,0.0118,CEBPB|CASP3|BMPR1B,10163,10312|10333|10294,3.60E-04,,GO:0008585,0.192811799,0,
95,3,GO Biological Process,,Negative regulation of transforming growth factor beta receptor signaling pathway,0.0118,STUB1|TP53|SKI,10163,10315|10291|10270,3.60E-04,,GO:0030512,0.192811799,0,
95,3,GO Biological Process,,Embryonic skeletal system morphogenesis,0.0118,SMAD2|SMAD3|CTNNB1,10163,10267|10252|10285,3.60E-04,,GO:0048704,0.192811799,0,
18,2,GO Biological Process,,Mammary gland epithelial cell differentiation,0.0119,CEBPB|AKT1,10163,10312|10330,3.60E-04,,GO:0060644,0.192445304,0,
343,5,Monarch Phenotype,,Hypogonadism,0.0119,STUB1|TP53|BMPR1B|AKT1|CTNNB1,10163,10315|10291|10294|10330|10285,1.20E-04,,HP:0000135,0.192445304,0,
78,3,COMPARTMENTS,,PML body,0.012,TP53|SKI|SUMO2,10163,10291|10270|10273,2.00E-04,,GOCC:0016605,0.192081875,0,
892,7,COMPARTMENTS,,Transferase complex,0.012,STUB1|CDK2|PRKACA|CDK1|ACVR1|SUMO2|AKT1,10163,10315|10303|10261|10327|10279|10273|10330,2.00E-04,,GOCC:1990234,0.192081875,0,
46,2,WikiPathways,,Envelope proteins and their potential roles in EDMD physiopathology,0.012,SMAD2|SMAD3,10163,10267|10252,0.0021,,WP4535,0.192081875,0,
65,3,Monarch Phenotype,,Fibroma,0.0122,BMPR1A|AKT1|CTNNB1,10163,10300|10330|10285,1.20E-04,,HP:0010614,0.191364017,0,
1117,8,Monarch Phenotype,,Abnormal reproductive system morphology,0.0122,TP53|SMAD3|BMPR1A|SKI|BMPR1B|AKT1|MYC|CTNNB1,10163,10291|10252|10300|10270|10294|10330|10318|10285,1.20E-04,,HP:0012243,0.191364017,0,
66,3,Monarch Phenotype,,Hypoalbuminemia,0.0123,TP53|BMPR1A|CTNNB1,10163,10291|10300|10285,1.30E-04,,HP:0003073,0.191009489,0,
10,2,Monarch Phenotype,,Abdominal wall muscle weakness,0.0123,CYP27B1|SKI,10163,10255|10270,1.30E-04,,HP:0009023,0.191009489,0,
97,3,GO Biological Process,,Negative regulation of myeloid cell differentiation,0.0124,MYB|MYC|CTNNB1,10163,10288|10318|10285,3.80E-04,,GO:0045638,0.190657831,0,
47,2,WikiPathways,,Thymic stromal lymphopoietin (TSLP) signaling pathway,0.0124,AKT1|MYC,10163,10330|10318,0.0022,,WP2203,0.190657831,0,
67,3,Monarch Phenotype,,Hypokalemia,0.0124,TP53|BMPR1A|CTNNB1,10163,10291|10300|10285,1.30E-04,,HP:0002900,0.190657831,0,
67,3,Monarch Phenotype,,Abnormal circulating albumin concentration,0.0124,TP53|BMPR1A|CTNNB1,10163,10291|10300|10285,1.30E-04,,HP:0012116,0.190657831,0,
98,3,GO Biological Process,,Response to heat,0.0127,STUB1|PRKACA|AKT1,10163,10315|10261|10330,3.90E-04,,GO:0009408,0.189619628,0,
243,4,GO Biological Process,,Negative regulation of cellular catabolic process,0.0127,CSNK2A1|TP53|E2F1|AKT1,10163,10306|10291|10264|10330,3.90E-04,,GO:0031330,0.189619628,0,
353,5,GO Molecular Function,,RNA polymerase II-specific DNA-binding transcription factor binding,0.0127,SMAD2|TP53|CEBPB|SMAD3|CTNNB1,10163,10267|10291|10312|10252|10285,1.30E-04,,GO:0061629,0.189619628,0,
356,5,Monarch Phenotype,,Limitation of joint mobility,0.0127,SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10270|10294|10279|10330|10285,1.40E-04,,HP:0001376,0.189619628,0,
7004,19,TISSUES,,Gland,0.0128,STUB1|CYP27B1|RBL2|SMAD2|TP53|PLK1|CEBPB|SMAD1|PRKACA|SMAD3|MYB|E2F1|BMPR1A|E2F4|BMPR1B|SUMO2|AKT1|MYC|CTNNB1,10163,10315|10255|10276|10267|10291|10297|10312|10282|10261|10252|10288|10264|10300|10321|10294|10273|10330|10318|10285,5.10E-04,,BTO:0000522,0.189279003,0,
108,3,TISSUES,,Prostate cancer cell line,0.0128,TP53|CASP3|AKT1,10163,10291|10333|10330,5.10E-04,,BTO:0001033,0.189279003,0,
183,3,WikiPathways,,Vitamin D receptor pathway,0.0128,CYP27B1|CDK2|MYC,10163,10255|10303|10318,0.0023,,WP2877,0.189279003,0,
19,2,GO Biological Process,,Ectoderm development,0.013,BMPR1A|CTNNB1,10163,10300|10285,4.00E-04,,GO:0007398,0.188605665,0,
99,3,GO Biological Process,,Regulation of G2/M transition of mitotic cell cycle,0.013,CDK2|PLK1|CDK1,10163,10303|10297|10327,4.00E-04,,GO:0010389,0.188605665,0,
19,2,GO Biological Process,,Pericardium development,0.013,SMAD2|SMAD3,10163,10267|10252,4.00E-04,,GO:0060039,0.188605665,0,
12,2,DISEASES,,Head and neck cancer,0.013,TP53|AKT1,10163,10291|10330,1.70E-04,,DOID:11934,0.188605665,0,
12,2,DISEASES,,Nephroblastoma,0.013,TP53|CTNNB1,10163,10291|10285,1.70E-04,,DOID:2154,0.188605665,0,
69,3,Monarch Phenotype,,Hamartoma,0.013,BMPR1A|ACVR1|AKT1,10163,10300|10279|10330,1.40E-04,,HP:0010566,0.188605665,0,
247,4,GO Biological Process,,Heart morphogenesis,0.0132,TP53|SMAD3|BMPR1A|ACVR1,10163,10291|10252|10300|10279,4.10E-04,,GO:0003007,0.187942607,0,
3463,13,GO Biological Process,,Cellular nitrogen compound metabolic process,0.0132,STUB1|SMAD2|CDK2|TP53|CEBPB|SMAD1|PRKACA|SMAD3|E2F1|SKI|CDK1|AKT1|CTNNB1,10163,10315|10267|10303|10291|10312|10282|10261|10252|10264|10270|10327|10330|10285,4.10E-04,,GO:0034641,0.187942607,0,
49,2,WikiPathways,,IL-3 signaling pathway,0.0132,PRKACA|AKT1,10163,10261|10330,0.0024,,WP286,0.187942607,0,
49,2,WikiPathways,,TROP2 regulatory signaling,0.0132,CDK2|CTNNB1,10163,10303|10285,0.0024,,WP5300,0.187942607,0,
248,4,GO Biological Process,,Gliogenesis,0.0134,TP53|SKI|AKT1|CTNNB1,10163,10291|10270|10330|10285,4.20E-04,,GO:0042063,0.18728952,0,
362,5,Monarch Phenotype,,Abnormal sternum morphology,0.0134,CYP27B1|SMAD2|SMAD3|SKI|AKT1,10163,10255|10267|10252|10270|10330,1.50E-04,,HP:0000766,0.18728952,0,
1151,8,Monarch Phenotype,,Abnormal respiratory system physiology,0.0134,SMAD2|TP53|SMAD3|BMPR1A|SKI|ACVR1|AKT1|CTNNB1,10163,10267|10291|10252|10300|10270|10279|10330|10285,1.50E-04,,HP:0002795,0.18728952,0,
11,2,Monarch Phenotype,,Epigastric pain,0.0134,TP53|CTNNB1,10163,10291|10285,1.50E-04,,HP:0410019,0.18728952,0,
20,2,GO Biological Process,,Positive regulation of chondrocyte differentiation,0.0141,SMAD3|BMPR1B,10163,10252|10294,4.40E-04,,GO:0032332,0.185078089,0,
20,2,GO Biological Process,,Positive regulation of transforming growth factor beta production,0.0141,SMAD3|BMPR1A,10163,10252|10300,4.40E-04,,GO:0071636,0.185078089,0,
252,4,GO Biological Process,,Response to alcohol,0.0141,SMAD2|CDK1|AKT1|CTNNB1,10163,10267|10327|10330|10285,4.40E-04,,GO:0097305,0.185078089,0,
1491,9,GO Molecular Function,,ATP binding,0.0141,CSNK2A1|CDK2|PLK1|PRKACA|BMPR1A|CDK1|BMPR1B|ACVR1|AKT1,10163,10306|10303|10297|10261|10300|10327|10294|10279|10330,1.50E-04,,GO:0005524,0.185078089,0,
1199,8,DISEASES,,Central nervous system disease,0.0142,STUB1|CYP27B1|TP53|CASP3|E2F4|ACVR1|AKT1|CTNNB1,10163,10315|10255|10291|10333|10321|10279|10330|10285,2.00E-04,,DOID:331,0.184771166,0,
193,4,Monarch Phenotype,,Alopecia,0.0142,STUB1|CYP27B1|PRKACA|ACVR1,10163,10315|10255|10261|10279,1.60E-04,,HP:0001596,0.184771166,0,
1165,8,Monarch Phenotype,,Abnormality of skin adnexa morphology,0.0142,CSNK2A1|STUB1|CYP27B1|PRKACA|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10315|10255|10261|10294|10279|10330|10285,1.60E-04,,HP:0011138,0.184771166,0,
253,4,GO Biological Process,,Regulation of chromosome organization,0.0143,CDK2|PLK1|MYC|CTNNB1,10163,10303|10297|10318|10285,4.50E-04,,GO:0033044,0.184466396,0,
461,5,GO Biological Process,,Positive regulation of protein localization,0.0143,PLK1|PRKACA|SMAD3|CDK1|AKT1,10163,10297|10261|10252|10327|10330,4.50E-04,,GO:1903829,0.184466396,0,
73,3,Monarch Phenotype,,Bone pain,0.0144,CYP27B1|TP53|CTNNB1,10163,10255|10291|10285,1.70E-04,,HP:0002653,0.184163751,0,
73,3,Monarch Phenotype,,Osteolysis,0.0144,CYP27B1|TP53|CTNNB1,10163,10255|10291|10285,1.70E-04,,HP:0002797,0.184163751,0,
1513,9,Monarch Phenotype,,Abnormality of body weight,0.0144,CSNK2A1|CYP27B1|TP53|PRKACA|BMPR1A|SKI|ACVR1|AKT1|CTNNB1,10163,10306|10255|10291|10261|10300|10270|10279|10330|10285,1.70E-04,,HP:0004323,0.184163751,0,
3173,13,Monarch Phenotype,,Abnormality of the musculoskeletal system,0.0144,CSNK2A1|STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10315|10255|10267|10291|10261|10252|10300|10270|10294|10279|10330|10285,1.70E-04,,HP:0033127,0.184163751,0,
73,3,Monarch Phenotype,,Chest pain,0.0144,SMAD2|SMAD3|CTNNB1,10163,10267|10252|10285,1.70E-04,,HP:0100749,0.184163751,0,
104,3,GO Biological Process,,Negative regulation of small molecule metabolic process,0.0145,CYP27B1|TP53|AKT1,10163,10255|10291|10330,4.60E-04,,GO:0062014,0.1838632,0,
254,4,GO Biological Process,,Regulation of protein modification by small protein conjugation or removal,0.0145,STUB1|PLK1|AKT1|CTNNB1,10163,10315|10297|10330|10285,4.60E-04,,GO:1903320,0.1838632,0,
12,2,Monarch Phenotype,,Thin bony cortex,0.0145,CYP27B1|AKT1,10163,10255|10330,1.70E-04,,HP:0002753,0.1838632,0,
74,3,Monarch Phenotype,,Skin nodule,0.0145,ACVR1|AKT1|CTNNB1,10163,10279|10330|10285,1.70E-04,,HP:0200036,0.1838632,0,
27,2,Reactome Pathways,,VEGFR2 mediated vascular permeability,0.0147,AKT1|CTNNB1,10163,10330|10285,7.70E-04,,HSA-5218920,0.183268267,0,
27,2,Reactome Pathways,,Pyroptosis,0.0147,TP53|CASP3,10163,10291|10333,7.70E-04,,HSA-5620971,0.183268267,0,
521,5,Reactome Pathways,,Signaling by Receptor Tyrosine Kinases,0.0147,STUB1|PRKACA|AKT1|MYC|CTNNB1,10163,10315|10261|10330|10318|10285,7.80E-04,,HSA-9006934,0.183268267,0,
105,3,GO Biological Process,,Regulation of signal transduction by p53 class mediator,0.0149,TP53|AKT1|MYC,10163,10291|10330|10318,4.70E-04,,GO:1901796,0.182681373,0,
21,2,GO Biological Process,,Regulation of transcription involved in G1/S transition of mitotic cell cycle,0.0151,E2F1|E2F4,10163,10264|10321,4.80E-04,,GO:0000083,0.182102305,0,
21,2,GO Biological Process,,Lens morphogenesis in camera-type eye,0.0151,SKI|CTNNB1,10163,10270|10285,4.80E-04,,GO:0002089,0.182102305,0,
259,4,GO Biological Process,,Positive regulation of growth,0.0154,CSNK2A1|BMPR1A|CDK1|AKT1,10163,10306|10300|10327|10330,4.90E-04,,GO:0045927,0.181247928,0,
201,4,Monarch Phenotype,,Cerebral ischemia,0.0154,SMAD2|SMAD3|BMPR1A|CTNNB1,10163,10267|10252|10300|10285,1.90E-04,,HP:0002637,0.181247928,0,
201,4,Monarch Phenotype,,Tissue ischemia,0.0154,SMAD2|SMAD3|BMPR1A|CTNNB1,10163,10267|10252|10300|10285,1.90E-04,,HP:0033401,0.181247928,0,
381,5,Monarch Phenotype,,Abnormal cerebral vascular morphology,0.0154,SMAD2|SMAD3|BMPR1A|AKT1|CTNNB1,10163,10267|10252|10300|10330|10285,1.90E-04,,HP:0100659,0.181247928,0,
41,3,InterPro Domains,,Snake toxin-like superfamily,0.0156,BMPR1A|BMPR1B|ACVR1,10163,10300|10294|10279,3.26E-05,,IPR045860,0.18068754,0,
54,2,WikiPathways,,IL-4 signaling pathway,0.0157,CEBPB|AKT1,10163,10312|10330,0.0029,,WP395,0.180410035,0,
14,2,DISEASES,,Glioblastoma multiforme,0.016,TP53|AKT1,10163,10291|10330,2.30E-04,,DOID:3068,0.179588002,0,
13,2,Monarch Phenotype,,Enlarged pituitary gland,0.016,AKT1|CTNNB1,10163,10330|10285,2.00E-04,,HP:0012505,0.179588002,0,
13,2,Monarch Phenotype,,Bitemporal hemianopia,0.016,AKT1|CTNNB1,10163,10330|10285,2.00E-04,,HP:0030521,0.179588002,0,
78,3,Monarch Phenotype,,Benign neoplasm of the central nervous system,0.016,TP53|BMPR1A|AKT1,10163,10291|10300|10330,2.00E-04,,HP:0100835,0.179588002,0,
29,2,Reactome Pathways,,Downregulation of ERBB2 signaling,0.0162,STUB1|AKT1,10163,10315|10330,8.80E-04,,HSA-8863795,0.179048499,0,
1539,9,GO Cellular Component,,Catalytic complex,0.0165,CSNK2A1|STUB1|RCOR1|CASP6|CDK2|PRKACA|CASP3|CDK1|ACVR1,10163,10306|10315|10324|10309|10303|10261|10333|10327|10279,1.90E-04,,GO:1902494,0.178251606,0,
198,4,GO Molecular Function,,Phosphatase binding,0.0165,SMAD2|TP53|SMAD3|CTNNB1,10163,10267|10291|10252|10285,1.80E-04,,GO:0019902,0.178251606,0,
54,2,KEGG Pathways,,Regulation of lipolysis in adipocytes,0.0168,PRKACA|AKT1,10163,10261|10330,0.0029,,hsa04923,0.177469072,0,
30,2,Reactome Pathways,,Regulation of TP53 Activity through Acetylation,0.0171,TP53|AKT1,10163,10291|10330,9.40E-04,,HSA-6804758,0.176700389,0,
30,2,Reactome Pathways,,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",0.0171,SMAD2|SMAD3,10163,10267|10252,9.40E-04,,HSA-9615017,0.176700389,0,
111,3,GO Biological Process,,Regulation of cyclin-dependent protein serine/threonine kinase activity,0.0172,PLK1|CASP3|AKT1,10163,10297|10333|10330,5.50E-04,,GO:0000079,0.176447155,0,
747,6,GO Biological Process,,Positive regulation of protein phosphorylation,0.0172,TP53|PLK1|BMPR1A|BMPR1B|ACVR1|AKT1,10163,10291|10297|10300|10294|10279|10330,5.60E-04,,GO:0001934,0.176447155,0,
111,3,GO Biological Process,,Positive regulation of histone modification,0.0172,TP53|MYB|CTNNB1,10163,10291|10288|10285,5.50E-04,,GO:0031058,0.176447155,0,
23,2,GO Biological Process,,Signal transduction involved in regulation of gene expression,0.0176,SMAD2|SMAD3,10163,10267|10252,5.70E-04,,GO:0023019,0.175448733,0,
23,2,GO Biological Process,,Positive regulation of cardiac muscle cell proliferation,0.0176,BMPR1A|CDK1,10163,10300|10327,5.70E-04,,GO:0060045,0.175448733,0,
15,2,DISEASES,,Cervical cancer,0.0176,TP53|AKT1,10163,10291|10330,2.60E-04,,DOID:4362,0.175448733,0,
203,3,KEGG Pathways,,Human immunodeficiency virus 1 infection,0.0176,CASP3|CDK1|AKT1,10163,10333|10327|10330,0.003,,hsa05170,0.175448733,0,
1917,9,Reactome Pathways,,Metabolism of proteins,0.0176,CSNK2A1|SMAD2|TP53|SMAD1|SMAD3|CDK1|SUMO2|MYC|CTNNB1,10163,10306|10267|10291|10282|10252|10327|10273|10318|10285,9.80E-04,,HSA-392499,0.175448733,0,
635,6,Monarch Phenotype,,High palate,0.0177,CSNK2A1|SMAD2|SMAD3|SKI|AKT1|CTNNB1,10163,10306|10267|10252|10270|10330|10285,2.40E-04,,HP:0000218,0.175202673,0,
14,2,Monarch Phenotype,,Budd-Chiari syndrome,0.0177,TP53|CTNNB1,10163,10291|10285,2.30E-04,,HP:0002639,0.175202673,0,
14,2,Monarch Phenotype,,Abnormal visual field test,0.0177,AKT1|CTNNB1,10163,10330|10285,2.30E-04,,HP:0030588,0.175202673,0,
113,3,GO Biological Process,,Negative regulation of protein serine/threonine kinase activity,0.0179,PLK1|CASP3|AKT1,10163,10297|10333|10330,5.80E-04,,GO:0071901,0.174714697,0,
272,4,GO Biological Process,,Cellular response to chemical stress,0.018,TP53|CASP3|CDK1|AKT1,10163,10291|10333|10327|10330,5.90E-04,,GO:0062197,0.174472749,0,
13,2,GO Molecular Function,,Nuclear glucocorticoid receptor binding,0.0181,CEBPB|SMAD3,10163,10312|10252,2.00E-04,,GO:0035259,0.174232143,0,
114,3,GO Biological Process,,Stem cell population maintenance,0.0182,BMPR1A|SKI|CTNNB1,10163,10300|10270|10285,6.00E-04,,GO:0019827,0.173992861,0,
17,2,COMPARTMENTS,,Enzyme activator complex,0.0184,TP53|CASP3,10163,10291|10333,3.30E-04,,GOCC:0150005,0.173518218,0,
274,4,GO Biological Process,,Negative regulation of transferase activity,0.0184,TP53|PLK1|CASP3|AKT1,10163,10291|10297|10333|10330,6.10E-04,,GO:0051348,0.173518218,0,
2389,11,Monarch Phenotype,,Abnormality of the digestive system,0.0187,CSNK2A1|STUB1|CYP27B1|SMAD2|TP53|SMAD3|BMPR1A|SKI|AKT1|MYC|CTNNB1,10163,10306|10315|10255|10267|10291|10252|10300|10270|10330|10318|10285,2.50E-04,,HP:0025031,0.172815839,0,
682,6,COMPARTMENTS,,Plasma membrane protein complex,0.0188,CASP3|BMPR1A|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10333|10300|10294|10279|10330|10285,3.40E-04,,GOCC:0098797,0.172584215,0,
16,2,DISEASES,,Ovarian carcinoma,0.0192,TP53|MYC,10163,10291|10318,2.90E-04,,DOID:4001,0.171669877,0,
59,2,KEGG Pathways,,Inflammatory bowel disease,0.0192,SMAD2|SMAD3,10163,10267|10252,0.0034,,hsa05321,0.171669877,0,
648,6,Monarch Phenotype,,Abnormal lower limb bone morphology,0.0195,CYP27B1|TP53|SKI|BMPR1B|ACVR1|AKT1,10163,10255|10291|10270|10294|10279|10330,2.60E-04,,HP:0040069,0.170996539,0,
61,2,WikiPathways,,Notch signaling pathway,0.0196,AKT1|MYC,10163,10330|10318,0.0036,,WP61,0.170774393,0,
1253,8,Monarch Phenotype,,Abnormality of body height,0.0197,CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1B|AKT1|CTNNB1,10163,10255|10267|10291|10261|10252|10294|10330|10285,2.70E-04,,HP:0000002,0.170553377,0,
650,6,Monarch Phenotype,,Hypertelorism,0.0197,CSNK2A1|SMAD2|SMAD3|BMPR1A|SKI|AKT1,10163,10306|10267|10252|10300|10270|10330,2.70E-04,,HP:0000316,0.170553377,0,
118,3,GO Biological Process,,Positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,0.0199,SMAD2|BMPR1A|ACVR1,10163,10267|10300|10279,6.60E-04,,GO:0090100,0.170114692,0,
33,2,Reactome Pathways,,Oncogene Induced Senescence,0.02,TP53|E2F1,10163,10291|10264,0.0011,,HSA-2559585,0.169897,0,
61,2,KEGG Pathways,,Longevity regulating pathway - multiple species,0.0201,PRKACA|AKT1,10163,10261|10330,0.0036,,hsa04213,0.169680394,0,
62,2,WikiPathways,,Prader-Willi and Angelman syndrome,0.0201,TP53|E2F1,10163,10291|10264,0.0037,,WP3998,0.169680394,0,
5378,16,TISSUES,,Viscus,0.0205,STUB1|CYP27B1|RBL2|SMAD2|TP53|PLK1|CEBPB|PRKACA|SMAD3|MYB|E2F1|E2F4|CDK1|SUMO2|AKT1|CTNNB1,10163,10315|10255|10276|10267|10291|10297|10312|10261|10252|10288|10264|10321|10327|10273|10330|10285,8.50E-04,,BTO:0001491,0.168824614,0,
506,5,GO Biological Process,,Negative regulation of protein modification process,0.0206,PLK1|CASP3|SKI|AKT1|CTNNB1,10163,10297|10333|10270|10330|10285,6.90E-04,,GO:0031400,0.168613278,0,
778,6,GO Biological Process,,Regulation of kinase activity,0.0206,RBL2|PLK1|CASP3|BMPR1A|BMPR1B|AKT1,10163,10276|10297|10333|10300|10294|10330,6.90E-04,,GO:0043549,0.168613278,0,
5438,17,GO Cellular Component,,Cytosol,0.0206,CSNK2A1|STUB1|RBL2|SMAD2|CASP6|CDK2|TP53|PLK1|SMAD1|PRKACA|CASP3|SMAD3|MYB|CDK1|SMAD5|AKT1|CTNNB1,10163,10306|10315|10276|10267|10309|10303|10291|10297|10282|10261|10333|10252|10288|10327|10258|10330|10285,2.50E-04,,GO:0005829,0.168613278,0,
15,2,GO Cellular Component,,Caspase complex,0.0206,CASP6|CASP3,10163,10309|10333,2.60E-04,,GO:0008303,0.168613278,0,
15,2,GO Cellular Component,,RNA polymerase II transcription repressor complex,0.0206,MYC|CTNNB1,10163,10318|10285,2.60E-04,,GO:0090571,0.168613278,0,
120,3,GO Biological Process,,Embryonic limb morphogenesis,0.0207,BMPR1A|SKI|CTNNB1,10163,10300|10270|10285,6.90E-04,,GO:0030326,0.168402965,0,
228,4,Monarch Phenotype,,Abnormality of the menstrual cycle,0.0208,STUB1|TP53|BMPR1B|AKT1,10163,10315|10291|10294|10330,3.10E-04,,HP:0000140,0.168193667,0,
949,7,Monarch Phenotype,,Failure to thrive,0.0208,CSNK2A1|CYP27B1|BMPR1A|SKI|ACVR1|AKT1|CTNNB1,10163,10306|10255|10300|10270|10279|10330|10285,3.00E-04,,HP:0001508,0.168193667,0,
225,4,Monarch Phenotype,,Abnormality of the pancreas,0.0208,STUB1|TP53|BMPR1A|MYC,10163,10315|10291|10300|10318,2.90E-04,,HP:0001732,0.168193667,0,
225,4,Monarch Phenotype,,Abnormality of the spinal cord,0.0208,SMAD2|SMAD3|AKT1|CTNNB1,10163,10267|10252|10330|10285,2.90E-04,,HP:0002143,0.168193667,0,
89,3,Monarch Phenotype,,Metaphyseal widening,0.0208,SKI|BMPR1B|ACVR1,10163,10270|10294|10279,3.00E-04,,HP:0003016,0.168193667,0,
1274,8,Monarch Phenotype,,Decreased body weight,0.0208,CSNK2A1|CYP27B1|TP53|BMPR1A|SKI|ACVR1|AKT1|CTNNB1,10163,10306|10255|10291|10300|10270|10279|10330|10285,3.00E-04,,HP:0004325,0.168193667,0,
16,2,Monarch Phenotype,,Progressive macrocephaly,0.0208,AKT1|CTNNB1,10163,10330|10285,2.90E-04,,HP:0004481,0.168193667,0,
16,2,Monarch Phenotype,,Descending thoracic aorta aneurysm,0.0208,SMAD2|SMAD3,10163,10267|10252,2.90E-04,,HP:0004959,0.168193667,0,
224,4,Monarch Phenotype,,Bowing of the long bones,0.0208,CYP27B1|PRKACA|SKI|BMPR1B,10163,10255|10261|10270|10294,2.90E-04,,HP:0006487,0.168193667,0,
420,5,Monarch Phenotype,,Abnormality of upper limb joint,0.0208,CYP27B1|SMAD3|SKI|BMPR1B|AKT1,10163,10255|10252|10270|10294|10330,3.00E-04,,HP:0009810,0.168193667,0,
16,2,Monarch Phenotype,,Chronic fatigue,0.0208,SMAD3|BMPR1A,10163,10252|10300,2.90E-04,,HP:0012432,0.168193667,0,
16,2,Monarch Phenotype,,Abnormal brain FDG positron emission tomography,0.0208,AKT1|CTNNB1,10163,10330|10285,2.90E-04,,HP:0012658,0.168193667,0,
16,2,Monarch Phenotype,,Mucoid extracellular matrix accumulation,0.0208,SMAD2|SMAD3,10163,10267|10252,2.90E-04,,HP:0200146,0.168193667,0,
63,2,KEGG Pathways,,Basal cell carcinoma,0.0211,TP53|CTNNB1,10163,10291|10285,0.0038,,hsa05217,0.167571754,0,
64,2,WikiPathways,,3q29 copy number variation syndrome,0.0212,AKT1|MYC,10163,10330|10318,0.0039,,WP4906,0.167366414,0,
234,4,Monarch Phenotype,,Headache,0.0214,TP53|SMAD3|AKT1|CTNNB1,10163,10291|10252|10330|10285,3.40E-04,,HP:0002315,0.166958623,0,
17,2,Monarch Phenotype,,Hepatic encephalopathy,0.0214,TP53|CTNNB1,10163,10291|10285,3.30E-04,,HP:0002480,0.166958623,0,
94,3,Monarch Phenotype,,Abnormality of tibia morphology,0.0214,CYP27B1|TP53|BMPR1B,10163,10255|10291|10294,3.50E-04,,HP:0002992,0.166958623,0,
1294,8,Monarch Phenotype,,Abnormality of connective tissue,0.0214,CYP27B1|SMAD2|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|AKT1,10163,10255|10267|10261|10252|10300|10270|10294|10330,3.30E-04,,HP:0003549,0.166958623,0,
17,2,Monarch Phenotype,,Hamartomatous polyposis,0.0214,BMPR1A|AKT1,10163,10300|10330,3.30E-04,,HP:0004390,0.166958623,0,
17,2,Monarch Phenotype,,Abdominal aortic aneurysm,0.0214,SMAD2|SMAD3,10163,10267|10252,3.30E-04,,HP:0005112,0.166958623,0,
433,5,Monarch Phenotype,,Vascular skin abnormality,0.0214,SMAD2|PRKACA|SMAD3|BMPR1A|AKT1,10163,10267|10261|10252|10300|10330,3.40E-04,,HP:0011276,0.166958623,0,
675,6,Monarch Phenotype,,Abnormal long bone morphology,0.0214,CYP27B1|TP53|PRKACA|SKI|BMPR1B|ACVR1,10163,10255|10291|10261|10270|10294|10279,3.30E-04,,HP:0011314,0.166958623,0,
682,6,Monarch Phenotype,,Abnormal hair quantity,0.0214,CSNK2A1|STUB1|CYP27B1|PRKACA|ACVR1|AKT1,10163,10306|10315|10255|10261|10279|10330,3.40E-04,,HP:0011362,0.166958623,0,
17,2,Monarch Phenotype,,Carotid artery dilatation,0.0214,SMAD2|SMAD3,10163,10267|10252,3.30E-04,,HP:0012163,0.166958623,0,
17,2,Monarch Phenotype,,Paroxysmal dyspnea,0.0214,SMAD2|SMAD3,10163,10267|10252,3.30E-04,,HP:0012763,0.166958623,0,
19,2,COMPARTMENTS,,Caspase complex,0.0215,CASP6|CASP3,10163,10309|10333,4.00E-04,,GOCC:0008303,0.166756154,0,
95,3,Monarch Phenotype,,Abnormal circulating calcium concentration,0.0219,CYP27B1|TP53|CTNNB1,10163,10255|10291|10285,3.60E-04,,HP:0004363,0.165955589,0,
123,3,GO Biological Process,,Regulation of myeloid leukocyte differentiation,0.0221,CEBPB|MYC|CTNNB1,10163,10312|10318|10285,7.40E-04,,GO:0002761,0.165560773,0,
1673,9,Monarch Phenotype,,Abnormality of the vasculature,0.0221,SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|AKT1|MYC|CTNNB1,10163,10267|10291|10261|10252|10300|10270|10330|10318|10285,3.60E-04,,HP:0002597,0.165560773,0,
1312,8,Monarch Phenotype,,Abnormality of the hand,0.0222,STUB1|SMAD2|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1,10163,10315|10267|10252|10300|10270|10294|10279|10330,3.70E-04,,HP:0001155,0.165364703,0,
18,2,Monarch Phenotype,,Medulloblastoma,0.0222,TP53|CTNNB1,10163,10291|10285,3.60E-04,,HP:0002885,0.165364703,0,
18,2,Monarch Phenotype,,Adenomatous colonic polyposis,0.0222,BMPR1A|CTNNB1,10163,10300|10285,3.60E-04,,HP:0005227,0.165364703,0,
18,2,Monarch Phenotype,,Prostate cancer,0.0222,TP53|BMPR1A,10163,10291|10300,3.60E-04,,HP:0012125,0.165364703,0,
18,2,Monarch Phenotype,,Descending aortic dissection,0.0222,SMAD2|SMAD3,10163,10267|10252,3.60E-04,,HP:0012499,0.165364703,0,
1680,9,Monarch Phenotype,,Abnormality of cardiovascular system morphology,0.0222,CSNK2A1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|AKT1|CTNNB1,10163,10306|10267|10291|10261|10252|10300|10270|10330|10285,3.70E-04,,HP:0030680,0.165364703,0,
18,2,Monarch Phenotype,,Liver abscess,0.0222,TP53|CTNNB1,10163,10291|10285,3.60E-04,,HP:0100523,0.165364703,0,
1108,7,GO Biological Process,,Regulation of protein phosphorylation,0.0223,TP53|PLK1|CASP3|BMPR1A|BMPR1B|ACVR1|AKT1,10163,10291|10297|10333|10300|10294|10279|10330,7.50E-04,,GO:0001932,0.165169514,0,
20,2,COMPARTMENTS,,Transforming growth factor beta complex,0.0225,SMAD2|SMAD3,10163,10267|10252,4.40E-04,,GOCC:0099126,0.164781748,0,
124,3,GO Biological Process,,Regulation of DNA binding,0.0225,E2F1|SKI|CTNNB1,10163,10264|10270|10285,7.60E-04,,GO:0051101,0.164781748,0,
149,3,Reactome Pathways,,DNA Double-Strand Break Repair,0.0226,CDK2|TP53|SUMO2,10163,10303|10291|10273,0.0013,,HSA-5693532,0.164589156,0,
149,3,Reactome Pathways,,G2/M Checkpoints,0.0226,CDK2|TP53|CDK1,10163,10303|10291|10327,0.0013,,HSA-69481,0.164589156,0,
27,2,GO Biological Process,,Gastrulation with mouth forming second,0.0227,ACVR1|CTNNB1,10163,10279|10285,7.70E-04,,GO:0001702,0.164397414,0,
27,2,GO Biological Process,,Adrenal gland development,0.0227,SMAD2|SMAD3,10163,10267|10252,7.70E-04,,GO:0030325,0.164397414,0,
27,2,GO Biological Process,,Positive regulation of histone H3-K4 methylation,0.0227,MYB|CTNNB1,10163,10288|10285,7.70E-04,,GO:0051571,0.164397414,0,
98,3,Monarch Phenotype,,Renal neoplasm,0.0227,TP53|AKT1|CTNNB1,10163,10291|10330|10285,3.90E-04,,HP:0009726,0.164397414,0,
98,3,Monarch Phenotype,,Deviation of the hallux,0.0227,BMPR1B|ACVR1|AKT1,10163,10294|10279|10330,3.90E-04,,HP:0010051,0.164397414,0,
67,2,WikiPathways,,AMP-activated protein kinase signaling,0.023,TP53|AKT1,10163,10291|10330,0.0043,,WP1403,0.163827216,0,
19,2,Monarch Phenotype,,Hepatic necrosis,0.0231,TP53|CTNNB1,10163,10291|10285,4.00E-04,,HP:0002605,0.163638802,0,
99,3,Monarch Phenotype,,Abdominal distention,0.0231,CYP27B1|TP53|CTNNB1,10163,10255|10291|10285,4.00E-04,,HP:0003270,0.163638802,0,
99,3,Monarch Phenotype,,Abnormal blood potassium concentration,0.0231,TP53|BMPR1A|CTNNB1,10163,10291|10300|10285,4.00E-04,,HP:0011042,0.163638802,0,
255,4,COMPARTMENTS,,Plasma membrane signaling receptor complex,0.0232,BMPR1A|BMPR1B|ACVR1|AKT1,10163,10300|10294|10279|10330,4.60E-04,,GOCC:0098802,0.163451202,0,
67,2,KEGG Pathways,,Acute myeloid leukemia,0.0233,AKT1|MYC,10163,10330|10318,0.0043,,hsa05221,0.163264408,0,
68,2,WikiPathways,,Sterol regulatory element-binding proteins (SREBP) signaling,0.0235,PRKACA|AKT1,10163,10261|10330,0.0044,,WP1982,0.162893214,0,
804,6,GO Biological Process,,Response to cytokine,0.0238,CYP27B1|TP53|CEBPB|PRKACA|CASP3|AKT1,10163,10255|10291|10312|10261|10333|10330,8.20E-04,,GO:0034097,0.162342304,0,
3471,13,Monarch Phenotype,,Abnormality of the nervous system,0.0239,CSNK2A1|STUB1|CYP27B1|SMAD2|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10315|10255|10267|10291|10261|10252|10300|10270|10294|10279|10330|10285,4.20E-04,,HP:0000707,0.16216021,0,
298,4,GO Biological Process,,T cell activation,0.024,TP53|CEBPB|SMAD3|CTNNB1,10163,10291|10312|10252|10285,8.20E-04,,GO:0042110,0.161978876,0,
28,2,GO Biological Process,,Regulation of skeletal muscle tissue development,0.024,ACVR1|CTNNB1,10163,10279|10285,8.20E-04,,GO:0048641,0.161978876,0,
249,4,Monarch Phenotype,,Abnormal diaphysis morphology,0.0241,CYP27B1|PRKACA|SKI|BMPR1B,10163,10255|10261|10270|10294,4.20E-04,,HP:0000940,0.161798296,0,
6,2,InterPro Domains,,"E2F transcription factor, CC-MB domain",0.0243,E2F1|E2F4,10163,10264|10321,5.41E-05,,IPR032198,0.161439373,0,
250,4,Monarch Phenotype,,Abnormal blood cation concentration,0.0243,CYP27B1|TP53|BMPR1A|CTNNB1,10163,10255|10291|10300|10285,4.30E-04,,HP:0010929,0.161439373,0,
300,4,GO Biological Process,,Embryonic organ morphogenesis,0.0245,SMAD2|SMAD3|ACVR1|CTNNB1,10163,10267|10252|10279|10285,8.50E-04,,GO:0048562,0.161083392,0,
236,3,KEGG Pathways,,Parkinson disease,0.0245,TP53|PRKACA|CASP3,10163,10291|10261|10333,0.0046,,hsa05012,0.161083392,0,
12,2,SMART Domains,,"Caspase, interleukin-1 beta converting enzyme (ICE) homologues",0.0246,CASP6|CASP3,10163,10309|10333,1.70E-04,,SM00115,0.160906489,0,
11,2,SMART Domains,,E2F/DP family winged-helix DNA-binding domain,0.0246,E2F1|E2F4,10163,10264|10321,1.50E-04,,SM01372,0.160906489,0,
20,2,Monarch Phenotype,,Visceral angiomatosis,0.0248,BMPR1A|AKT1,10163,10300|10330,4.40E-04,,HP:0100761,0.160554832,0,
20,2,Monarch Phenotype,,Dural ectasia,0.0248,SMAD2|SMAD3,10163,10267|10252,4.40E-04,,HP:0100775,0.160554832,0,
19,2,DISEASES,,Infratentorial cancer,0.0249,TP53|ACVR1,10163,10291|10279,4.00E-04,,DOID:4706,0.160380065,0,
130,3,GO Biological Process,,Endocrine system development,0.0251,SMAD2|SMAD3|BMPR1A,10163,10267|10252|10300,8.70E-04,,GO:0035270,0.160032628,0,
130,3,GO Biological Process,,Positive regulation of apoptotic signaling pathway,0.0251,TP53|BMPR1B|MYC,10163,10291|10294|10318,8.70E-04,,GO:2001235,0.160032628,0,
451,5,DISEASES,,Cell type cancer,0.0251,TP53|ACVR1|AKT1|MYC|CTNNB1,10163,10291|10279|10330|10318|10285,4.10E-04,,DOID:0050687,0.160032628,0,
253,4,Monarch Phenotype,,Abnormality of femur morphology,0.0251,CYP27B1|TP53|BMPR1B|ACVR1,10163,10255|10291|10294|10279,4.50E-04,,HP:0002823,0.160032628,0,
29,2,GO Biological Process,,Branching involved in blood vessel morphogenesis,0.0253,ACVR1|CTNNB1,10163,10279|10285,8.80E-04,,GO:0001569,0.159687948,0,
131,3,GO Biological Process,,Regulation of generation of precursor metabolites and energy,0.0253,TP53|CDK1|AKT1,10163,10291|10327|10330,8.90E-04,,GO:0043467,0.159687948,0,
29,2,GO Biological Process,,Pharyngeal system development,0.0253,BMPR1A|ACVR1,10163,10300|10279,8.80E-04,,GO:0060037,0.159687948,0,
29,2,GO Biological Process,,Cell fate commitment involved in formation of primary germ layer,0.0253,SMAD1|CTNNB1,10163,10282|10285,8.80E-04,,GO:0060795,0.159687948,0,
29,2,GO Biological Process,,T cell apoptotic process,0.0253,TP53|AKT1,10163,10291|10330,8.80E-04,,GO:0070231,0.159687948,0,
29,2,GO Biological Process,,Centriole assembly,0.0253,CDK2|E2F4,10163,10303|10321,8.80E-04,,GO:0098534,0.159687948,0,
104,3,Monarch Phenotype,,Hypoplasia of the maxilla,0.0255,PRKACA|SKI|AKT1,10163,10261|10270|10330,4.60E-04,,HP:0000327,0.159345982,0,
538,5,GO Biological Process,,Inflammatory response,0.0256,CEBPB|SMAD1|BMPR1B|ACVR1|AKT1,10163,10312|10282|10294|10279|10330,9.00E-04,,GO:0006954,0.159176003,0,
72,2,WikiPathways,,Primary focal segmental glomerulosclerosis (FSGS),0.026,AKT1|CTNNB1,10163,10330|10285,0.0049,,WP2572,0.158502665,0,
72,2,WikiPathways,,MECP2 and associated Rett syndrome,0.026,E2F1|AKT1,10163,10264|10330,0.0049,,WP3584,0.158502665,0,
39,2,Reactome Pathways,,Ovarian tumor domain proteases,0.0264,TP53|CDK1,10163,10291|10327,0.0015,,HSA-5689896,0.157839607,0,
21,2,Monarch Phenotype,,Micronodular cirrhosis,0.0265,TP53|CTNNB1,10163,10291|10285,4.80E-04,,HP:0001413,0.157675413,0,
258,4,Monarch Phenotype,,Fatigue,0.0265,TP53|SMAD3|BMPR1A|CTNNB1,10163,10291|10252|10300|10285,4.80E-04,,HP:0012378,0.157675413,0,
30,2,GO Biological Process,,Negative regulation of cyclin-dependent protein serine/threonine kinase activity,0.0266,PLK1|CASP3,10163,10297|10333,9.40E-04,,GO:0045736,0.157511836,0,
134,3,GO Biological Process,,Branching morphogenesis of an epithelial tube,0.0266,ACVR1|MYC|CTNNB1,10163,10279|10318|10285,9.50E-04,,GO:0048754,0.157511836,0,
33,2,TISSUES,,Mesoderm,0.0267,MYB|CTNNB1,10163,10288|10285,0.0011,,BTO:0000839,0.157348874,0,
2388,10,TISSUES,,Internal male genital organ,0.0268,RBL2|TP53|CEBPB|PRKACA|CASP3|BMPR1A|BMPR1B|SUMO2|AKT1|MYC,10163,10276|10291|10312|10261|10333|10300|10294|10273|10330|10318,0.0011,,BTO:0003096,0.157186521,0,
6291,18,DISEASES,,Disease,0.0268,STUB1|CYP27B1|SMAD2|CDK2|TP53|PRKACA|CASP3|SMAD3|MYB|E2F1|BMPR1A|SKI|E2F4|BMPR1B|ACVR1|AKT1|MYC|CTNNB1,10163,10315|10255|10267|10303|10291|10261|10333|10252|10288|10264|10300|10270|10321|10294|10279|10330|10318|10285,4.40E-04,,DOID:4,0.157186521,0,
136,3,GO Biological Process,,Regulation of DNA replication,0.0277,CDK2|TP53|CDK1,10163,10303|10291|10327,9.90E-04,,GO:0006275,0.155752023,0,
137,3,GO Biological Process,,Response to glucose,0.028,SMAD2|PRKACA|CASP3,10163,10267|10261|10333,0.001,,GO:0009749,0.155284197,0,
31,2,GO Biological Process,,Response to X-ray,0.028,TP53|CASP3,10163,10291|10333,0.001,,GO:0010165,0.155284197,0,
31,2,GO Biological Process,,Myelination in peripheral nervous system,0.028,SKI|AKT1,10163,10270|10330,0.001,,GO:0022011,0.155284197,0,
314,4,GO Biological Process,,Response to lipopolysaccharide,0.028,CYP27B1|CEBPB|CASP3|AKT1,10163,10255|10312|10333|10330,0.001,,GO:0032496,0.155284197,0,
315,4,GO Biological Process,,Regulation of leukocyte differentiation,0.0281,CEBPB|MYB|MYC|CTNNB1,10163,10312|10288|10318|10285,0.001,,GO:1902105,0.155129368,0,
22,2,Monarch Phenotype,,Increased circulating prolactin concentration,0.0281,AKT1|CTNNB1,10163,10330|10285,5.30E-04,,HP:0000870,0.155129368,0,
22,2,Monarch Phenotype,,Ascending aortic dissection,0.0281,SMAD2|SMAD3,10163,10267|10252,5.30E-04,,HP:0004933,0.155129368,0,
1384,8,Monarch Phenotype,,Abnormality of the gastrointestinal tract,0.0281,STUB1|TP53|SMAD3|BMPR1A|SKI|AKT1|MYC|CTNNB1,10163,10315|10291|10252|10300|10270|10330|10318|10285,5.20E-04,,HP:0011024,0.155129368,0,
22,2,Monarch Phenotype,,Abnormal ascending aorta morphology,0.0281,SMAD2|SMAD3,10163,10267|10252,5.30E-04,,HP:0031784,0.155129368,0,
743,6,Monarch Phenotype,,Abnormal thorax morphology,0.0285,CYP27B1|SMAD2|PRKACA|SMAD3|SKI|AKT1,10163,10255|10267|10261|10252|10270|10330,5.40E-04,,HP:0000765,0.154515514,0,
110,3,Monarch Phenotype,,Genu valgum,0.0285,CYP27B1|PRKACA|SKI,10163,10255|10261|10270,5.40E-04,,HP:0002857,0.154515514,0,
111,3,Monarch Phenotype,,Gastrointestinal hemorrhage,0.0289,BMPR1A|MYC|CTNNB1,10163,10300|10318|10285,5.50E-04,,HP:0002239,0.153910216,0,
32,2,GO Biological Process,,Maternal placenta development,0.0294,CYP27B1|AKT1,10163,10255|10330,0.0011,,GO:0001893,0.153165267,0,
32,2,GO Biological Process,,Mitotic G1 DNA damage checkpoint signaling,0.0294,CDK2|TP53,10163,10303|10291,0.0011,,GO:0031571,0.153165267,0,
32,2,GO Biological Process,,Positive regulation of ubiquitin-protein transferase activity,0.0294,STUB1|PLK1,10163,10315|10297,0.0011,,GO:0051443,0.153165267,0,
32,2,GO Biological Process,,Regulation of intrinsic apoptotic signaling pathway by p53 class mediator,0.0294,TP53|MYC,10163,10291|10318,0.0011,,GO:1902253,0.153165267,0,
140,3,GO Biological Process,,Negative regulation of leukocyte cell-cell adhesion,0.0294,CEBPB|CASP3|AKT1,10163,10312|10333|10330,0.0011,,GO:1903038,0.153165267,0,
321,4,GO Biological Process,,Cellular component disassembly,0.0297,TP53|PLK1|CDK1|MYC,10163,10291|10297|10327|10318,0.0011,,GO:0022411,0.152724355,0,
2189,10,Monarch Phenotype,,Abnormality of the genitourinary system,0.0297,STUB1|CYP27B1|TP53|SMAD3|BMPR1A|SKI|BMPR1B|AKT1|MYC|CTNNB1,10163,10315|10255|10291|10252|10300|10270|10294|10330|10318|10285,5.70E-04,,HP:0000119,0.152724355,0,
23,2,Monarch Phenotype,,Uterine leiomyosarcoma,0.0297,AKT1|CTNNB1,10163,10330|10285,5.70E-04,,HP:0002891,0.152724355,0,
113,3,Monarch Phenotype,,Abnormal blood inorganic cation concentration,0.0298,CYP27B1|TP53|CTNNB1,10163,10255|10291|10285,5.80E-04,,HP:0010927,0.152578374,0,
1063,7,Monarch Phenotype,,Abnormality of joint mobility,0.0298,CSNK2A1|SMAD3|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10252|10270|10294|10279|10330|10285,5.90E-04,,HP:0011729,0.152578374,0,
113,3,Monarch Phenotype,,Abnormality of adrenal physiology,0.0298,PRKACA|AKT1|CTNNB1,10163,10261|10330|10285,5.80E-04,,HP:0011733,0.152578374,0,
141,3,GO Biological Process,,Positive regulation of Wnt signaling pathway,0.0299,CSNK2A1|SMAD3|SKI,10163,10306|10252|10270,0.0011,,GO:0030177,0.152432881,0,
852,6,GO Biological Process,,Regulation of protein localization,0.03,PLK1|PRKACA|SMAD3|CDK1|AKT1|CTNNB1,10163,10297|10261|10252|10327|10330|10285,0.0011,,GO:0032880,0.152287875,0,
42,2,Reactome Pathways,,Deactivation of the beta-catenin transactivating complex,0.0302,AKT1|CTNNB1,10163,10330|10285,0.0018,,HSA-3769402,0.151999306,0,
24,2,COMPARTMENTS,,TOR complex,0.0303,TP53|AKT1,10163,10291|10330,6.20E-04,,GOCC:0038201,0.151855737,0,
142,3,GO Biological Process,,Regulation of smooth muscle cell proliferation,0.0303,BMPR1A|AKT1|CTNNB1,10163,10300|10330|10285,0.0011,,GO:0048660,0.151855737,0,
274,4,Monarch Phenotype,,Abnormal form of the vertebral bodies,0.0303,CYP27B1|SKI|ACVR1|AKT1,10163,10255|10270|10279|10330,6.10E-04,,HP:0003312,0.151855737,0,
274,4,Monarch Phenotype,,Anorectal anomaly,0.0303,TP53|BMPR1A|AKT1|CTNNB1,10163,10291|10300|10330|10285,6.10E-04,,HP:0012732,0.151855737,0,
33,2,GO Biological Process,,Histone phosphorylation,0.0305,CDK2|CDK1,10163,10303|10327,0.0011,,GO:0016572,0.151570016,0,
33,2,GO Biological Process,,Positive regulation of monooxygenase activity,0.0305,CYP27B1|AKT1,10163,10255|10330,0.0011,,GO:0032770,0.151570016,0,
143,3,GO Biological Process,,Response to ionizing radiation,0.0307,TP53|CASP3|MYC,10163,10291|10333|10318,0.0011,,GO:0010212,0.151286162,0,
116,3,Monarch Phenotype,,Abnormal aortic valve morphology,0.0307,SMAD2|SMAD3|SKI,10163,10267|10252|10270,6.30E-04,,HP:0001646,0.151286162,0,
24,2,Monarch Phenotype,,Subarachnoid hemorrhage,0.0307,SMAD2|SMAD3,10163,10267|10252,6.20E-04,,HP:0002138,0.151286162,0,
24,2,Monarch Phenotype,,Aplasia/Hypoplasia of the phalanges of the toes,0.0307,BMPR1B|ACVR1,10163,10294|10279,6.20E-04,,HP:0010173,0.151286162,0,
24,2,Monarch Phenotype,,Endometrial carcinoma,0.0307,BMPR1A|AKT1,10163,10300|10330,6.20E-04,,HP:0012114,0.151286162,0,
326,4,GO Biological Process,,Regulation of Wnt signaling pathway,0.0309,CSNK2A1|SMAD3|SKI|CTNNB1,10163,10306|10252|10270|10285,0.0011,,GO:0030111,0.151004152,0,
43,2,Reactome Pathways,,Condensation of Prophase Chromosomes,0.0313,PLK1|CDK1,10163,10297|10327,0.0019,,HSA-2299718,0.150445566,0,
1600,8,TISSUES,,Lymphoid tissue,0.0316,RBL2|SMAD2|CASP6|TP53|PLK1|CASP3|CDK1|MYC,10163,10276|10267|10309|10291|10297|10333|10327|10318,0.0014,,BTO:0000753,0.150031292,0,
1814,9,Monarch Phenotype,,Abnormal forebrain morphology,0.0317,CSNK2A1|STUB1|SMAD2|TP53|SMAD3|SKI|ACVR1|AKT1|CTNNB1,10163,10306|10315|10267|10291|10252|10270|10279|10330|10285,6.50E-04,,HP:0100547,0.149894074,0,
34,2,GO Biological Process,,Mitotic G2 DNA damage checkpoint signaling,0.0318,PLK1|CDK1,10163,10297|10327,0.0012,,GO:0007095,0.149757288,0,
34,2,GO Biological Process,,Fibroblast proliferation,0.0318,TP53|CDK1,10163,10291|10327,0.0012,,GO:0048144,0.149757288,0,
34,2,GO Biological Process,,Positive regulation of telomerase activity,0.0318,MYC|CTNNB1,10163,10318|10285,0.0012,,GO:0051973,0.149757288,0,
34,2,GO Biological Process,,Intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,0.0318,TP53|CEBPB,10163,10291|10312,0.0012,,GO:0070059,0.149757288,0,
118,3,Monarch Phenotype,,Abnormality of the maxilla,0.0318,PRKACA|SKI|AKT1,10163,10261|10270|10330,6.60E-04,,HP:0000326,0.149757288,0,
25,2,Monarch Phenotype,,Multiple lipomas,0.032,BMPR1A|AKT1,10163,10300|10330,6.70E-04,,HP:0001012,0.149485002,0,
25,2,Monarch Phenotype,,Metabolic alkalosis,0.032,TP53|CTNNB1,10163,10291|10285,6.70E-04,,HP:0200114,0.149485002,0,
81,2,KEGG Pathways,,ErbB signaling pathway,0.0323,AKT1|MYC,10163,10330|10318,0.0062,,hsa04012,0.149079748,0,
263,3,KEGG Pathways,,Prion disease,0.0323,CSNK2A1|PRKACA|CASP3,10163,10306|10261|10333,0.0062,,hsa05020,0.149079748,0,
10,2,STRING Clusters,,"Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)",0.0323,CDK2|E2F1,10163,10303|10264,1.30E-04,,CL:6926,0.149079748,0,
540,5,UniProt Keywords,,Host-virus interaction,0.0324,RCOR1|TP53|E2F1|CDK1|CTNNB1,10163,10324|10291|10264|10327|10285,9.20E-04,,KW-0945,0.148945499,0,
103,3,GO Cellular Component,,PML body,0.0328,TP53|SKI|SUMO2,10163,10291|10270|10273,4.50E-04,,GO:0016605,0.148412616,0,
3154,12,Monarch Phenotype,,Abnormal nervous system physiology,0.0329,CSNK2A1|STUB1|CYP27B1|TP53|PRKACA|SMAD3|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10315|10255|10291|10261|10252|10300|10270|10294|10279|10330|10285,6.90E-04,,HP:0012638,0.14828041,0,
19,2,GO Molecular Function,,BMP binding,0.033,BMPR1A|BMPR1B,10163,10300|10294,4.00E-04,,GO:0036122,0.148148606,0,
35,2,GO Biological Process,,Negative regulation of macroautophagy,0.0332,TP53|AKT1,10163,10291|10330,0.0013,,GO:0016242,0.147886192,0,
35,2,GO Biological Process,,Hindlimb morphogenesis,0.0332,BMPR1A|CTNNB1,10163,10300|10285,0.0013,,GO:0035137,0.147886192,0,
334,4,GO Biological Process,,Camera-type eye development,0.0332,SMAD3|SKI|BMPR1B|CTNNB1,10163,10252|10270|10294|10285,0.0013,,GO:0043010,0.147886192,0,
148,3,GO Biological Process,,Positive regulation of cysteine-type endopeptidase activity,0.0332,CASP6|SMAD3|MYC,10163,10309|10252|10318,0.0013,,GO:2001056,0.147886192,0,
286,4,Monarch Phenotype,,Tooth malposition,0.0334,PRKACA|SMAD3|SKI|ACVR1,10163,10261|10252|10270|10279,7.10E-04,,HP:0000692,0.147625353,0,
1448,8,Monarch Phenotype,,Abdominal symptom,0.0334,CSNK2A1|CYP27B1|TP53|BMPR1A|SKI|AKT1|MYC|CTNNB1,10163,10306|10255|10291|10300|10270|10330|10318|10285,7.10E-04,,HP:0011458,0.147625353,0,
149,3,GO Biological Process,,Placenta development,0.0336,CYP27B1|CEBPB|AKT1,10163,10255|10312|10330,0.0013,,GO:0001890,0.147366072,0,
149,3,GO Biological Process,,Regulation of epithelial cell differentiation,0.0336,CYP27B1|CEBPB|CTNNB1,10163,10255|10312|10285,0.0013,,GO:0030856,0.147366072,0,
83,2,WikiPathways,,MicroRNAs in cardiomyocyte hypertrophy,0.0336,AKT1|CTNNB1,10163,10330|10285,0.0064,,WP1544,0.147366072,0,
83,2,WikiPathways,,EGFR tyrosine kinase inhibitor resistance,0.0336,AKT1|MYC,10163,10330|10318,0.0064,,WP4806,0.147366072,0,
122,3,Monarch Phenotype,,"High, narrow palate",0.0337,SMAD2|SMAD3|SKI,10163,10267|10252|10270,7.20E-04,,HP:0002705,0.14723701,0,
26,2,Monarch Phenotype,,Hereditary nonpolyposis colorectal carcinoma,0.0337,AKT1|CTNNB1,10163,10330|10285,7.20E-04,,HP:0006716,0.14723701,0,
26,2,Monarch Phenotype,,Testicular neoplasm,0.0337,TP53|AKT1,10163,10291|10330,7.20E-04,,HP:0010788,0.14723701,0,
26,2,Monarch Phenotype,,Bone cyst,0.0337,CYP27B1|AKT1,10163,10255|10330,7.20E-04,,HP:0012062,0.14723701,0,
2254,10,Monarch Phenotype,,Abnormality of brain morphology,0.0337,CSNK2A1|STUB1|SMAD2|TP53|SMAD3|BMPR1A|SKI|ACVR1|AKT1|CTNNB1,10163,10306|10315|10267|10291|10252|10300|10270|10279|10330|10285,7.20E-04,,HP:0012443,0.14723701,0,
709,6,GO Molecular Function,,Protein homodimerization activity,0.0342,STUB1|CEBPB|SMAD3|BMPR1A|ACVR1|AKT1,10163,10315|10312|10252|10300|10279|10330,4.20E-04,,GO:0042803,0.146597389,0,
26,2,COMPARTMENTS,,NF-kappaB complex,0.0344,TP53|AKT1,10163,10291|10330,7.20E-04,,GOCC:0071159,0.146344156,0,
493,5,DISEASES,,Cardiovascular system disease,0.0351,CASP3|SMAD3|BMPR1B|AKT1|CTNNB1,10163,10333|10252|10294|10330|10285,6.10E-04,,DOID:1287,0.145469288,0,
27,2,Monarch Phenotype,,Stomach cancer,0.0353,TP53|BMPR1A,10163,10291|10300,7.70E-04,,HP:0012126,0.145222529,0,
293,4,Monarch Phenotype,,Cardiovascular disease,0.0354,TP53|SMAD3|SKI|BMPR1B,10163,10291|10252|10270|10294,7.80E-04,,EFO:0000319,0.145099674,0,
1470,8,Monarch Phenotype,,Abnormality of the nose,0.0355,CSNK2A1|TP53|PRKACA|BMPR1A|SKI|BMPR1B|AKT1|CTNNB1,10163,10306|10291|10261|10300|10270|10294|10330|10285,7.80E-04,,HP:0000366,0.144977165,0,
354,4,TISSUES,,Blood vessel,0.0358,CASP3|MYB|SUMO2|AKT1,10163,10333|10288|10273|10330,0.0015,,BTO:0001102,0.144611697,0,
87,2,KEGG Pathways,,Gap junction,0.0359,PRKACA|CDK1,10163,10261|10327,0.007,,hsa04540,0.144490555,0,
87,2,KEGG Pathways,,PD-L1 expression and PD-1 checkpoint pathway in cancer,0.0359,CSNK2A1|AKT1,10163,10306|10330,0.007,,hsa05235,0.144490555,0,
153,3,GO Biological Process,,Regulation of mitochondrion organization,0.036,CASP6|TP53|AKT1,10163,10309|10291|10330,0.0014,,GO:0010821,0.14436975,0,
153,3,GO Biological Process,,Regulation of extrinsic apoptotic signaling pathway,0.036,BMPR1B|ACVR1|AKT1,10163,10294|10279|10330,0.0014,,GO:2001236,0.14436975,0,
37,2,GO Biological Process,,Endocardial cushion morphogenesis,0.0364,BMPR1A|ACVR1,10163,10300|10279,0.0014,,GO:0003203,0.143889862,0,
154,3,GO Biological Process,,Female gamete generation,0.0364,PLK1|BMPR1B|CTNNB1,10163,10297|10294|10285,0.0014,,GO:0007292,0.143889862,0,
154,3,GO Biological Process,,Hindbrain development,0.0364,TP53|SMAD1|CTNNB1,10163,10291|10282|10285,0.0014,,GO:0030902,0.143889862,0,
37,2,GO Biological Process,,Regulation of megakaryocyte differentiation,0.0364,RCOR1|MYB,10163,10324|10288,0.0014,,GO:0045652,0.143889862,0,
37,2,GO Biological Process,,Smooth muscle cell differentiation,0.0364,ACVR1|CTNNB1,10163,10279|10285,0.0014,,GO:0051145,0.143889862,0,
8,2,InterPro Domains,,E2F Family,0.0367,E2F1|E2F4,10163,10264|10321,8.68E-05,,IPR015633,0.143533394,0,
127,3,Monarch Phenotype,,Abnormality of the wrist,0.0368,CYP27B1|BMPR1B|AKT1,10163,10255|10294|10330,8.10E-04,,HP:0003019,0.143415218,0,
282,3,KEGG Pathways,,Cytokine-cytokine receptor interaction,0.037,BMPR1A|BMPR1B|ACVR1,10163,10300|10294|10279,0.0075,,hsa04060,0.143179828,0,
88,2,WikiPathways,,T-cell activation SARS-CoV-2,0.037,TP53|AKT1,10163,10291|10330,0.0072,,WP5098,0.143179828,0,
28,2,Monarch Phenotype,,Transitional cell carcinoma of the bladder,0.0373,AKT1|CTNNB1,10163,10330|10285,8.20E-04,,HP:0006740,0.142829117,0,
28,2,Monarch Phenotype,,Short phalanx of the thumb,0.0373,BMPR1B|ACVR1,10163,10294|10279,8.20E-04,,HP:0009660,0.142829117,0,
91,2,KEGG Pathways,,IL-17 signaling pathway,0.0374,CEBPB|CASP3,10163,10312|10333,0.0077,,hsa04657,0.14271284,0,
774,6,DISEASES,,Connective tissue disease,0.0378,CYP27B1|TP53|SKI|BMPR1B|ACVR1|CTNNB1,10163,10255|10291|10270|10294|10279|10285,6.70E-04,,DOID:65,0.14225082,0,
902,6,GO Biological Process,,Protein modification by small protein conjugation or removal,0.038,STUB1|PLK1|CDK1|SUMO2|AKT1|CTNNB1,10163,10315|10297|10327|10273|10330|10285,0.0015,,GO:0070647,0.14202164,0,
110,3,GO Cellular Component,,Serine/threonine protein kinase complex,0.0381,CDK2|CDK1|ACVR1,10163,10303|10327|10279,5.40E-04,,GO:1902554,0.141907502,0,
130,3,Monarch Phenotype,,Bruising susceptibility,0.0389,SMAD2|PRKACA|SMAD3,10163,10267|10261|10252,8.70E-04,,HP:0000978,0.14100504,0,
303,4,Monarch Phenotype,,Joint dislocation,0.0392,CYP27B1|SKI|BMPR1B|AKT1,10163,10255|10270|10294|10330,8.80E-04,,HP:0001373,0.140671393,0,
29,2,Monarch Phenotype,,Peripheral arterial stenosis,0.0392,SMAD2|SMAD3,10163,10267|10252,8.80E-04,,HP:0004950,0.140671393,0,
29,2,Monarch Phenotype,,Non-Hodgkin lymphoma,0.0392,TP53|MYC,10163,10291|10318,8.80E-04,,HP:0012539,0.140671393,0,
39,2,GO Biological Process,,Animal organ formation,0.0396,BMPR1A|CTNNB1,10163,10300|10285,0.0015,,GO:0048645,0.140230481,0,
39,2,GO Biological Process,,Regulation of neuroblast proliferation,0.0396,TP53|CTNNB1,10163,10291|10285,0.0015,,GO:1902692,0.140230481,0,
160,3,GO Biological Process,,Muscle cell development,0.0397,BMPR1A|SKI|CDK1,10163,10300|10270|10327,0.0016,,GO:0055001,0.140120949,0,
160,3,GO Biological Process,,Positive regulation of intracellular protein transport,0.0397,PRKACA|SMAD3|CDK1,10163,10261|10252|10327,0.0016,,GO:0090316,0.140120949,0,
26,2,DISEASES,,Lung non-small cell carcinoma,0.0397,TP53|AKT1,10163,10291|10330,7.20E-04,,DOID:3908,0.140120949,0,
145,3,UniProt Keywords,,Biological rhythms,0.0397,CSNK2A1|TP53|CDK1,10163,10306|10291|10327,0.0012,,KW-0090,0.140120949,0,
821,6,Monarch Phenotype,,Abnormality of the dentition,0.0399,CYP27B1|PRKACA|SMAD3|SKI|ACVR1|AKT1,10163,10255|10261|10252|10270|10279|10330,9.10E-04,,HP:0000164,0.13990271,0,
95,2,KEGG Pathways,,Melanogenesis,0.04,PRKACA|CTNNB1,10163,10261|10285,0.0083,,hsa04916,0.139794001,0,
295,3,KEGG Pathways,,Huntington disease,0.04,RCOR1|TP53|CASP3,10163,10324|10291|10333,0.0085,,hsa05016,0.139794001,0,
2323,10,Monarch Phenotype,,Neurodevelopmental abnormality,0.0401,CSNK2A1|STUB1|CYP27B1|TP53|BMPR1A|SKI|BMPR1B|ACVR1|AKT1|CTNNB1,10163,10306|10315|10255|10291|10300|10270|10294|10279|10330|10285,9.20E-04,,HP:0012759,0.139685563,0,
612,5,GO Biological Process,,Chromatin organization,0.0404,RBL2|RCOR1|TP53|MYB|MYC,10163,10276|10324|10291|10288|10318,0.0016,,GO:0006325,0.139361863,0,
97,2,KEGG Pathways,,Chagas disease,0.0404,SMAD2|AKT1,10163,10267|10330,0.0087,,hsa05142,0.139361863,0,
40,2,GO Biological Process,,Regulation of hormone metabolic process,0.0408,STUB1|CYP27B1,10163,10315|10255,0.0016,,GO:0032350,0.138933984,0,
40,2,GO Biological Process,,T cell homeostasis,0.0408,CASP3|AKT1,10163,10333|10330,0.0016,,GO:0043029,0.138933984,0,
40,2,GO Biological Process,,Positive regulation of DNA replication,0.0408,CDK2|CDK1,10163,10303|10327,0.0016,,GO:0045740,0.138933984,0,
40,2,GO Biological Process,,Regulation of protein localization to cell surface,0.0408,AKT1|CTNNB1,10163,10330|10285,0.0016,,GO:2000008,0.138933984,0,
99,2,KEGG Pathways,,Th17 cell differentiation,0.0414,SMAD2|SMAD3,10163,10267|10252,0.009,,hsa04659,0.138299966,0,
190,3,Reactome Pathways,,ESR-mediated signaling,0.0414,MYB|AKT1|MYC,10163,10288|10330|10318,0.0025,,HSA-8939211,0.138299966,0,
3470,12,GO Biological Process,,Organelle organization,0.0415,RBL2|RCOR1|CASP6|CDK2|TP53|PLK1|MYB|E2F4|CDK1|AKT1|MYC|CTNNB1,10163,10276|10324|10309|10303|10291|10297|10288|10321|10327|10330|10318|10285,0.0017,,GO:0006996,0.13819519,0,
131,3,COMPARTMENTS,,Serine/threonine protein kinase complex,0.0416,CDK2|CDK1|ACVR1,10163,10303|10327|10279,8.90E-04,,GOCC:1902554,0.138090667,0,
100,2,KEGG Pathways,,Glucagon signaling pathway,0.0416,PRKACA|AKT1,10163,10261|10330,0.0092,,hsa04922,0.138090667,0,
101,2,KEGG Pathways,,Amoebiasis,0.0418,PRKACA|CASP3,10163,10261|10333,0.0093,,hsa05146,0.137882372,0,
164,3,GO Biological Process,,Negative regulation of binding,0.0419,STUB1|E2F1|AKT1,10163,10315|10264|10330,0.0017,,GO:0051100,0.137778598,0,
135,3,Monarch Phenotype,,Aortic aneurysm,0.0419,SMAD2|SMAD3|SKI,10163,10267|10252|10270,9.70E-04,,HP:0004942,0.137778598,0,
41,2,GO Biological Process,,Ventricular septum morphogenesis,0.0423,BMPR1A|ACVR1,10163,10300|10279,0.0017,,GO:0060412,0.137365963,0,
9,2,InterPro Domains,,E2F-DP heterodimerization region,0.0423,E2F1|E2F4,10163,10264|10321,1.10E-04,,IPR037241,0.137365963,0,
2275,10,DISEASES,,Nervous system disease,0.0425,STUB1|CYP27B1|CDK2|TP53|CASP3|E2F1|E2F4|ACVR1|AKT1|CTNNB1,10163,10315|10255|10303|10291|10333|10264|10321|10279|10330|10285,7.80E-04,,DOID:863,0.137161107,0,
1525,8,Monarch Phenotype,,Growth delay,0.0427,STUB1|CYP27B1|TP53|PRKACA|BMPR1A|BMPR1B|AKT1|CTNNB1,10163,10315|10255|10291|10261|10300|10294|10330|10285,9.90E-04,,HP:0001510,0.136957212,0,
103,2,KEGG Pathways,,Toxoplasmosis,0.0429,CASP3|AKT1,10163,10333|10330,0.0097,,hsa05145,0.136754271,0,
31,2,Monarch Phenotype,,Pituitary hypothyroidism,0.0429,AKT1|CTNNB1,10163,10330|10285,0.001,,HP:0008245,0.136754271,0,
104,2,KEGG Pathways,,"Parathyroid hormone synthesis, secretion and action",0.0431,CYP27B1|PRKACA,10163,10255|10261,0.0099,,hsa04928,0.136552273,0,
44,2,TISSUES,,Kidney cell line,0.0432,CYP27B1|MYC,10163,10255|10318,0.0019,,BTO:0000067,0.136451625,0,
639,5,TISSUES,,Colon,0.0432,STUB1|TP53|PLK1|CEBPB|CTNNB1,10163,10315|10291|10297|10312|10285,0.0019,,BTO:0000269,0.136451625,0,
954,6,TISSUES,,Connective tissue,0.0432,SMAD2|TP53|CEBPB|SMAD3|SUMO2|MYC,10163,10267|10291|10312|10252|10273|10318,0.002,,BTO:0000421,0.136451625,0,
2112,9,TISSUES,,Integument,0.0432,STUB1|TP53|CEBPB|E2F1|CDK1|BMPR1B|SUMO2|AKT1|CTNNB1,10163,10315|10291|10312|10264|10327|10294|10273|10330|10285,0.0019,,BTO:0000634,0.136451625,0,
839,6,Monarch Phenotype,,Abnormality of globe location,0.0434,CSNK2A1|SMAD2|SMAD3|BMPR1A|SKI|AKT1,10163,10306|10267|10252|10300|10270|10330,0.001,,HP:0100886,0.136251027,0,
6403,17,TISSUES,,Endocrine gland,0.0435,STUB1|RBL2|SMAD2|TP53|PLK1|CEBPB|PRKACA|SMAD3|MYB|E2F1|BMPR1A|E2F4|BMPR1B|SUMO2|AKT1|MYC|CTNNB1,10163,10315|10276|10267|10291|10297|10312|10261|10252|10288|10264|10300|10321|10294|10273|10330|10318|10285,0.002,,BTO:0001488,0.136151074,0,
840,6,Monarch Phenotype,,Functional abnormality of the gastrointestinal tract,0.0435,STUB1|SMAD3|BMPR1A|SKI|MYC|CTNNB1,10163,10315|10252|10300|10270|10318|10285,0.001,,HP:0012719,0.136151074,0,
42,2,GO Biological Process,,Chromosome condensation,0.0441,PLK1|CDK1,10163,10297|10327,0.0018,,GO:0030261,0.135556141,0,
42,2,GO Biological Process,,Positive regulation of protein import into nucleus,0.0441,SMAD3|CDK1,10163,10252|10327,0.0018,,GO:0042307,0.135556141,0,
368,4,GO Biological Process,,Response to oxidative stress,0.0442,TP53|CASP3|CDK1|AKT1,10163,10291|10333|10327|10330,0.0018,,GO:0006979,0.135457773,0,
168,3,GO Biological Process,,Male sex differentiation,0.0442,BMPR1A|SMAD5|CTNNB1,10163,10300|10258|10285,0.0018,,GO:0046661,0.135457773,0,
368,4,GO Biological Process,,Regulation of leukocyte cell-cell adhesion,0.0442,CEBPB|CASP3|MYB|AKT1,10163,10312|10333|10288|10330,0.0018,,GO:1903037,0.135457773,0,
97,2,WikiPathways,,B cell receptor signaling pathway,0.0442,AKT1|MYC,10163,10330|10318,0.0087,,WP23,0.135457773,0,
32,2,Monarch Phenotype,,Polycythemia,0.0447,TP53|CTNNB1,10163,10291|10285,0.0011,,HP:0001901,0.134969248,0,
32,2,Monarch Phenotype,,Slow decrease in visual acuity,0.0447,AKT1|CTNNB1,10163,10330|10285,0.0011,,HP:0007924,0.134969248,0,
32,2,Monarch Phenotype,,Abnormality of blood volume homeostasis,0.0447,SMAD2|SMAD3,10163,10267|10252,0.0011,,HP:0011104,0.134969248,0,
32,2,Monarch Phenotype,,Hypovolemia,0.0447,SMAD2|SMAD3,10163,10267|10252,0.0011,,HP:0011106,0.134969248,0,
558,5,Monarch Phenotype,,Abnormal bone ossification,0.0447,CYP27B1|PRKACA|SMAD3|SKI|ACVR1,10163,10255|10261|10252|10270|10279,0.0011,,HP:0011849,0.134969248,0,
845,6,Monarch Phenotype,,Morphological abnormality of the gastrointestinal tract,0.0447,TP53|SMAD3|BMPR1A|AKT1|MYC|CTNNB1,10163,10291|10252|10300|10330|10318|10285,0.0011,,HP:0012718,0.134969248,0,
849,6,Monarch Phenotype,,Abnormality of digestive system morphology,0.0447,TP53|SMAD3|BMPR1A|AKT1|MYC|CTNNB1,10163,10291|10252|10300|10330|10318|10285,0.0011,,HP:0025033,0.134969248,0,
32,2,Monarch Phenotype,,Mucosal telangiectasiae,0.0447,BMPR1A|AKT1,10163,10300|10330,0.0011,,HP:0100579,0.134969248,0,
169,3,GO Biological Process,,Response to reactive oxygen species,0.0448,CASP3|CDK1|AKT1,10163,10333|10327|10330,0.0018,,GO:0000302,0.134872199,0,
169,3,GO Biological Process,,Regulation of intrinsic apoptotic signaling pathway,0.0448,TP53|AKT1|MYC,10163,10291|10330|10318,0.0018,,GO:2001242,0.134872199,0,
43,2,GO Biological Process,,Positive regulation of nitric oxide biosynthetic process,0.0454,SMAD3|AKT1,10163,10252|10330,0.0019,,GO:0045429,0.134294415,0,
170,3,GO Biological Process,,Mesenchymal cell differentiation,0.0454,BMPR1A|ACVR1|CTNNB1,10163,10300|10279|10285,0.0018,,GO:0048762,0.134294415,0,
170,3,GO Biological Process,,Epithelial cell proliferation,0.0454,CEBPB|BMPR1A|CTNNB1,10163,10312|10300|10285,0.0018,,GO:0050673,0.134294415,0,
23,2,GO Molecular Function,,Phosphatase activator activity,0.0454,BMPR1A|BMPR1B,10163,10300|10294,5.70E-04,,GO:0019211,0.134294415,0,
23,2,GO Molecular Function,,Histone acetyltransferase binding,0.0454,TP53|CEBPB,10163,10291|10312,5.70E-04,,GO:0035035,0.134294415,0,
108,2,KEGG Pathways,,Serotonergic synapse,0.0456,PRKACA|CASP3,10163,10261|10333,0.0106,,hsa04726,0.134103516,0,
109,2,KEGG Pathways,,Cholinergic synapse,0.0459,PRKACA|AKT1,10163,10261|10330,0.0108,,hsa04725,0.133818731,0,
54,2,Reactome Pathways,,Signaling by PTK6,0.0459,CDK2|AKT1,10163,10303|10330,0.0029,,HSA-8848021,0.133818731,0,
2384,10,Monarch Phenotype,,Abnormality of the musculature,0.046,CSNK2A1|STUB1|CYP27B1|TP53|PRKACA|SMAD3|SKI|BMPR1B|AKT1|CTNNB1,10163,10306|10315|10255|10291|10261|10252|10270|10294|10330|10285,0.0011,,HP:0003011,0.133724217,0,
114,3,GO Molecular Function,,Transcription coregulator binding,0.0461,SMAD3|MYC|CTNNB1,10163,10252|10318|10285,6.00E-04,,GO:0001221,0.133629907,0,
325,4,Monarch Phenotype,,Abnormal rib cage morphology,0.0463,CYP27B1|PRKACA|SKI|AKT1,10163,10255|10261|10270|10330,0.0011,,HP:0001547,0.133441901,0,
1405,7,Reactome Pathways,,Post-translational protein modification,0.0465,SMAD2|TP53|SMAD1|SMAD3|CDK1|SUMO2|MYC,10163,10267|10291|10282|10252|10327|10273|10318,0.003,,HSA-597592,0.133254705,0,
24,2,GO Molecular Function,,Transforming growth factor beta receptor binding,0.0469,SMAD2|SMAD3,10163,10267|10252,6.20E-04,,GO:0005160,0.132882716,0,
24,2,GO Molecular Function,,R-SMAD binding,0.0469,SMAD2|SMAD3,10163,10267|10252,6.20E-04,,GO:0070412,0.132882716,0,
112,2,KEGG Pathways,,Neurotrophin signaling pathway,0.0476,TP53|AKT1,10163,10291|10330,0.0113,,hsa04722,0.132239305,0,
10,2,InterPro Domains,,"Peptidase family C14A, His active site",0.048,CASP6|CASP3,10163,10309|10333,1.30E-04,,IPR016129,0.131875876,0,
145,3,Monarch Phenotype,,Type II diabetes mellitus,0.048,STUB1|TP53|CTNNB1,10163,10315|10291|10285,0.0012,,HP:0005978,0.131875876,0,
45,2,GO Biological Process,,Embryonic axis specification,0.049,SMAD2|CTNNB1,10163,10267|10285,0.002,,GO:0000578,0.130980392,0,
45,2,GO Biological Process,,Branching involved in ureteric bud morphogenesis,0.049,MYC|CTNNB1,10163,10318|10285,0.002,,GO:0001658,0.130980392,0,
